var title_f29_14_29920="TNM stage breast cancer";
var content_f29_14_29920=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F65393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F65393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tumor node metastases (TNM) staging system for carcinoma of the breast",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Primary tumor (T)*&bull;&Delta;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TX",
"      </td>",
"      <td colspan=\"3\">",
"       Primary tumor cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T0",
"      </td>",
"      <td colspan=\"3\">",
"       No evidence of primary tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tis",
"      </td>",
"      <td colspan=\"3\">",
"       Carcinoma in situ",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tis (DCIS)",
"      </td>",
"      <td colspan=\"3\">",
"       Ductal carcinoma in situ",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tis (LCIS)",
"      </td>",
"      <td colspan=\"3\">",
"       Lobular carcinoma in situ",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tis (Paget's)",
"      </td>",
"      <td colspan=\"3\">",
"       Paget's disease (Paget disease) of the nipple NOT associated with invasive carcinoma and/or carcinoma in situ (DCIS and/or LCIS) in the underlying breast parenchyma. Carcinomas in the breast parenchyma associated with Paget's disease are categorized based on the size and characteristics of the parenchymal disease, although the presence of Paget's disease should still be noted.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       T1",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"3\">",
"       Tumor &le;20 mm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T1mi",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Tumor &le;1 mm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T1a",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Tumor &gt;1 mm but &le;5 mm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T1b",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Tumor &gt;5 mm but &le;10 mm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T1c",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Tumor &gt;10 mm but &le;20 mm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor &gt;20 mm but &le;50 mm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor &gt;50 mm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       T4&loz;",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"3\">",
"       Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T4a",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Extension to the chest wall, not including only pectoralis muscle adherence/invasion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T4b",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Ulceration and/or ipsilateral satellite nodules and/or edema (including peau d'orange) of the skin, which do not meet the criteria for inflammatory carcinoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T4c",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Both T4a and T4b",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T4d",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Inflammatory carcinoma&sect;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"4\">",
"       <strong>",
"        Posttreatment ypT.&yen;",
"       </strong>",
"       The use of neoadjuvant therapy does not change the clinical (pretreatment) stage. Clinical (pretreatment) T will be defined by clinical and radiographic findings, while y pathologic (posttreatment) T will be determined by pathologic size and extension. The ypT will be measured as the largest single focus of invasive tumor, with the modifier \"m\" indicating multiple foci. The measurement of the largest tumor focus should not include areas of fibrosis within the tumor bed.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Regional lymph nodes (N)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Clinical",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       NX",
"      </td>",
"      <td colspan=\"3\">",
"       Regional lymph nodes cannot be assessed (eg, previously removed)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       N0",
"      </td>",
"      <td colspan=\"3\">",
"       No regional lymph node metastases",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       N1",
"      </td>",
"      <td colspan=\"3\">",
"       Metastases to movable ipsilateral level I, II axillary lymph node(s)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       N2",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"3\">",
"       Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected&Dagger; ipsilateral internal mammary nodes in the",
"       <em>",
"        absence",
"       </em>",
"       of clinically evident axillary lymph node metastases",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       N2a",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Metastases in ipsilateral level I, II axillary lymph nodes fixed to one another (matted) or to other structures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       N2b",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Metastases only in clinically detected&Dagger; ipsilateral internal mammary nodes and in the",
"       <em>",
"        absence",
"       </em>",
"       of clinically evident level I, II axillary lymph node metastases",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       N3",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"3\">",
"       Metastases in ipsilateral infraclavicular (level III axillary) lymph node(s) with or without level I, II axillary lymph node involvement; or in clinically detected&Dagger; ipsilateral internal mammary lymph node(s) with clinically evident level I, II axillary lymph node metastases; or metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       N3a",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Metastases in ipsilateral infraclavicular lymph node(s)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       N3b",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Metastases in ipsilateral internal mammary lymph node(s) and axillary lymph node(s)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       N3c",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Metastases in ipsilateral supraclavicular lymph node(s)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Pathologic (pN)&dagger;**",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       pNX",
"      </td>",
"      <td colspan=\"3\">",
"       Regional lymph nodes cannot be assessed (eg, previously removed, or not removed for pathologic study)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       pN0",
"      </td>",
"      <td colspan=\"3\">",
"       No regional lymph node metastasis identified histologically",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       pN0(i-)",
"      </td>",
"      <td colspan=\"3\">",
"       No regional lymph node metastases histologically, negative immunohistochemistry (IHC)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       pN0(i+)",
"      </td>",
"      <td colspan=\"3\">",
"       Malignant cells in regional lymph node(s) no greater than 0.2 mm (detected by H&amp;E; or IHC including isolated tumor cell clusters (ITC))",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       pN0(mol-)",
"      </td>",
"      <td colspan=\"3\">",
"       No regional lymph node metastases histologically, negative molecular findings (RT-PCR)&bull;&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       pN0(mol+)",
"      </td>",
"      <td colspan=\"3\">",
"       Positive molecular findings (RT-PCR)&bull;&bull;, but no regional lymph node metastases detected by histology or IHC",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       pN1",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"3\">",
"       Micrometastases; or metastases in 1-3 axillary lymph nodes; and/or in internal mammary nodes with metastases detected by sentinel lymph node biopsy but not clinically detected &Delta;&Delta;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       pN1mi",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Micrometastases (greater than 0.2 mm and/or more than 200 cells, but none greater than 2.0 mm)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       pN1a",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Metastases in 1-3 axillary lymph nodes, at least one metastasis greater than 2.0 mm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       pN1b",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Metastases in internal mammary nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected &Delta;&Delta;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       pN1c",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Metastases in 1-3 axillary lymph nodes and in internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       pN2",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"3\">",
"       Metastases in 4-9 axillary lymph nodes; or in clinically detected&loz;&loz; internal mammary lymph nodes in the",
"       <em>",
"        absence",
"       </em>",
"       of axillary lymph node metastases",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       pN2a",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Metastases in 4-9 axillary lymph nodes (at least one tumor deposit greater than 2.0 mm)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       pN2b",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Metastases in clinically detected&loz;&loz; internal mammary lymph nodes in the",
"       <em>",
"        absence",
"       </em>",
"       of axillary lymph node metastases",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       pN3",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"3\">",
"       Metastases in ten or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or in clinically detected&loz;&loz; ipsilateral internal mammary lymph nodes in the",
"       <em>",
"        presence",
"       </em>",
"       of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and in internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected &Delta;&Delta;; or in ipsilateral supraclavicular lymph nodes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       pN3a",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Metastases in ten or more axillary lymph nodes (at least one tumor deposit greater than 2.0 mm); or metastases to the infraclavicular (level III axillary lymph) nodes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       pN3b",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Metastases in clinically detected&loz;&loz; ipsilateral internal mammary lymph nodes in the",
"       <em>",
"        presence",
"       </em>",
"       of one or more positive axillary lymph nodes; or in more than three axillary lymph nodes and in internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected &Delta;&Delta;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       pN3c",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Metastases in ipsilateral supraclavicular lymph nodes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Posttreatment ypN",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"4\">",
"       - Post-treatment yp \"N\" should be evaluated as for clinical (pretreatment) \"N\" methods above. The modifier \"sn\" is used only if a sentinel node evaluation was performed after treatment. If no subscript is attached, it is assumed that the axillary nodal evaluation was by axillary node dissection (AND).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"4\">",
"       - The X classification will be used (ypNX) if no yp posttreatment SN or AND was performed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"4\">",
"       - N categories are the same as those for pN",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Distant metastasis (M)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M0",
"      </td>",
"      <td colspan=\"3\">",
"       No clinical or radiographic evidence of distant metastases",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       cM0(i+)",
"      </td>",
"      <td colspan=\"3\">",
"       No clinical or radiographic evidence of distant metastases, but deposits of molecularly or microscopically detected tumor cells in circulating blood, bone marrow, or other nonregional nodal tissue that are no larger than 0.2 mm in a patient without symptoms or signs of metastases",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M1",
"      </td>",
"      <td colspan=\"3\">",
"       Distant detectable metastases as determined by classic clinical and radiographic means and/or histologically proven larger than 0.2 mm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"4\">",
"       <strong>",
"        Posttreatment yp M classification.",
"       </strong>",
"       The M category for patients treated with neoadjuvant therapy is the category assigned in the clinical stage, prior to initiation of neoadjuvant therapy. Identification of distant metastases after the start of therapy in cases where pretherapy evaluation showed no metastases is considered progression of disease. If a patient was designated to have detectable distant metastases (M1) before chemotherapy, the patient will be designated as M1 throughout.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Anatomic stage/prognostic groups&sect;&sect;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       Tis",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IA",
"      </td>",
"      <td>",
"       T1 &yen;&yen;",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       IB",
"      </td>",
"      <td>",
"       T0",
"      </td>",
"      <td>",
"       N1mi",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1 &yen;&yen;",
"      </td>",
"      <td>",
"       N1mi",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       IIA",
"      </td>",
"      <td>",
"       T0",
"      </td>",
"      <td>",
"       N1 &Dagger;&Dagger;",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1 &yen;&yen;",
"      </td>",
"      <td>",
"       N1 &Dagger;&Dagger;",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       IIB",
"      </td>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"5\">",
"       IIIA",
"      </td>",
"      <td>",
"       T0",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1 &yen;&yen;",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       IIIB",
"      </td>",
"      <td>",
"       T4",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IIIC",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       N3",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IV",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M1",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The T classification of the primary tumor is the same regardless of whether it is based on clinical or pathologic criteria, or both. Designation should be made with the subscript \"c\" or \"p\" modifier to indicate whether the T classification was determined by clinical (physical examination or radiologic) or pathologic measurements, respectively. In general, pathologic determination should take precedence over clinical determination of T size.",
"     <br>",
"      &bull; Size should be measured to the nearest millimeter. If the tumor size is slightly less than or greater than a cutoff for a given T classification, it is recommended that the size be rounded to the millimeter reading that is closest to the cutoff.",
"      <br>",
"       &Delta; Multiple simultaneous ipsilateral primary carcinomas are defined as infiltrating carcinomas in the same breast, which are grossly or macroscopically distinct and measurable. T stage is based only on the largest tumor. The presence and sizes of the smaller tumor(s) should be recorded using the \"(m)\" modifier.",
"       <br>",
"        &loz; Invasion of the dermis alone does not qualify as T4; dimpling of the skin, nipple retraction, or any other skin change except those described under T4b and T4d may occur in T1, T2, or T3 without changing the classification. The chest wall includes ribs, intercostal muscles, and serratus anterior muscle, but not the pectoralis muscles.",
"        <br>",
"         &sect; Inflammatory carcinoma is a clinical-pathologic entity characterized by diffuse erythema and edema (peau d'orange) involving a third or more of the skin of the breast. These skin changes are due to lymphedema caused by tumor emboli within dermal lymphatics. Although dermal lymphatic involvement supports the diagnosis of inflammatory breast cancer, it is neither necessary nor sufficient, in the absence of classical clinical findings, for the diagnosis of inflammatory breast cancer.",
"         <br>",
"          &yen; If a cancer was designated as inflammatory before neoadjuvant chemotherapy, the patient will be designated to have inflammatory breast cancer throughout, even if the patient has complete resolution of inflammatory findings.",
"          <br>",
"           ������",
"           <em>",
"            Clinically detected",
"           </em>",
"           is defined as detecting by imaging studies (excluding lymphoscintigraphy) or by clinical examination and having characteristics highly suspicious for malignancy or a presumed pathologic macrometastasis based on fine needle aspiration biopsy with cytologic examination. Confirmation of clinically detected metastatic disease by fine needle aspiration without excision biopsy is designated with an (f) suffix, for example, cN3a(f). Excisional biopsy of a lymph node or biopsy of a sentinel node, in the absence of assignment of a pT, is classified as a clinical N, for example, cN1. Information regarding the confirmation of the nodal status will be designated in site specific factors as clinical, fine needle aspiration, core biopsy, or sentinel lymph node biopsy. Pathologic classification (pN) is used for excision or sentinel lymph node biopsy only in conjunction with a pathologic T assignment.",
"           <br>",
"            ������ Classification is based on axillary lymph node dissection with or without sentinel lymph node biopsy. Classification based solely on sentinel lymph node biopsy without subsequent axillary lymph node dissection is designated (sn) for \"sentinel node,\" for example, pN0(sn).",
"            <br>",
"             ** Isolated tumor cell clusters (ITC) are defined as small clusters of cells not greater than 0.2 mm, or single tumor cells, or a cluster of fewer than 200 cells in a single histologic cross-section. ITCs may be detected by routine histology or by immunohistochemical (IHC) methods. Nodes containing only ITCs are excluded from the total positive node count for purposes of N classification but should be included in the total number of nodes evaluated.",
"             <br>",
"              &bull;&bull; RT-PCR: reverse transcriptase/polymerase chain reaction.",
"              <br>",
"               &Delta;&Delta; \"Not clinically detected\" is defined as not detected by imaging studies (excluding lymphoscintigraphy) or not detected by clinical examination.",
"               <br>",
"                &loz;&loz; \"Clinically detected\" is defined as detected by imaging studies (excluding lymphoscintigraphy) or by clinical examination and having characteristics highly suspicious for malignancy or a presumed pathologic macrometastasis based on fine needle aspiration biopsy with cytologic examination.",
"                <br>",
"                 &sect;&sect; Anatomic stage:",
"                 <br>",
"                  - M0 includes M0(i+).",
"                  <br>",
"                   - The designation pM0 is not valid; any M0 should be clinical.",
"                   <br>",
"                    - If a patient presents with M1 prior to neoadjuvant systemic therapy, the stage is considered Stage IV and remains Stage IV regardless of response to neoadjuvant therapy.",
"                    <br>",
"                     - Stage designation may be changed if postsurgical imaging studies reveal the presence of distant metastases, provided that the studies are carried out within 4 months of diagnosis in the absence of disease progression and provided that the patient has not received neoadjuvant therapy.",
"                     <br>",
"                      - Postneoadjuvant therapy is designated with the&nbsp;\"y\"&nbsp;prefix. For patients with a pathologic complete response (pCR)&nbsp;to neoadjuvant therapy, no stage group is assigned (ie, yT0N0M0).",
"                      <br>",
"                       &yen;&yen; T1 includes T1mi.",
"                       <br>",
"                        ������������ T0 and T1 tumors with nodal micrometastases only are excluded from Stage IIA and are classified Stage IB.",
"                       </br>",
"                      </br>",
"                     </br>",
"                    </br>",
"                   </br>",
"                  </br>",
"                 </br>",
"                </br>",
"               </br>",
"              </br>",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_14_29920=[""].join("\n");
var outline_f29_14_29920=null;
var title_f29_14_29921="HSV encephalitis MRI";
var content_f29_14_29921=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80797&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80797&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Herpes virus encephalitis magnetic resonance imaging",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    T2-weighted MR image shows the entire left temporal lobe to be swollen and to show abnormal hyperintensity of cortex and white matter from edema (open arrow). In addition, notice similar but less extensive changes on the right (small arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wolters Kluwer. Copyright &copy;2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_14_29921=[""].join("\n");
var outline_f29_14_29921=null;
var title_f29_14_29922="M mode aortic valve HCM";
var content_f29_14_29922=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56575&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56575&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aortic valve in hypertrophic cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 242px; height: 343px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFXAPIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKpalfGyEZEXmBs5+bbjH4Vi+HvFY1jS4rxbMRByw2+cG+6xHXHtQB09FZiaozgEW/XOMvjOPwp0mplEDGA57gtjH6UAaNFcpceLmh8QWemGw3C5iklEgm5GzHG3HPXrkYrH+IPxQsvBOixalf2TywvcJblUlwwLdTgjoACfwoA9DorLt9VNwqMkHyOu4Nv6jHHalutUMFrNK0SBkRmUNLgOQCQM49vSgDTorO0XUm1LSrS8MBiM8KylNxYKSM4zjnH0q08zICdnA9Tg4/KgCeiqr3gUAhGbjJC1nT66Ytfs9NFtuS5glmWYScDYRxjHfPrQBt0VXiuGkYgIM4zw3/ANakS4d1YiMYzgfN1/TjtQBZoqpPeGNGKxhiq5wWx/Ssrwv4hfXNCt9SayNsJULeUZNxGGI/uj0oA6Ciqpum3gLEWUjIOefy/P8AKla5KlgUxjnk80AWaKwL/wARfZNa03TzbBjerKVkMmApQA4xjnOa1ReDBLLgAZ60AWqKpDUFKFgnA65PI9acbw7WKx5IUkDd1wM+lAFuivKfhB8Xl+It1rUH9iHTm05lwftXnearMy5+4uOV9+td54h10aNoWo6l9n88WcDzmMPt3bR0zjjNAG1RXC+KviAPD+i6Jqb6d51rqF3BayHz9vkCUcN907gDgfw/Wtu98Qtbarp1kbQsbxJGD+ZgIUAOCMdTmgDfoqkL/pmI4OOQcjmrcb70DdM0AOooooAKKKKAOZ8aRebY3S4z/o7An8D1rI8FsjeENGKn/l0UHPB4GOp7dq6rWk8yGRWXcjJ06Z69/wAa5j4fRKfB+mHjARkYkc8My8fkKAN23RvusNwHKkc4H1pZpFGA6bl+nf6H+dWEicAK5G7OOo6042zLIQNx4LcnP1/z70AcgtvDJ8RVMpV0GnHyhjOw+YM4PYkdSK8T/adgvb3xDoFjDcPPa2sE+oXEB/1cgjdfmKdM7Sw/P1r3C4t2h+IemOq4jmsJkGDjlXBJNcF480ldY+L99YlQfL8J3ZYjk7nYKP5UAevWKwmGNo1AhdEZYx91VIGAAOgxivnr9rDWtTsdV8L2+nTTJaIZL24hjJKkI6AM46EDJ6+te/eDv9M8LaFPuwzWULsTznKDj9Otee/FLQU1nxVqdpIpl2+Er3YCDgFpBtP1yooA9X0lY49JsRbIixeUmERQFwQOgHSrEiZRy4Yn2PbPaua+FN8NT+Gvhi93bmm02Def9oIAf1Brqz09aAK2xfMO1BxgDcCB/wDXNc9IBL4/SJo8+VpzSRDgbCz4PT1A7+g6V1ROBk9K56bYPHlscKWl06Rck9QJFP8AWgDXjiB3lQ4C52g8HPfmpFjIYlcr2AznHHX+VSBehblgOtOHvQBieIZJ4NBv5bbLTCGZ4yF6MFJHB9xWX4FtwnhPTPKVo1NujAA5+ZvmJ56ck966HVYvMtLv5ct9ndQcHnIPGfwFZPgPbJ4R0iSJmK+Qqkg4yBx/n/GgDUeAiUBclAecc/n+VOIZ1ZmO5cYUDvz+ffrV3lRxk89z70zy9pkZf4ucDjn/ADigDkdStDd+OdJSfbtgtpriLAwS+QpB9sEduvftXTeUu7arc4A4U55xzWXqCFPGWjspZRJbzocd8bTzW/tGSccnqRQBR8k52oFye+Oo+v8AXmsL4g6vJ4e8Da9q1gkf2qzs5bmMTKSu8LhQQCM/TNdS6biM9AQRzXnn7QLeV8IPEuw7ZJoFhUA9S8ir+fNAHKfArw3Bol84i81ZX0q0lJyAWWUtKzMcckMWAxjj867L4qyvH4J1CNY9/wBqZbRyoJwkjBGIOeu0nBOfp2pPANl9mudJk8zEkuhQxsMdSjdR+dbHj+28zw26AFgbq3OCeg85e/brQBwfx60+VPgnqcdqqulmLd3yMOscbLllPGGAGQcevHPFyy1my1zVvCpsrxJbVbF7tZ2cEuhCqVOMAEdSfUdBXo2r6Va6rpl7pl7CrWd1C0EgJPKuMH8f/rV8P+IPhD8QdI8Ur4e0xLy5tXeSOzkjn2xvDnJJ54HOSD3oA+1La9sDJ5aXcLTMM+SrjcR9Ow4rbg/1KZJPHcYr4ki+G/jv4RrB4+vRbSixlAuYEmLsY3Ow7j6fN17HB7V9i+Ddes/E/hbTNZ0xma0vIRIm7qOxB9wQQfpQBs0UUUAFFFFAGfqpyjrjdlOBjOT7VzHw8jkPg20zHk7pNoGQcCQ9R615r8Yv2gl8D+NL3w7ZaGb2W1jjE0k0ojVmdA+BgEkbXXk45zx3PmPhH9pO80W2+y3OiRyWyvJIuyY7/mJIXJ4AGevPTGOcgA+xIV2uI+W9crwAecev51KwEmexABz1IPXpXylF+1dcI0hk8MIScFcXRH5/L/n2rDvf2lfH1zcSfYtK0+CMt8qC3dyo9M55+tAH1TqUWfGeiSFlYGC4UYOSfunFcX4Qkh1f47eO5IyClnp1pYcc7Sxd2H8q+fjq3xs1nV7PWhDq0ctsrS2yx2wCKjfKcKeoPTnNfRnwG8Fav4T0TVL3xRcLca9rV0Ly5YNuKjaMKxwOQS2QOBnigDpPh0JpPBGkIxCGLfG4Vs8I7LgH8B/Ko7yAyePLt5MbToZjYdQcyn/69ZFn4y8PeCfB8N/4j1OKxsry8uGtQys7sDKzbdqgnIzzjIHrXO6f8bPAN543klj1pFt5LFIfNlidFL+Yx24IyTg0Aa/7N92Zvhqlix50y+ubLGckKshZf0YV6jXh3wY8U+HdM1LxVbHWtOitZ9QieDfOqbpHQBkAJyfur8wGOevBw/4jftCeGdDtbmz8MTf23rRykSxK3kB845k6Nj0XP1oA9nnvLa3kSO4uIYnkOEV3Clz7A9ay9QKp4t0fpveC4XnjgbDx618oD4K/E74jzTeIvFV/BY3kuHgju5CW29QFVMiMD0OD7VlXHw4+MOnatHYQTanNcQoZIJor0sqL0O1iRtPTpQB9v0V8RCP46eDJuBrn7wK7OCLpMZIAP3gOc8deee1af/CW/HjJlkj1RF2Fz/oC7QOeemKAPshl3DDHjngcVznw8ZV8G2CgqFj3pkcDh2r5W/tz47+KiJLE6vBDCB88cAtlOB1yQM+/aqfh34S/FjXbCLN5dWNmoaWJbi8ZAxYnkLnqck9On1oA+2sdeSM012CDLcKASWJwAPevkJ7f4/3iLG1xrMQz1GxOQeCT/nNRH4ZfGnX1/s/VtWvY7C6zJM1xfZUk/wB4A5/CgD6Y8R6lptt4n8MzXF7bxlmnVC0gwQ0fXOcY4FdFa6hZXUnl2t3bzPs8zbHIGO3147V8gT/s2+L5byGC71iydCwSJmmkfaoHJAxkKP6itKT9nDxlokIm0DxBC94xELNFK8JEWMnk9uAMUAfV09/aW5InureIg4IeQLz+NeLfFnxpofivVfDvgnQtThv7671u3F4ludwjhjJd8sOD0HT0Oa81T9mnxfqBSbUtdtElYfOryvJt/HHpXq3wj+A2leAtYg1q4vZNQ1aJHVDsCRxlhgkDqeMjn1oA7XSkkttQ8OAZ2tFc27k99pBX/wBBNanjUZ0B/lLYngPB6fvUrH8d+JLXwpolrrl8GFlZ37LcMq7ikbeYpIH1K187eKP2mtT1e3mh03w9bQWStGxeaRnfcjBj0wACRxQB9eFVYDIGAc4I71ja4q/2xosjKTiSRBgcZKcZ9uK+ZV/auvXhEdz4Vh83cCfLu2XpgjtnrVHxJ+0L4n8UJZ2Ph3RBpupiX93JG32hixBUBVI5PPegD6A+Knjnwh4X0qax8W3sM32qCRGsQA8silCfu9s4wCe5FU/2ZzC3wU8Pm1V1ty92Y1c5YL9rmwD74ryTwT+zrqvieeTXfifqd0t7cusht1k3zMNwJ8x+gyoK4HTPtivpnw7omneHNGttJ0W1S00+2BEUKZwuWLHr6kk/jQBo0UUUAFFFFAHMav4A8Kaxqs+papoNhdX8+3zJ5YgzNhQozn0AA/Csfwx4D8KXnhaxS48P6bKobzeYFyXUsASQPQnivNfih8RvHXw0+JmoX9zpsuo+BbhoRCpUBU/dIH2yAfK24OcNwa9U+EvjHRPGPhWG60K4jJQt51tuHmQEsThl7ex6GgDR/wCEH8LLKsg8PaZvHAP2ZeP0rbjsLOJAkdrAiAABVjAAA6dqsgg9OaKAMq6cr4ksFD4DQS5T15TmtWs68ZBrWmhgS7LKFI7cKT/KtGgD5L0X4Ral49+J3iWw8VXN7b+G9CvJxaqvBcTStIqoTwBggk49BXSP+zR4YuP7ctYL3UIngZRaSM4bZmMN8wxzycdq+kKo2KH7bqRKja0y/j+7SgD4pv8A4IRaZ440/QNb8RwWw1TTjc2F1Iu1HmBx5LZ6HkHIz+fFZng74W6r4s13VLXwTPHNY6ZKUbUZztSRx0CHrjrjH1719X/FX4aWPxI8KafatcNZ31iPMs7lBkI20DaR/dOB9MV0nw68JWfgjwhp+h2GGW3TMsu3BlkP3nP1P6ACgDzL4PfEbUrHXD8PviQ/keJrcAWtzJjbdr2Xd0LY6H+Ie/X1u7uI4PEdmsssaeZbShVZsE4ZDx61yvxe+GWnfETSohJJ9i1m0y1nfouWjP8Adb1UnB9QeR3z4Dd/s/8AxAvrqC11HxJFIgVkhmluZHwBz05IB4/KgD6+orxP4NeJrrwjZat4P+JWswxavo7+bbz3MuBNZso2srt9/BDe4HHavXtH1aw1mzW70q9t721bpLBIGH6UAc/418bR+HdT0vSLLS7zWdd1Pe1tY2rIh2IMs7u5Cooz1J5NYvi34qab4L0HQ7vXNG1Kzm1B3Q2KohktkjOHdsNjYMryCchhWn448E3Ou69o+v6HrLaLrumLJFHcG2FzHJFJjcjxkrnpwQRjJ9sc7rXwhk8TXzXfi3xRfahJ/Zzaen2aIWoG52Z2YKxDA5UbcDhBknrQBo+OfirY+E9dl01tI1DUvI0oazPNaPDsjtvMMZb53Xcc44Gc7h713um3kOpadaX1tuMFzEk8ZZcHaygjI7HBrxnWPgHFr0didd8Qtd3VjoKaNb3As9rRyxzGSO4/1hyQp2FT1BJ3DPHqOhaZrlnepLquvpqFuLKOA26WKwgzqTun3BifmGBszgY4oA5DVvi5pemeKr/TLvRtSNvp17Bp9xqKCJo4pJ1BT5d+/ae5CnGPpXo017awSCOe5hjcjIV5Apx64NcHp/wr0dPHuteKdWEepXN7dQXdrFJGyraPGm0HG4q57glRjtV7UPh5pniF7x/GiW2uu920tnIbYW8lrbkALb74yGdVJY5J5LcjgUAdX/aVj/z+23/f1f8AGvNPi/8AGbSvh1JpCG2TV/tryLKlvcqGhVAvJGDkneMA4781uQfCTwFCQU8L6ccf31L/AMya8s/aD+Cc3iCPw3H8PtE061aGSZLrywkC7WCFWY9wCrDjJ+agCa++JPwo+I3gyx0vxLq0tgkNxFIbe4idHBU8AsoZdpGQSD9cV6breh+HL+38NTWWnaXLZT3qSwtDAhSVHjdsqQMEEfNnvXjXgP8AZZ05ES58ZavNdyByDaWI8uPKsRguw3MDjsFNew6B4E8M+CrjTLTw7ZS2iT3rS7GuJZV3CKQ5AdiBxgZH45oA318G+GluWuF0DSlmYbSwtUHH5U2DQ9L0nWLGTS9Os7MsJEYwQKmQRnqB7V0FV7kfv7QgDIkPUf7DUAWKKBRQAUUUUAFFFFAFfULK21Kyms7+3iuLWdSkkUqhldT2INfL3ir4Y6/8LL6bxl8LJbmQrNJbz6cY/Pxb5z9WTKLnuOCOlfVNQWW426lxh8nd9c0AeDeAf2kdK1SeCx8X6e+jXj4Vp0JaHcfUH5kH5173a3EF3bxz2s0c8Eg3JJGwZWHqCODXI+Pfhv4d8aaVc2l/YwQXEwOLyCFBKrdjnHP0NeCxfDf4tfDWdf8AhDdTbVNLQ7jDFLwwA4Bibv8ASgD6hu4i17YygqAjsDkckFD0/KrlfN+iftD32n6rFp/xA8OS2E0akO0KsH3cDcY256Z6HnNe++Gde03xNolrq+iXK3VhcqWjlUEZwSCCDyCCCPwoA06oaY2651M5z/pOPpiNKv1j+E5PtOjreEq0l1I8rMp4b5iB/wCOhR+FAGjZII7VEAAC5GB061PTIuY0OeoyffNPoAKq3QX7XZsysSHYBgeFyp61aqCRgbqBODwzj6jA6/8AAjQB5x8XPg7o3xKvbG9v7u5sr21jMPmwAHfHkkKQfQlsf7xry6/+AHirwpcfaPhz4nuFRuWieYwODgc8fK3I719P00siMAWUM54BP3jjt+AoA+a9N+LXjj4eXcNl8UNHludPb7t6iBZAB1OR8r/TINekfDv4w+FPFUj2cd2dPvd7MkF4PL3qSSMN0J9s/SvRNT06z1WyltNStYbq2kUq8UyBlYfQ149rfwE8K69pqS6araRdmUymSDLr1Py4J6CgD2uivn+2+GPxJuIV+3eMGHlYCIbuU5x1ORUd74f+LPhFkv8ATdWfWYYiPMgaVrguO/yNjj6HNAH0BMcNEc8b/wChFRalfWumWM97fzpb2sCl5JHOAorwhfjH4p1WKO20zwkx1DzAqnD7XOew9OOeTgVft/h7408cNBcfELWjaWO8M+m238W05XodqnluSCf6AC61+0b4atDKLTS9UvIlfy/M2qgbjtk5xz6VmXP7SdvLbS/2V4Xvp7gZCq8oC+xOBn8K9k07wZ4b062it7XRNPWOMYXdArn8SQSTWlBpWnW8okgsLSKQYwyQqp46cgUAfPml/GfxsLhkPhIXMG8ufLjkLLuy20kcetd74R+Idj478ReH4tMhmiubeGe4v4JYyDbuFEe3Pf5nIz6enSvTraNI0YRqFUuxwPUnn9c1m6d4b0jTdbvtXsbGKHUL0AXEy5y/JP6k5PrQBr0x1BaMnPytkfkRT6a5I2gdScUAKyhlKsAQeoNLRRQAUUUUAFFFFAGZd+INHtJWjudUso5FbayNOu4H0IznNZ+jeMdB1ASLBqltvVnJDuE+XdgHn6ivkP4hR3f/AAsDxIyM6wDVLnO7jrI5wD+HasLSrS/uD56BpYWBQryA2Dnj0zQB9xXHivw/buUm1rT1YDJHnqSP1qjdfEDwparun1yzUbgudxPJ7cCvi640XU5lLhNgVQ2HOc549eo/WtjSdEvnEiS2zgkFSrYG/wBvY9/zoA+g/FPjr4c67f2cWpfYtURRIGLw5KAcZBOO+a8Y1azv/h/rEmsfC7xGZdOncz/YWJ2xK5LbHQ5DhQcZ68VgXnhe4VYAzJiSQowj5I4wAT29RU2p6PqSBEtYcBCN4VcliB97jpnNAHoWnftN3K2zW+q+HV+3lGCS28pWMMB3VgT154Nek+CfiV4Zs/CmkWd3qG28htIxIojY5YABsHGDz/OvnBfDlzHHEl3Cxn3mVSyfdHrnr65HvXSt4ZuZoYp8I0zoUDDkfh0yKAPf9O+LHhW7SE/bWjDqWDeWSuB7ipZ/ir4SiRm/tLeVwSqocgGvmbS/Dd2iMYZfKddyJlRubDYOR6cVcTwvc7ESdfKjVCqyEjBySdx9un/6qAPoab4t+GERmjlupipwyxxZwe2eaz7z4uaJlJIoLx4lVvMZeNoIOBweuR+FeJ6X4XuEkbzC4B5IDYAX+vStK98OE6bAEZkgd+NwI+XqeR15GfXgigD1uy+M2gzRt59texzdUjjUPuXsc5GOQR+FJrfxj0fTrVZUsrqV3cIithckjrnn3rxaLwtcieNd8mzLFXLYUBu2ewzgHkdAall8MPeLF9qvHd4y2VbjjHG3HTHH55oA9KPx2tWkl8rTAYoo9zsZuA3HGce/41U8M/GQxWsEdzYI0bSM7FXw6ozE5x0zyeK81HhULDNHvnkjeEM4KEbjk/N0IwO3096NF8LS28cdvHKXSNiNxzudTnaWUfTPWgD6Bn+JdkiZisppWK7gokAJ9qo3/wAUfI2+VpbFmXIG/cc88cD2riE8OptknkLoTHtY5IGMYPTv6fWrTeHfNgV0k8kKpUDk4OPu9c89cnvQBoX/AMVL43NniyhilRizKe4xjB546g1LbfGOQSyxzWMEzk4j8pyvbJHPXtj8a5DUfDJa3gZ5mY+dh1zlj6AcdOtWJvCapBBcqhZANsrD5Qy5449cZoA3Z/jVdrKYYtHiaY8hd7HAyPTqeazbv41a3I0i2mnWsbq6grIrfKO/OefXj1FZFr4RT98xdikqbztBK7TjkD+lJd+F7fyWWJXRIwNrD5iemSx9xx6/0AJZfi14otbSOOM2qE7n3eWGJySe/AGf0NW/+F3a/HZQkadZSSbFLSPkDOMHODxzz0qjo3hi2njEcyOIGfadnJ44JUHqabqnhiy8p7e3iuUSR2ZQy/OTngZHoKAJtV+OfiEBFtrTT4CwAZnVjtYnoATzjBNVJ/i74olaKSaeG3WBs5aJRvOCucf0NZ9p4GiWZEmw7KzKoYFucc4HTH49qS90BWt4WCzCEMnKoQEzwcnr/LFAHQWnxi8SQSYuhbTSOCqI0OAM9GO08n9K9r+HusXev+D7DUtSWJbubzBIIhhQVkZePwUV88ah4SiuYkm/fiTOVBXbtAGMZ9DzzXv/AMLIRb+BNMiUKAvm8KcjmVzQB1dFFFABRRRQB8reIodP1DxHqlz56Ol1c3E0JZT8ylyynBwTx2qpplukscItHVYQ+U3KAML147DPTvXl1v4juru82RyBHjyQ7v8AN+f48itrQdeuFikieZHfdiTA+Xrjv1zQB6lJZIIBskG7azFcDAI7H1/zxT7AxOyLI0kkrpsZj1X8TjIrz6PxDJAWNxNwxxE2MFOvBxwRUkXi6QXG66uWV42EblcY59P0oA9A1SKFp7VoZWWQSAoFH3zg5z36elWpLUEmSCVWlcoTEzAcA8+9eX3/AIot21S0C3atcgsjAZUMeg5P1/StWXX44hbIs7AIqvlxyFI656eg9etAHoH2SO5uA6tIkIkYbhj5eP8A9fSrmp+Uq2dyt4Ad5R4xkFegX5gCCDyc9sc15XH4lV0nBne4kLtIiiQgOPYjpUV34uWNrcW7SSAKU24+4eR+XrQB6Po1sR5TSThCzSuh2Z3jOMgjqvPXpnB+urdW9v5IaZsMTuEkR+7njn2PArynQ/EQW0QS/uiqEsYHzjBPI/Ec/XPrV+78SRw6ak1vO7qnzySM+SxxnkHnBoA9Mto4rSNlyXIIJMuNwHsP89arauLWwSxWMbv37FpMbcjrnjqfwrzPTPEV3LAt04lzI+5QW5UHGevf0NP1nXLWQWyRJI7vKy71YgpkDJ/HP1GaAPTXuo8ZSSNC4IRcZPXGcmobm7tooo4sYk+4pK43MAcj1ByM1wVlqcuLaR4FheRvKc56L/dz78evX1qp4h1658iZ4CFb5WO8DL852genHb+tAHf2uowJK5U9HUmMKBz1yT06n2FZXh51+0XUZhjAlfd5mScseM55HOODXFnWLuO0kT9+okYKUlG3Knk+5GcYqDw/d3ccCSkuUjY7WJwBzjv1HHXt+dAH0LavZsixTlceXjaWBJb6eg6Zp9zPb29i4jCM2wBcdgfSvJodY1Bovs/2ZQoIUtnDgMeRyOPqefpV/T5r+a2jhuZJXaMspbJyAMcdec+v+QAdZe39t9kVSd6rMqxptwSRwf05zWjb6nE5InMOdobcvTBJ6e3rXml/foht5I7d2zIMqi/KR7c896dDrFxaukklsCXh+WJiSx7bfbgjp9fqAejS6naRK6uV3NHnejBgcE7R+PbjtWUutx+cyIiklcuuO/HI7A1wmsazPHNiO2uS0iq4jUcxrxnk4yeRzVX7ZetKUjgEZlHlw543E88nvj8+aAO30nxBGl9PCsb+ZFKx3+UMKODz9RjgZrZuNct1TMDo+3MbMOdgJycD3GeleP6Hd6oga7jALF2EjKoDZHQe/wDnritCHU7yVDbrZkzEAb0XLcfhjpnoaAO51LxDGkixRyRsXYvsQ52jHOQOw61jeJ/E8SaWYYWkEgdCHhG5kAOckHg//qrg7i+1G3leZrVpCFyrd0A5Oc9c9B9KxdVu9VuNPhYo8UMrruHGXYnAU9wT6++e9AHqo8SW8gi83zXCK3cDLY6HPXpn8K9x+Gs6XPgnTZozlW8zBxj/AJaN2r47QatYIJLy3DRM2PLMh4OP4uOnb8DX1j8EfO/4Vhov2mMxT/vt6EYwfPkoA7miiigAooooA/O/T/DgdnAVfOkYKwx0pNP0LZHKN0lvMsgYlgFIPuV6f/X+teqxaMZbndbOwAJ3OsPGepwQOnrTdB0x21DUVSQMUmZySgLLkdP0oA82bw4zotwUn8tsFWDAc5GQev8Ak1s2HhEysz/Y1Zc7Dn7wI5/Hjv8ApXcyWkrMsccSyMmeUGQSc87RjP0+v49j4a0+2uLBm1K4linRlEZ8vJOTxkf0oA8iXwhDHfWNxGsk4M20K5IG7A7HoKuXfhVopjGI5BOkhUgKMZXv9McgV61rljpyx6KYPtLRLeKuHi27icn19c8/41f1iGB4VWKKUukgSRTHwpzjnHXGMZ9vegDy628KxCzEcEDecPuOw5YnngevB4qeHwbF9jjK2HkE9QrH5mJ9+cHBwc45r1HS7WxW5tYJbW9csVIdcAYH+1n16Zq7rNppZ1A+RJdsFUFV+9yRyDnj1z9KAPFdP8LvJHLLFZbWzLFu24P3xg5HUdQR9TxV6y8MMdkjRoxjOGdAQSD3HqOn4V1+jQxmC6iuRLEUuZDv2kqee46j+dXdONvbwSpK87SFiRIFIZsdW9hz09PpQBzM+kRSWpkmtFjIfdwuSDgfl79qG8NRR3FtIEjxI+YwQMbipydvcHv7iu6to7cWjM/lyfPuDr8wdj1Of8ah14RyQxXccEsg85AFAO7B4JyeDjmgDlNT8LhZI3jijVH+6Q+fL7EHHrnp9e9K/hpUjMjQoI4lbtgDoBnvzxk13DW8MyCRbY7FBYpGuVL9uD3470T25lhacRuckAZY4Z/ugkj6kGgDze90gSTTz7YlVI0ZkVQdoHQjjkfT9MUvg/SZBYzxuEkWCVtrONx25OR7AkY6f410VzaXAaeOS1QyKjIAwLYbjJxj5l9h78VU8KWbM2pRMkTETtu2nJwMFQpPRCMHjnn8aANa38P/AGuC4kiSKKct9xBkKduQrHr0wc+hxVuHSCIdiJvCqF8wkgAn+ED8hmus0DTPLZbktvEkAJL5+T2x0B/wrqraySGF1Z7eQ92ZQNo+v40AeJa54eK2lqGcwslwCSykDknIGOvf2/Grsvht1jcowJTKiEqWY45yOvPQ/jXoHjXTXu9IjmFxEuy7iKkjKt+8AwRnkZPTjpUj6Ldq75uUmiZWBYoA3Pbr09D70AebT6I8pl2yK8rN8iunGM9SO/r+dQx6FI9wWn8+R8EltgJJznAHQcfnXo1pojvvtoL6OKYncVWP5QOeOvXrnpWXrWmyaJcpG19cytMfMysZYg85PHfg0AcPoeg+bLdOEO0TMmQnlllAzwP1+vNOs/C11EZZjJOPLy7BgdrdeB14rf0Ly7vVtQWZp5Q03yIA277oYFvzBx7Cuu05JobK6glvHcgE7SoGenfrj+dAHl50dZ5VSRZEVcOyIuSB7k9v/r1h6tpNncacjBpFaOQkHARUOecDHXGMeteiX+nXmpSCdLj7M8b8GM4PBGcjHTArB8UaI8UMstqG8q3ZZArnG5j/ABDpxz/+rigDm9R0ZBaRCIbZVGGaUk7u+Pb1r3T4URmL4f6TG0TRFRKNjAgj96/rXkCRXhg3QWwZnUhSXBCkZJ/z9K9s8Awi38IadGDn5Wbrnq7Hr+NAHQUUUUAFU9avRpuj39820rawSTnccD5VJ5/KrlYHxBKDwF4lMpxH/ZlzuPoPKbNAHjOkeJdBtrWSSNGeQ8qof7xHTj8+a5bRvFWkvqmrvdWgS8mmyg6IQOOB2OMdc1x+myW6S+a1sY7eBNqMwIByeoPvVCxnikluTPascOWLIPnYH0HfgUAett4m0qzDyny9oGSzt8u4Y6449fSq48YW0Vw282iOMHy0JVmB4HtnrXGzX2n2unxCO0Q+amPm6qfcY68Vzei3tvdSzEW2zZLmbcmWOOgGP5+lAHrWpeMvtraYXWY2/wBoAZU4I2gkFewBIFdlN4w069gt7ee7ZWuAGJCjch2569xnFeIy62w/s7fFI0Rl2xgHABA4Yn39Kdp2s2aPLLGzGRXDFJEA2A9xn6+lAHtulavoVpNNvuhcMEO8uPMTOCM4Bxkc8Gsiy8a2kUe1fO3CQmPdEdq4bqSeec9SOelefvezLG8lgk8AkcDeOSxz9zgd/U9q6to7q3jFxJC8aGUxsm0bhnH3B6Y9vSgDS0LxHbQG9uWjMaXNw0zwhcquWAwo6++Oh7U+31ewSKaaOQsVl2hSMEbj19fY9/yrlbE/8Si3V7ZhAtzIF8xyzMQT14zu6cfhT5NXWe3klsIEAlOJDGPm3AdOmQRjOO9AHU3/AMQl06GOyht3lRjwAgBIycDHcdqoah42/tOzt7eO1cp5oO8ANscc7QM8k+vIHvXH6mlw8ckTRMkMRQ7iBg59CDwc49CO2angttTthbwSxYZZAV+XsRngYzj6+poA75fGptYxGkZNxDlW2rsOOMDPc9O3r9Kp3vjW8Fi8drG0ktw+1mzwR0K9gTxj2/Q89O95HqIin3N5yLuwOp6nPH6kfjWkbe5u7JoY28own5ogcnJGCM9x6n3oApz6zqz24ESSCZiEaYn5sEDk8YxkD1NZXhm/1Fru5uJLYANOTJhyrK+OwA6H+p6Vc0y2vWuLqGPe8/3Y9xCjkkbuQc4HOetZWg/ara6vJlhmRhJIUKpyoI+YkZyc44B+vpQB6zZeIFms47eWMiY4YrnlTwBu7A8n1qvcavcxRN9maQHbypJZs8sAOffr+HNc7ZmeaaMMmIo4ACRHj1O0NjIP61Z8Qw39naxG0Q7ZW6KASoz/AC6HNAEd7ruqvo7RvGPLmnSNVbkLg8YB6+v1FbFrquoR2abNzu0mCpfdwcZX8Oa5rVYbmPTbCSIxuWKkMp+4x69Op69afLJqkOYo5ZGjyRIEA4xgbeo9M+vNAHTHxHcQRjzUZJgnmKAvIY5GWwcn2HJ4qW18VajmO5uLuFXB2LLIvT16ZwcCuUW01OaAThnIclfNLbS2D05Oeh56mq0ek37tFp0bKrBQBuJAUk9tuevr2zQBtaPr15davrM7GGV5JV5jUDgDB98+5/xq/qfiG4v7e1W3igNw7ZPJCkKMA59T+Vc34a0bUoxcwl44n80q4U546Yz9a27PTjLZme6m2LbAb0jXiRvQe2Of8OtAGBqmqeIlsrp9MES3h2mLzC3l7NwV2Ix2yeKytY1O+/saSKKWINK4wzrgljwcDk8c8ECut12ygJtEjl3l+rp1B689vw68Vi674VlGn390kqRy2xjlBJyzgnBA7Fjj8KAK1rK0AgSHUsOo8r5wMkYweR7gY49ea93+GDTN4G003IxLmUEZz/y1f+leCX2gG7tLRbDzYryXLTKkeSeBhMduPSvd/hRay2XgHS7e4Vkkj80FXOSo818An6YoA62iiigArI8YxLP4R1yFhlZLGdCMZyDGw6Vr1l+KpIovDWqNcMFjNtIvJAySpAA9ySAPc0AeB6TpCRaVPFc21sLYOrdBvHOBkHnPTmuRm00jXNR8sQ4Mrb1hJBxs4I/wr1K48NNfaZd6lexGMuE8u0LfNIM4U7RzyOcDmua0/RWbxJfpAiko6ibjcqkj7oPqOQRmgDnLTR4Z47YXFuFWFQVLYbHJzkfoKksPCqW0kp2SLbyOWDBwq5/n09a9M/4RCSG0EyzQXEZUSFC2fuHOBkcEelU47Kw1bVorm0Nvds8kTrbSqSiYPzMT0LDg80Acjq+nxaf4d02VNPdo476NzI/Kn/cz057enFTJ4HEM0V7FCsMbjzVPlYG088jBGPf+Vej/ABWspoPDT28FrAmkxXEMitjcd5bGQB2yRWToo8UeINOtIgQ9kCIXdAEG0HlfXGMflQBhW+nWSQwR3MePMJlZtmOAMHA/HNa+oWVzPYmSOY3DvOCnyDoB1JzgAjjmtG0t7abUDc/YZHMMzx+TtwB5ecknvnB5rb/s6FhdfZYZY7RcYQqF2NgfdJ65yc/QUAcloGjSnR9UN1CjRG5I8lmyyH0C+wwPfINV9Ns7G10yaG4t3abzGAcjOQec47fn27VPozuLvVrZCjPBe+W7gjZkgfKR/CBxzz0rduJrG2ggjuybe7L7ZNsbHdyew6A469KAOd1K1hfT4IFgwCyuQ7ku7H+L68Y9vStbWLGzudEsrxbZkv4bqKPy8Elu2BnJP41o2+sW3kzwCLzJem4j5dvAzk9Pxz2xVTVNRxGrRoVVZ43ZgcjGfXr+PtQBn2OmQRvJNOXWQ42YOSig/MPTPBGe1XtJhj3yl7jDP+7yoBXk9B7Ag/nVm8miXWfMDsMJ8wwBtXv9evTrWvpNhbmZZYXj8qciKIucbNgycdDz6f5ABzMWlWJ1aM2waNMHcVIKtnPY+uM1VXw35c2oyIX8xLsh3GDsTCnGff8An+NddZx6Umt3nlzJBfW8i+UzvhXYjLKM84BzxWO7yQavq0VxcxyWMkkcT4YHLsuenbkfpQBd0e2s4IXkuBhnTCJjkEnqCeD0ye9bknhOB0V/MLqqlig5V85457c1ZtLiyutHeNIgkliMNHL1RgMk/lnmnXZhspNMaO4kitd+9kOTuBHH5HH50AcV4r8NC00kSxIsIaVAAQARyOf0Gc+lMn0kzx+YtnKjMGUGEenc+vOPyrb8aJrVxp11OjRrBHPiNVOBs3YDHPX1NbljLrNvcyWjWdu0SDcro5wQeMD05BOO2aAMm3jgHh62jiMUM0fBTdypzzkDv71WtPCsN3N5trwAzMJd3GT+p/pV690xbK1t4nYS6ncOWLs5wOc/4DtW5daddSWUK2d0bOdF5EYGxj3yKAOT0uzl0rVdQ+22yyWkciKxOD5m5cgf1NJJbTySRpJaFbVJCPNJABA6cd/WoNJ0q6uPFOom81SNvJijllVCSrHB5OT6Dr/hXZw3C6jcX1uZontCo2lG+YHGGBB6jigDgJ7UbL1bmNnVHLxo0YBK9QfoAO/rWT4omuriFy0fkQTIuG2fcAPAxnHPJAFdf4iWcyOkW2eG3jQB265J68HpgVha1IZvDd60qMYlXdEOEKjIOT3GCP1oAfoCS2N6Z5hGxQK0Yz8yEjnjr/8Aqr0Xw7OLnR4JhH5e8udmOh3nNeSzatPpy2s+nTRzyqAzIpJIOOMnPPc5r1Pwfeyah4dtLqbAkk3kgD/bYeg9KANmiiigArC8cRQzeF7xLpykGY2dh1AEin+lbtcf8XbwWPw81a4ZwgXylLHoN0yL/WgDitRluIDBdRXbCeVlRJQOEjUg4OOh71maN4g0bUtc1W3luDJbxSyTTTJwxGF5GOvOa8iu9T1C6uIyLxlikfiNPuEjjPsOnH+Th6VDd/a7+2glUmWU7huIGcfWgD6auLiw1n7Lb6bdJHpUTjyrh8Bj8uWB79RXnKeKbrw/ql/awFRBKAodSCrLnjvxz/OuCMVxFpiSxXxjictHsB3AHHT1zxWZJqkl5FJNcFBBahLbyclWkxyWBxkgnrknt0zQB7TqWtanbS2d412t4lzex3VuFkX92wyo6849j29a7G01DVbh5DHqEVtaSkH7IsijykyN4XI4wMjFfNUpvINKM6NP9mS4VgHBGR7/AE4/L0rp9W8QWV1oelx6I1wNSZ5J7rcwXK56gjoD3Hr1oA921PxKsgbTtLjs4LNUUiYOGZYhy2B6+n1rI8ReIo5dStNSjkmeEb4ns/MwDj7rAdRx3+ua8o8Mwzr5ULztDPNwZXJznPybcdOOK6rwjp1zqeoW8TSqk6zshifqAy9Se4JH60Aa/g1oY9GnuJUcEXciNyCSrEHPbjGcHnpxWnqmuFo2B2E7uOQSgIPOQeRgVwVpq16l1qtvFsZRdSQKWJK9QAfpnP51ZmutRitJikZWYTEJkZJYYyeP0zQB1llaR3dtJNDI8kMEgSVkGGbPRSfXrnrUusW8Vg9gySM1uJgTjIVRt+62Pfkf0rndBj1ya1eOIFwG3L8mwqDznOcMKPE2saygt9KlEccUki/IOCwx7c56dO3bpQB3FmYrmFjFkFwAnmZwxAyccdMfkD2ps+vafY/YzJCB9jAkKJyHbHJ/+v3xXKQ39008NrIuyKJJApUkenQ9c+vrxTdY0hZWHlZkPMiuDgAY7Y44AoA0b3VNFupDcTwyn5yyxMc9SMHJ64z1qva6rZxyXsbwsUWceW+3PyjBDfXoD161FqdjbWdzY2k+4yvZLKXGc5YZCj355+vNVrS2hniuBBhZ2YwhsDPTOMcY9DQB19rq1hp/iQTzSI0UkQAlD5MbN/ERnB71ZvvGkM1nPbxcT2+VjfbnzF4H3T0yK85sJbnUtSurNEVRO4j69AAeF74456VoW/hvVDp97LaLEpRChL8qjL1x6ntn2FAHRvrOljQ/NutSuJpDNEXVXPlhSwGB1x0ro18d2dvaz3K3LSwbiqJMuHUgd+nHSvItP0+4VZJri3kkM0iAkrlUCtgtk9ue/oKJ9LvTI620cTQl2dJXj3BUBwCw655z+P1FAHqkHjTw5d3Mt5d3Nw90oVDCoz5XfZxjJDA+9cl4j1iOS9mvW1CWVif3YcgYGQQeOmCMc1hJ4Y1MMrFWUjBWNF+/g/K2T1459ulab+GNR1GR76G2dI5R5bjbtGV4K4PH4jvQBNoLR32pXUkks0Y3iN/LwCqHkKwPJGT1Pr6YrXk1nS9EvCmitLPIAYP3g7Y+Y57nNYulq3hi+v7W5sTJc3yIqKD80TOBjJz6ZP5Clbw7d6Ube4jiaSSS6WNV4UYZSd2Mdu596ANGPVDHCsep3LW1s8bMgXIaQk8Aj2wMd+KreKZVXw5cbWknhdM7c44J25J7Hvn2q02ma5qFhNa3OlOZrOR2RiOTwCpBzx7dTWHqun3h0y9iuNlrcR7A4AGXUkbsevPU0AV7PVoLSCN9im2jwrhX+UAH8Oeme1e2eAbhLvwlYzRiMI3mYEbbhxIw69682034a21zAmox3qwWUilnV87QwPGB26kfhXqPhHSf7D8PWunCUSiHeQ47hnZh+hoA2KKKKACuZ+JVhb6n4Lv7O93fZ5Gh37RkgCVDn9K6auR+KN3cW3hby7VCXubiOFnDY8tc7i2Mc/dxj3oA891b4d2tnptndeGrWS8mkbyhHI+FGOjfXrXLap4IjvNam06CAWFyLeKaSJcHDLndk9s8dK3fDWuXeq+IG0a7uZrSxCLLEBltzIcqQe2484pqaZfX3xI1Mf2hLDObhI3l83KgYB5HHXOMDigDiNO8LX1zqraZGGYodq7h8hJb2HXrWl8QZvCPhv4n2mhwaPpraDBJbQ6x595N5yvcbtrIDL91FCMxxxuFegeNPFur6Z4th0mz02CCMoQZsB9w9ScZzgYxXb33w58J39trEF7osFwurzG4vHkd2kkc45Dk7kHyjAUgDsBQB5nJL4Jj1n+xx4QnbQo9YTw8dQ+2uSLxgGC7C28qCVG/PXtiuYv7zRLXQodW8LfDgpbz6smmNc3V/lJiZjE6oBMHBJHBYAAnvXtMvg/wdYeLdMvJdOI1meQyWxLzOjSxR48xlyY/MCD77DcfUmm3XhvwV9mi8DT2yhLkvqkdkJpg+RLuaVZA25SHbsw68cUAedPf+HdD8U65FJ4eubjVIrzTtMs9PEwCrPc25k2eZuxgfOS7ZxjjivQ4BF4d8J6l4jk8KvaalawPJLYx3ImZ1jJPyP0OQMjgHsav3Pw88L3UeoLc6X5pv2t3nd7iUuzQIEidW3ZRlUY3KQT1JJNbOiaHp+iaUNN0+Fls8uxWaV5mYsSWLM5LNkk9SaAPHrvxl4Tu4NR1nTPD0d2kd5a+XcPe+StzPNCJiEAySyjblFUklunU1HpnjqLXdd8N3+k6K6Wt5YaldT6awBle4tmAVVbtzux06jIFd1d/D/wHofhBLC6srbTNCsbn7csr3skHkTHjzPO3hlPOPvegrV0HwD4a0G406bSdN8iXT1nW2bz5X8sTNuk+8xzkjPOcdsUAcIfjH4efw7d3lnpVzNY29tZHEcgXdPdcpbk9ivVj0A7HjOx4XudH8f6TqGq3XhmaHUbG4eIwySsPNZVUqUkGNysMDJA5ByKdpOifDhNH1Xw7p1jbtp97qz215bKkzj7aFVyNxyUIAUgghR2wa7Pw54d03w5ay2+lRzrHK/mOZ7qW4dmwB9+RmboBxnFAHjL/ABY8FyWi3K6FdPu04X6IspG64eRUa2HP+s+dT6YJqXX/ABvfWEssWn6NHqLxeJ4dDaC52KsSSxruSMqVyTuIDvnHfjFd5d/DnwLpmnvdXGjQQ2llfvrrMZJSI7gDLSY3cjCj5Pu8fdqwng7wh4k0WW6jsvtNjrNxFrJmSeaNpJdqmOZGDBkO3bjbt+nWgDzXTPGkum+KNVj1rw5LdaXb69Do8V0lwgFkHjQIhTOZMM3LehHJ6V7H/wAIvo/2y4uhZ4nnOZGEjjPbpnA/CqJ8A+GjBPEdOJSe+i1KTNxKS1xGFCPndnjavHQ45BrqKAMpvD2kmdJvsMSyJyrLlccY7VzFjpNjd6he2P72BYZnJkEp+cZ6Ak5yBxXeVwniDw/Zm51WW5uprWGdVlDjIUPklmyOemP88UAUPF2paLBpF34YW3dUaOPyXTkP82SxOOxHXkHNZfjLQzohs1tbmU2zkfMU4XgAA4HJJB/lVqOXQL3R2s4WmkubaJzb3DrtMz54UIeSemAR+VdXp9xrd3qr22p6dELBGBWQ5BbjIPXqMgfgaAOO0PxvfWdiNPhsvPuY2IjMnA2Y4A6H/PNbvge6v9eur6bVZhG8EpWK2VSAo9evP/16n1DwP/xMnvtMvEtZQuVzGOue57D6CtjSPDsOlQPKhFxqbF5GuJMgs7Dn8PagDFvtK0RLvUY9XcSHECiR2+ZWbIBH0wDWcugyRa1HfNIbnRwSVmYcxrkYI7nBA/Kui/4RuyvdY1GW/Q3Dzxx+Z8x2q2GBAGeMDaR+FXrmW20TSoY7hCyPtgbYc8YxuOT0A60AZmt67PaTW7rH5ljck7TEAcqB1z7159ruqQ6LFqc8irOoX5SegQkfLkg5xUfiLxVdWV5b6fpKG7tbWVwjSckDpjjrxUWqaIL/AEe4uL2BIJApZlBw2fTkZznpkUAdDdapp2ueFDc2EywxMFeazLd2GVGM/XnjH616B4WuLe60Czlsxi32lUGScBSR3+leK29qugWIuprSaXfEphjIzz09PnJ7e/TvXr3w+tbqy8IWEF8nlzr5hK+imRiv/jpFAHQ0UUUAFch8ULDVNQ8PwR6IGa5S5WRgvdQj/wBSK6+oLjzfMt/K+75n7z/d2t/XFAHzzbeGNV0mSw1PUY51/wBIEojcg7ghzjHbPpik07xRLqGsa5q0FqYL7zPNaGQDKLs2gc+46+/Sum+KGr3/AIfvH1EXSsbdy/2VxuyD0IH5muY8Oa3beKrzUb62WKPVbtFgUWwxlhk5K+vb60AeleBPD8dzoFgdYT7VdyxyTSSs+7bv/hHpjNcb42+H3iHW/Guv6tb2968b6tpb2EsWpGILbLEqXRVRINvQg8Bj/Dmt/TLbXtO0rUdLWKRru6wqsjkLGTyTnqMgn8a2/ht4V1jQdMuo9Wvg7XSgGNXLeUwBGQT655xQB59pfhjxF4b1fSPOuBpeiWOta00MtzqKGOG1mhK2hIZyWG88LyQeSBVH4UeENak8R6dfwwvp7w6RcWd9rUGo2180928qN5qgs/3gCfmXjoRwK7X4r+Dr2806zu7W9aSO1KLOkp++Cw+fHc9BVS+ste8JznSfCxSTzZldYlI6HqcdumMn0oAyfi54I8W39xpclhPfa+1pbOGnvpLaK23M+cyRq0JQquB5iAnHbIyaWl295d/HOTQrfWYptEhVPELQQXZI+1tD5YhVicld2ZQORjrVjW9R8V+HE1CTxJ5stlqMbRIA+ACflxjoMAgDkZrb8La/Gmh3Guf2W8k2kw/Z7fah3PuONpoA8xPw88R3HhzxbpF3BALiezUWx1DUYheS3ImV9rGOZkcbQfncIcleAM10/iDwj4h1W8efQrCWFZ4LKHRrg6wh/sKSOQmYPiQ+YWHOU35+7WFp11rV3+0WNN1SV4YtR06S4msixVWbynK5HY5A/ACvb/G/laL4PlisVKmyVXV8fdOeT9cHNAHn+maDrMHiRJIXhSGfxzcamRHfxfvbRoAgbAfLfMMbPve1afwz0i68J6pCfGOneRrEhuI5/ENxq6GPUHeQFFSIvuJIxgFRt28ZzXbeGPDVtYWf26zl86WaHzINygCNmGSR9Tj8q88vfEl6mg2Njrtk9wYWjkLsMSBxJyCPQD+ftmgCPxD4R1qfXfGLX2hzazeXryvp2qrqqQx2Vu8BVIWiZwRg7h90q27JIxmsPxB4H8WRaNosLW5Nwmgadp9hcf2oluuj3kYHmuRvG/OPvJuJ24xjmvao54PEFtKLBnxdFVnkK4aJNmdp985H1NUPH+jy3GgSCOdgLaIFMjjA4OfwNAHmOveE/Es3xPutSh2PZzyFWvdQvYxHEnlFQYSkokXLciMxlc9Se+Xb6V431HR1spLX7Ncad4XudJZl1qCQzXRK7HOH+UkKSC3TnJHfsPAGuPqukS6LqMquVYSRnHz4BHIJ6k/nUPhiK90n4nahbXsUszTxGIfKSASu5cnPP3R+VAGd40+HWs3WneHI9EW+1DTUtpDqNpHqXmzC6dEHnBppQrY2kD5ht6qOa9e8HQXMHhTTNN1gTG6htY4JTdSLJJIwTB3EcM3HJGc9a07CKPTtPt4C6IqL/EccdTjPpXD+KzN4hBFpcyJ9muH+zS2x+98o7+oYdaAN/wAU2ek2GkwTyxRQiyljeLbwR86jjHJ610FzeW1tB51zcRRRZxvdwBn0zXmvizw3d6r4Zka6u5BqNhEIpA2SrAEEMpPfHfnpWbrXgLWpJJ7Tz2ns/ME0P7zChgCTkH3z1z+dAHqttqtjcGQRXlu+zLHa44X1P+NQSeItHikEcmpWqOyhgGkAyp6Eeo968z0b4XXDwXLyXstnI52FCCd4xkkn6njg8g1Y1T4SPeNa+VqnlJGMMNpJA64HJ4oA6TTvEul3XiLWbS1v186UxhJFbKqdmM8+/GBXK+JZtV8SxR6Uk27VbVGlnhj+VWUNjPTGenFbXgfwRp+i67rsc3lXMr+W6tu+ZVYNnI7His/UND1628Z/Z9DnhFhJDvWSbnJJ+Zcg5J4z9KAJPCPh7bpN1rtzD5Wo3SGKJFz+7O7buqpe6Ktj4b1WzupmW83oVBbGcEEkHryCDXXaba6xb+J/s09wraVFCskaBc7mzgnP5nFX/Fml2d3pGpTTRqkvkEGU56AZFAGLYRSy3cjQ2nmuY4xBIxyAuMBs/UGuq0Pzv7MiF00jTBnDl+udx/z9Ky9Q1FNFtrG8ZE+ymLbMFI+UYBUj8ePxrW0bU7XWNMgv7CQSW8wO1h6gkEfgQR+FAF2iiigAoopD94HPtj1oAy9c0DTdbgkj1C1SQvGY/MxhlB9DXzhoHhWey8co3ge+INq2yVLhAjOQSCQvrjH86+pK8t1fwLJe/ETU9c0m8+yX0UcLqrICjsQQc+x2jNAEV54zj8NfaLmbTdQfUNoikilztzkkYPvmvPtX+MXirUriSzsIobFnIKGNNxwemCeeO9e1anq1/ZaJcSatoJvLqCJTi3AdJWJxxnp6141rGu+IbnVFvRoFva2qSYjiEHyj17c5/KgDm9T1vxVZ3NxqOrvc3SzoqqgJKttwSSvauo8PfE57LV7y/utKWe/u9ibix/dhRjAODjrWRrt5rd/ppuL+GSO23KcFdiopI7Y4z0z+orrPDPiXwVZaK8OuafMl0jDzWMWSwIOOeOOOlAC+LfEWs+Nm0y00jTn82LfLJak5yRwCSOhHY9ie9dd8KND12xj1KDxBvS2MiPFDJ8xBHo3ccAe+KseCtYtLzVYZtH0NrXTrmIiOYoVZiOfmHbPHNc74z8bpqkkehfaGhhuE+z3ckTlWVpMrlSv90EHr1+lAGHr8dtF+2F4aeLaZp9OlWUZHUQS4yPoO9eueOdXbTNOWGKD7RPfE28UZBIBwckjvxX51HQNTPjE+HzG51g332Eqc5M2/Z9etfoT4Et4otAsTfKM6exsrSSaTe5jQ+UHJz95ipznnmgDzTTPD/jZo7S8P2kwhSY41f5kIJ52k+3HXPFTXf/CT6HBPqur29y9ukCC53gbQA4YsOvOcZHf3r3UkKCxwB1JrmfGl1DeeGdUt4ZlwHW2nIAJUMyhgMjGcGgDobN4praKaFVCSoHGMcgjPb61Fqhl+xSiC3S5fAzE5ADjPI546VS8JWzWvh6xilYmRIljOSSBt4AHpWxQB5FqOgaTqmvwra211ol1KrNDMyjHmDH8Ocdu1XHj8R6Rqd9eSWTahqCWqCN4yHHVgD6ngNn6j1r054o3dHdFZ05ViMlfp6Vy0i6qniXVbnTTFcbEjiEEj7Ryu7Oc9j9Ov1JAPJ9Z03xdr2omTU2uknt48DgxhdxzjAGOQcDioNL0zXNIhW+s5btdpZYnUHkkAEYHBA/z3r0EzeMNfnuIZ7VLG0iyGU/L5gK46nr39K29OstestMS0jgtCkaMse8Anvjdz79qAPO9d8QeOT4cvYbqyLQS2+DJ5RDKpGOf55rOsPFvjy3hbTZGbzVUPGzorO6sNwAPXjIxXoHiHVvEMHhi/trnSUCpCI5biZgysrfKxwCB0OevFOXWPE+jxwWkvh37W0YEf2iElgRjjoO3AzxQByUuoeNXhUW93dSNgl1RCdox6+x9KxoY/HniS1CMdQAQMqz87GweQe+4dj+Haum1r4qa5pfiPR9En8PLHf6qZPs8cjEMdoz09+lXdS1L4m3qywWWlWlqSuVlDAdcY5Y8Y5yOtAGV4J8L+Ire91Fb+4k+3raI2Q5TzTlgoY/gea3NA+H2qWmo2d5eaq3+j3SzmNWJDADkY6daoeE9E8by6/eXGpa5HHd20aQuGTeHVtzAYHHAbrzz61v8AibXbvw7pdna3d19o1eRZJF2/KHAyOTg9MjH0oA71WDDKkEeorgvjPrF7pPhYfYITKZ3Mb4UnA2k9vfFT/CzW59W0y8gvH/0mzlEbIfvDKhs9ehz+lbHjm4s7bw1dyajEssJHl7WGQC3y5/AEmgDzHwJ4ivfiJbDS9dt9lpJFlpIQRs2jAKt0AJU9c85r1bwnokPh3QLfS7Zy8MLSMrHqdzs//s1RaNp0WnW2nWOmLGLO3j5mTB3kcbfxyT+FbYAUAKAAOAB2oAWiiigAoPbjNFZmux3ctpJFYXAguHjZUcn7pyvzY745/OgDTrLtdy+Ir8E/K0MRA47Fua+dPi742+IHgzxDZQXM7yWgy0E0SBVm453epBzxV3w78eIUuxdazYSLqDWYjlVeFJDkqfxBFAH0lTGiRwodFbb03AHFcx4Q8c6L4lsreS1vIRcSRh3iLD5T3GaZ4x8c6d4YurOC5IlebJZUb5lXoMD1JPQ44BoA1PF1vDceHL2GeJXiZAGU9xkUN4X0NkVW0qzYLz80QOfr6/jWLqHijStY8J6hNp9zENsf3ZiF57DGeSe1XdY8QXWnaiiDS2uYWg81ZY5QMeuQfpQBo61dQaNod9NGscS21q8qIgC8KOgx74FeIeFPCh1Xwzrd7PDK14LcXMcjkY343bcD6frXQ/HDxLeSeGtH0WyTybzXJkjkQON0ceQRk+5/QGvVtLsI7HSbeyRdqxxLGcdThcE59aAPmb4VeEP7e+Nr+LZdklvZWguJyRkC827ACPXGX69RXtvgjXE1nxLrsNpHB/Z1q+2Axj+InLH2yTn1r5i8Uy6x4I8feJ9G0y7uITLOsqBOsy9UznI6E17T+zz4OvbPQIdV1KSa2eS4eVIRkeYp/if1yeaAPWdfvBYafHeTTrbQQyo8zN02Zww/WvMviDaXD6MniHQWlijtr0tKu3ieJipDfQHFeqalpltqOnyWd2nmxOuCW5I7g59jWb4ltUi8HXFthdkcKLhflB2kfl0oAteFdQt9U8PWN5aDbFLGDtJyVPcce+a1QQenNcLocNv4O0+7sG1BFtrW7EzNJ1WJznn+Wa5f48yeI7e0trvw7LO1q6hSIGPyvnOePUdKAPXY54ZJ5YUkRpYsb0B5XPIyPeqFgANd1XsWEP4/Ka8Lk8UeKdD0OfVLyCVpbyCOMzbMuHRsK2P/ANYrR+GnxYju9Y1M6/IsbSpGfMOFUFSVPGByd3T2oA92IDAhgCDwQe9CqFUAdBXHav8AEPRLKS3jtbqC8eYEARyfdPG3PHc1Q0D4paLfSm21F/sVzHkSM3+r3ZPAPXOBnkd6AOu8TIX0C+VQD+6JwRnIHJFadcx4j8TaJH4YvbptUszCYGKMJA2Tg44HPUUzVfHnhzTrCGe61KPE8SyKsZy+1gOw6Hnp1oA+NPjv49udQ+OU+r6ZN8uhXEdvZMDxmFsk/Qybz9MV9x+GtZtvEPh7TtYsTm2voEnT2DDOD7jpXyZ40+GHwziezutL8Sal/pd6kUqNKrBFbO4glM5BHcn9a9X0Pxfo/wAP/Duj6Loslze6dCHCq4LuQTu4b6k8cdeOlAHr1rga1fgDBMcTE+v3x/SvMPEEL+JPi1LBbOXbSVgjKlCUUN8zEkDrz0zXOn4t3FnqWryvbyzy3FusdtKu3EbBWKk+xLj8q9D+DNpIPC76nfMZNU1CUyXchOSzLwP/ANXvQB5x4h8UH4b/ABn+2ajbNDpOowiK5KAleTxIo9sDPtml+Lvxe0jULC70HSbdr1J7ct9pBxsfIxj8M/nXdfHvwX/wmHgmYW+Rf2WZ4do5YAcrXlnwK+F9xa6L4g1vxLaL5slqYbWN15BAJLjp6AfnQB6z8H/FcGt2NzpyqUmsghClSMoVGDXe2UBtrZITK8u3Pzv1OTmq2m6XZWbJPb2tvFcGFYmeJAuVHOMDtkk1oUAFFFFABXgv7SutazZapoMWhQ6hut4pZZpIEPlsHKqqlh3+RyQR3Hvj3qqOoX+n2e/7bcW8TbAxErgZHOOv40AfOPhz4yJf2UFn4t8P/bntuDI+fkJ6nJH0rok0rwP4/wBcSSKC2sTDagSQ5CNKxICqOm4YAznHX616zoMOhapE15Y6bZ7Zs7pBCh3ckcnHtXlmr/Dex8Q/ErVZLS8bT7hIRJiFOFO7HTsOB0oAzp/gzNb26tp1zd2rlshOu72OOn+frUD/AAcvV1mOOa7urvzot0kzfKIyP4Rk5/EflXdW+lfEjSjFHbahY38EPCCU4LrjGGyP8/zvQXHxHe6TzLbS0j53Ddx/U0AeW+IfhZLpPhi6klvbtPLVmCRxkxqT03d+uBn37Va0/wCHGs3unRXsHiOVBEESZZZG/cAD5myM5IHGPavStdj8WnRtQXUnsHtgisDCvzHDDIwf84rt/LC3BiFqphmBaRxjbu75HfPFAHjngX4crfajPdawZ54rfy0trmQnLqpBwAeQCMf417dTIidoUpswOg6AU+gDgpfCOm618RNQ1a7jE6W8cMWw8DzgCeR3+Ur7frXeABQAoAA4AHaua8OXqS+I/EiAkRi4i25XHJiVT+q101ACFQWUkAleQfSuD+J/h+8utBkm0e9a2kjl86SJnOJ+MBB7k4wO5Nd73rnPiG6x+EbySR9iRvDIW6Y2yoc/pQB4l8R/D3jTVfEd3P8A2fLcCWJUxEoKlCo4K565yOfQ9ah+G3i3xPoV42ialpV3fwbiSkqksMcBgewwOPoK+gvEOu2OgWMl1qEoVUQuEB+ZgMZwPxqho3iOz1eye8s2in8uDziImDOVwSuMeooA4eb4s+F7uZNM1K1uLfezKpwCUA5Deozx0z71Qn8E+HPE+r3s1g3nBrKN1lgxlWZyfmX174+ldfdeGdF8Qajcpr2m25kl2vbuVEcq5Qbl4xyM9a4WD4ZX+m+NNSHhHU5LFYkiJkZuQjKcLgdeV9ugoA29J+DumWGtS/aHubmweLeSXA+fP3cDkDvWrr3wv0m9UPaWwifGGVpDyc9fSoz4X8b3sZa98TC3lU7QLfIVhxkkAfhW1pPh/wAQ2CIJPEj3OOvmwg/X/PSgDzrxR8PtDj0/WLj7NqQ8i3LIm35CQp3dsjnvWT4O8CaRqAsludD1G5ikePezE7YcgZ59Bx+GK9L8e2fiSTwneL9ts2RV/e4jwzJuByPQgZ/KthNK8RSARz64kcSnCtHCC7AdCT6nv160AedeNvhjpmnNosekqkVtPqlvGUkG7BO7J9811/i46T4A+HWr6rcWtrP9hgaWMSxAhpSAqLz2LlR+NaHjsMsfhoSMGcazbZYDGT83atjxF4f0vxHa29trVqLq3guI7pImdlUyIcqWAI3AH+E5B7g0AeL+D/iFp954QupvEWg6JqPia21ePRlt9Pii8q4klb9wyucgIfm+b/YPFdTb/FSGK3sbSy8MXb6rLqlzo76dbzQr5VxCm9gHYqhUgg7uOvTtXTXnw38JXdxqM0uiwq+oLEtx5TvGG8o5jYBWAVlPRlAb3qxp/gTw3p40v7JpojbTbiS7tn86RmE0gKvI7FsyMQTkvuoA83ufil4g/sPxvdalpTaVHomoQ2kU9s0Usi7pYV8tlZmVmxISWAAx05rsLbxndeItQ1qw0vQZpdHs7mfS7nUnuEXZMiHfiI/MUDYXOe/TGasHwV4K8RNrdzFbw3qanMqah9mvpDHJLE6NyqPtV1aNM4APGD1NLrvgvw/aS6p4jt7F4dUEct0XhuJURpfKZfMMQbyy+M/MVzQB1mmMX020ZiCWhQkj6CrNRq0UVuG+WKFVHXChR/SmWV1BeW6z2sqywsWAdTwSCQf1BoAnooooAK+d/wBoLw5qfiL4gWcenXKwxxaZGWDSbRnzZef0r6Ir50/aQt9Xm8VwjS1byf7PhdypOSVllPboORQBjaV/wsLwXdWtnaGSW0nyRtYyLgDOfyPtXWeGfGst/wCMbOWa3NrfzWvkzznG07XHXPtxXP8AgDxP49GkXDrAk1pYKMNKoLE+i/hVrStNuPEnjSG5vLSTTo9QUidQMKQCpO0e45oA+h7K4iurZJreZZo2HDqQc/lUkbM/zEbRzx6+9cP4O1Kx0zxDc+GLGymhtohuhmYlg7AEtz26V1VxFqEmp2csFxElkqnzosZLk+/oKAI/FELTeH9TCuwJtnwOMDAJzV+0ctZwu27JjUnPXpVLxFPHHo2oxkgyG1lITOC3ymq/hHU4NQ8PafJG5B8lFIfhido9etAG3SZIbnG3+tQx3cMl29ukqmZF3MnfGcf0qV8AAsM8jH1oA5mxmhtPFXiRrl0jhCW03LeisC2PwH5Vr2Gt6ZqF5cWllfQT3FuqvKkbZ2q3Q/pXyb8dfiJd2/xS1mx00eXEscVm7gkh8HnPHTLEEDtXmS67rdrrc503UJYmaNovOifYJEb+mD0NAH058Sfjxoun6beR+F7v7TqVtP5LZX5OCQxHqB614Bf/ABd8SanZ63aX1z5ltqUao5fkRRg5G3PTOMfSuc0rwpqGoXEYS1kUOx+ZhkNxxjn9Peuok+G+o/2ZPLHaynbkjA2DjPUnt1NAHc/Di4k8e2F4NW137PPFGlrCJiSjOckpg9j3xWrrXgnxV4FaK70aSa5ZNpW4hckHapI4x07c+1cNa+CtRtrGOyLyIs4WaQEYG4D5enuepr07wM3iuW1/sCXVFhtvnXfM25sE8YYcelAFWw8f3urhrvX13+RGI2aP5TGcg7gAODgEZ7V2/hTxDqkPxM8TWEtvcXOni0t5Irg8MFG7bnPBzvA/X1qXw/4Ce1u3OqafBMl0PJmeLDD5gMtjsOAPzrqtTtzp3iS71GzjJb7JC0igZLojkFR+GPyoA6SwmN/p0U00TRNIvzR7unPqPpT23W4git4N8e7ax3AbFx156/8A16h1G/j0+1F1IJXhwFCRJk898VBYXp1K8We1nItEQrJA8WG3nBBz9KAIfG6b/COsjcQPscrcdeFJzWrayI1lFKOIzGGHsMVU8RFToWpIXUM1rL1PbYaxtE8V6c9rY2377z/s8bOqxkhDtHBP40AeaeNvjh4AubvRre31zzWtdUhnmdLaVkVEzk7guG69s11vj6ST4g/DSKbwJdNfJdXdu6TWs/kExpOvmYYlSCArcZB4x1r47+NfgybQfjFqeiafDuS+uVlso1/iExyqj6MSv/Aa+5PCFpYeD9D0TwtFuDWtoqKwU7XKj5mz6lsn8aAPL/iD8OvEDatPD4Zs7u6tDYwwaRcnVWQ6TcCYvJK5d975BzuG5uNuMVZk8F+Lj8R1v2ilkl/t2O9GuC9CxjThGA1n5O7dkkEY27ec54r00XDv4zuFttsgWwjyNw5PmN/Q1r3uoWmnxB766hgXpmRwOaAPPPgh4Ru/B6eJbO90mWz83UZJYLo3YmS5hLuY9q7yVKg87gpO4dccdX8Srl7P4deKrqIkSQ6VdSKR2KwsR/KvKP2nvFwXw5DoWjXKTTXm43IiYMBGMcNj1PbrXyde+GJo4fMiIxtLlCDkfT1oA9U8Q/tH65qnha30y3tYoLjyxHcTFsmQZweMdxj9a+kv2etRbVvg/oF6yKhk+0fKucAC4lA689B3r4d0/wAG3t2yPsZIioIkHAzgdeOK+6vgTpB0L4UaDpzSCRollJYerTOx/wDQsUAd7RRRQAV88fGHV9cvPHV9pGkxNN5CxIqxplsFFfBPplifXtX0PXMwWUdx4r1K5aJMQmNeBzI/lggn8MCgD5ftdT8RSTNbKJYG3bWijU888jb/AFrR0z4qa1o+tQQanYrcx26skELggg9Cw55z3z0r37xGdM0W6h1JbdWvLhhbINoySeefy7V5b8SdIbXbrS59LtbY6gyTCaOOLGzDDIwTkkA8880AWrj9oLT7eFo4NJZZkiUhiQQGxznFO1b4+xXGnbNFtwmoO+IxIARt45PbOf0ryjUdDv7G3IewceYoZSqYLdjx1rn/AOwrqKUA2skRdMrLs5Y9h69PxoA9VufjbqlvqDm7itpwVMbHbjapBBxg49+/T3ruIfiZ4HRtNgtri4820SNY3KgF+B94jqF7nHWvnZ9Cu109jDbtMzLySOMZHHfmoDoF1YIDcwuHZAygKdwUjI/xoA+gfHHxstNP1aBPD1sk7ktDLcSJjODztweRx3rh/iD8W/Fd7HpsPh9wnyMJZYztLSsfu4z2XkDqDnk9K5vwjFbS2Ukd3G1xGAWKHO7OOo54/wD1V0fh2HQ7S5mtZUnk8+ESpjOEcD8ielAHHf8ACvtUklup5z9snjjR5rhpNzpvySM9yD/nitvRvB0hlVtRxuUYVeMDHQntz/npXRaTFqVp4qkiFpcXCOkcjRIpKOpPXPfGP0rsHvruXUTbxaetrsVlbcdzHqPl46+n+cgHO6frR0u6Q6ZY2xkWPMZkXdlz3A9ffpz+VfVdX1CWzunl81SDuxg4A9MD1yePzr0zwHpOg21jLDeWLyyzz8yzR5VcYwAe3J7d63/F+kaTaeEtWWSC3h3xuybmClmxxg/pQB5Dax61q9raWmnQyTLbqFYMmHwAQARjoQP0qKy8O68urTTSW101zgqqjoMH7wx6c8V7ror2v2lrXTbWKGIRRs80X8RwuBkdeO9a19M1tEjwwGVywTCjoD3+lAHzbq1z4y8L3P2iO9vYI2fcqzHCnI7Kex5rU8GfE7UbXxPPP4pkM0bWoiTZHjJzkc5AHIx3z1r2LxXoEHiu1tre4fyZLaYSOvXgg8fjwc+1eJfEr4e3dt4wmTR7Z5bCS3SYBRuKfMVwfbP+etAHc+L/AIl6fPBBY2lw9pdSlZQ+4ZC/5/lVLwv8R7fSNFluNQaW/uricnCkAgdBz3zjjivHoPBWs/2sPtNlffM/lkMjEMAP5D269a3ZPB2t2/mTQadc7NxQMQ2GwR1Pb/6/agD1KP4t6VrPhrXryGxlxY253q5wTuBBGcZ/TtRonxH0Ow0G0H2YCVbdBJKgBydnXnk9O+K8Cu9C1m20+/VRc28ciN5qurdu5H9ajstHv0st4iuJ12bpFVSfL+YdSO4HbpQB3Hjzxv4R1X4j+E/E0FnI1zo7OZUKgCVSMxtx3R8n6mux1n9oLRUgUabZzSzurbXJGEPr7jkV5dF4L1MSsp0ydmYBjmE8ck5HHIPc1LZfDPX70SNb6WREXDn92FPp9RigCS4+LniG+8UNPpES28xtmtpZCo6E7htHTdxx0rmd3i7Wrm9TWr1xcSqBmbjdgggjtnhema6y5+Huq6NqLm5t45XiEUm2Jd2F+YAnHfAPNdHczPNp0EkEKyXEMqgT4yDt7Y9hQBy3gbwnDpdpcXPiW4+0X0zbVSLovJ/yTXR+KfDuhy6e88eLUQQcxRfMxY429evNdF4Y8NjxBd30t7cfYogd5kTA59s/0rc1nStCuPC98dEj+0TW0EjspPzy7ec47jIoA8rt4jNoy6XbRmT5BvWNcbiBgDIH+etfQXwt0ubRvAel2F1G0UsQkJRzkruldgCfoRWf8PNSstds4ZrbR0tl8tXeTy8KWGAAPfAFd1QAUUUUAFYMV7YP4jvbCJz9tG15o9vXKKFbPsB+tb1VUsLeO8mu44lW6lADSY5OBgfyoAS6s7a5aIXMUblTlAy5Ax6ehrifGGlSReI9Kl0rbFeTebukKjH3c4x6nHWu9cK+4FvmA59Bwe351zevWSvrujyROzvHK3yMchE2kN745AOfbpQBnar4is9ChtYtXsWaAx/NII9wBHP8643XPi54PkMsVvZNPcFcBjGoVT7969aht7e5iEc4WXaMMDzk45PtXJxfDbwtcXxuJtLgMiymRSgwGyc/MO/09qAPNNP+IqTvcWH9jWyW6xF+EwRxlSOPXH5UQfFDwv8A2RZS3OhC5vEh2TsFDMCoIH/6q9rl8M6MkNyz2dugki2SOEVcKO+QP5+lch4W+H/hjRvDINzZKzXClpZJRy2Seg+mKAPK/FupeEf+EbsdW0y0a11C9DNHEuQAyjJB9QR+tZnh828mk2uv6nO9rA5kRlRQS5UZwv1H9MV6rqvw+0jWH0z7PYNBpmnbnRNpUyZ7AHnHemWvwq0m3t7G3vr2RbBLmSYWUp6lj2A7cA8+1AGDpvivVbvXLW30WzaFGtIgjldyqiv/APXz+Jrp/hzfl/EFw2oQu0s7OzXEgAXcTwo9/b3rqLbw3a2XiiL7KWij/s8xhQemHUfyq1b+ELOCzMCyuSbxbwOeCGB6CgDfNpB5DQiMCNjuKjuc5/pWHr9hD4g8L3P9oWOyYxS+Wsn3o2AYK2e3Y10Y96gvRmzn/wCubDBHHSgDF0VItMs1h060lkijgEkuDlnOzhVycZPpkAe1dAjbkVipXIzg9RVTRSDo9iQQf3Ccj/dFXKAM7W9rWhhXcJ5vkjZB8yn+9+FefePfEGo+Ctahulja+s5bDyXkkzlZBJ8pPbndXptzH5kTbW2SAHa/901xsVvcX+uW+l+Kbe2uD9lZ1ZCdsm2RSGx+AoA851j436gNK8m20r7PqrcjfyAByTjvnHT3rnrD41+LN1xZtpayTytutmZSOAcsB69a+hho2n/2qZJdPt3fZmOQwqdvYjPryPwrQWxtFKlbWAFSSuIxwT3FAHgupfGNr7TJ9OuNBU3Ulu6XB5wcqfy7/Suc074ieJryyWz0bTAYxALdTDbZeQ4HU9Omfzr6UvtJsJY7l2s7fzZImjaQRDcVIPFc74Ts7sDS5bJI7bTBYgNlQTJIQOfy/OgDn/DuveN5PC1uLzQ5HvJFK+Y33x7sCa8/SL4j3E7p/psDStgRDKl+e2emPyr6RQP5YEhG/HJFMnby8SCJpHHA2jnmgD570DUfF/hnxjrJ1uCWctpDyx+Yu4K6n5Tkdhlh+debaL4quZtX1FdShkitPOEsioMde4xzivrlo1Pi07sMHsNrKcEYEn/1zXE+JdM8Kw6k1hr+iqs9yQIbi3XaZhngcdxxQBF8Pop9ZmV2sriDRfKZYvMAO7PcnHOf61H428HEa1eXtsGg05NPZyEJA3Dt174HFeo2NrDY2cNrbLshhQIi+gA4qv4ghS40LUIpQSj27g4P+yaAOe1bR7zVPBFtaaFLHp8s0aOXUbcfL2x74rotEtZLHSbS1nnaeWGMI0jHJYik0B9+iaeSck26dv8AZFX6ACiiigAquzHcyqc5bg56Y68f096sVlXEuJHTDfM2Cuc45PI9KALahWL/ADYUHIIONo6cfrWHcMF8T6UdyksJY2HPJ259Oa0RMT8zr2xg8Y/KsfVrlI9d0XIGfPYDccAZU9DQB1a7Qu5eBjGfYU1mAGVAwMHJ4HPvVdLhmf5mUDjg8frR9oZJSJkUvn5SvGAegP59aAF1FBLY3K+ZhTG6kDHUjFQ6IRPoNicq2YE+bH+zjNLcSkxyKqgKRnGM9uM/p0qn4TuJZvD9l8oJ8sgMW9CRQBsR7lTO7zfTpWda6LbwavPqIX/SZRgtuJwPYevvWgrnyixTYevIz+NPRiwyRgdqAMW3wPGV4pZTutInC9xhnH9Tz71uVgElPG2UUN5lgf8Ax1x/jWvMZpA6QkJlPlkzkgnPb8P1oAn3Lu27hu9M81leLRnwvqvzbcW0hz9FJq7aQLCgJ+aRvvMTklsY/pVbXmB0jUYy6Fmt3AQkA/dNAFuzYyWMDbjlo1bP1FT1k+HZpX0DTHkCjNtGXIBP8IrVHU8Y9/WgAzj7xHJ4rJQq3iyUMm5ls0ZHYfcy7BgPTOBn6CtYEEcVitMqeMVQsAHsM8jniT/69AG17cn3paiR/Mdlxt29+p/+tTlY5wxGc449cZoApeIXePQdReNzG627srA4IIU81btdgtYfJVRHsXaF4AGO34VV14g6HqIzg/ZpP/QTTdAm87RbB1O7MEeckZHy96ANGjvUUrFckttUc9Mk04yoDguuenWgDHtpfN8YXsTgEwWsZQ4GQGZs/wDoIrWntoJ2jaeGORozuQuoO0+o9K55pFh8dXDfd3afG24dGAkbj/PrXQPMnlhg5KnnK45/z/SgCasfxfcva+GtSlifZIkDOD6AdevHSrks4DqAwx/snkj/AD/OuZ+IFxcp4M1RrONWbyG8zJ4245OKAOisZYbfTbVbaP8A0YIqqFP3ePfrV6Jt6BiMH0rndDnM+iadOroVeFCQFzn5Rjn068Gt+0fzIFYd89unNAEtFFFABXMXU5S9uPmI2s2AAPX3+tdPUL2ls5YvbwsWOSSgOT60Ac4kjBcBiB1wSfyFZGvyeTd6TKWZ1F3Hz1wWyMfrkflXd/ZoOf3MXP8AsCo5rCzn2ie0t5ApDLvjU4I6EZFAGTJc+Sk7+Yqqinc0gACgD5jn2604zPGSS2Q/3RggnjGPzxWyIIVbcIow3XIUZoMERYExRkjodooAyDIYon3MrSYzj0rjfBmqaxJpaYhtmsbV5lTjaS6yMB07YNektDE33okP1UVHDY2kMflw20Ece4ttSMAZPJOPWgDnJvEEVvLbJe+YskwAfZyEJOME9AK3kcRq0YlRWTggDP41M9nbSKFe3hZQcgFARn1qXyo/7i/lQByzXpfxhZqu2MG2mRVJwDypB9jnNbpvEVvKAzMEBK4xgZx/PtU5s7UzLMbaEzKCFfyxuAPXBqXy03Fti5I25x29KAIQV3LggoTnPT5vp/nvWZqumxTte3KnMxgZMHPHBxx9e9bJRTjKqcZxx60pVSu0qCvTBHFAHOeEnkPhzRyoCg2qYA6A+hNbCsuGWd3BK46EHH+TU8VvDDCkMUUccKDCoqgKv0FSbRjGBjGPwoAyNQ1WOzmVZGYLI6xowGcsfX8qwbyd0+I1grj5H02UfLxkBxg/nXYvbwvjfDG2ORlQcUx7G0e5juXtYGuI1KJKYwWVT1APUA0AZ8Mxg81p5UWJTkO/G0H1z1qw07m0YJL+9YYVsg/iKmvNOsr2Ly7yztriP+7LErj8iKdHY2kYjEdrAgjG1AsYGweg9KAKOoyM+i3auWZxbSFsLgN8pH+RXM6S+pXXhrQxpt4sQa3TeWGWBx0HrXcvFG4O9FbPByM5pkFpb28Kw28EUUScKiIFUfQCgDItri4jgP8AaWwNGSQ+MLtH+NSafd20iFLe7EpQ4JU5K55xnuOelaxhiYYMaEehUVFBY2luCILWCIE7jsjC5PrxQBwXiSa6Ovy/2Y5hu5NOGzcoJyJTx6gYzWx4V1qHXPDttfuSobcHUYyjZKnp9K6V7G0kmEz2sDSgbQ5jBYDOcZ9KZZ6bY2MJhsrK2t4SSxSGJUXJ6nAFAGGZ7mPVLtbhFW0Ur5RJHIwOfzrP8UzpJ4c1e3JDmW0mUAHg4Xsf612BtLYvuNvCWxjOwZxTZLC0ljMclrbuhBUq0YIIPBGMdKAOJ8ATN/wi1nGsUipDAiKXUAN8vY55A4Ga7fT232cZHTnvnuaWOztYo1jjtoUjUYVVQAAewqVEWNQqKqqOwGBQA6iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    M mode echocardiogram shows the aortic root and aortic valve from a patient with a hypertrophic cardiomyopathy. The aortic valve shows a mid-systolic closure (arrow) or spike-dome configuration due to transient intraventricular obstruction and reduction of stroke volume.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_14_29922=[""].join("\n");
var outline_f29_14_29922=null;
var title_f29_14_29923="Eribulin: Patient drug information";
var content_f29_14_29923=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Eribulin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/42/28325?source=see_link\">",
"     see \"Eribulin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F11247325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Halaven&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F15572584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Halaven&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F11263507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691765",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat breast cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F11263647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2957279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to eribulin  or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F11263649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697133",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a fast heartbeat, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2770240",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F11263510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698221",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low white blood cell count or low platelet count. This drug may need to be stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698081",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals and good mouth care may help. Older children may suck hard, sugar-free candy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698243",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation or sores. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698288",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness and tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698249",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697916",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bone pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F11263509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F11263652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16097 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-201.65.114.212-1237D62C13-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_14_29923=[""].join("\n");
var outline_f29_14_29923=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11247325\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15572584\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11263507\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11263647\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11263649\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11263510\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11263509\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11263652\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/42/28325?source=related_link\">",
"      Eribulin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_14_29924="Follitropin alfa (recombinant human follicle stimulating hormone): Patient drug information";
var content_f29_14_29924=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Follitropin alfa (recombinant human follicle stimulating hormone): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/21/37205?source=see_link\">",
"     see \"Follitropin alfa (recombinant human follicle stimulating hormone): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3882602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gonal-f&reg;;",
"     </li>",
"     <li>",
"      Gonal-f&reg; RFF;",
"     </li>",
"     <li>",
"      Gonal-f&reg; RFF Pen",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F3888769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Gonal-f&reg;;",
"     </li>",
"     <li>",
"      Gonal-f&reg; Pen",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691380",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help you get pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help make sperm.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702158",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to follitropin alfa or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703455",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Cancer where hormones make it grow, ovarian cysts, adrenal gland disease, thyroid gland disease, or vaginal bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697565",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit working out while undergoing ovarian stimulation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697703",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of getting pregnant with more than one baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698292",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Ovarian cyst.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696435",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pimples (acne).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Enlarged breasts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698294",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Over stimulation of the ovaries.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain or soreness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696011",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10029105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699187",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to store closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10743 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-197.136.42.3-880E22D557-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_14_29924=[""].join("\n");
var outline_f29_14_29924=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3882602\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3888769\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029102\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029101\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029106\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029107\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029109\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029104\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029105\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029110\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029111\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/21/37205?source=related_link\">",
"      Follitropin alfa (recombinant human follicle stimulating hormone): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_14_29925="Rizatriptan: Drug information";
var content_f29_14_29925=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rizatriptan: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/47/37621?source=see_link\">",
"    see \"Rizatriptan: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/24/8581?source=see_link\">",
"    see \"Rizatriptan: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F218997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Maxalt-MLT&reg;;",
"     </li>",
"     <li>",
"      Maxalt&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F218998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Rizatriptan&reg;;",
"     </li>",
"     <li>",
"      CO Rizatriptan;",
"     </li>",
"     <li>",
"      CO Rizatriptan ODT;",
"     </li>",
"     <li>",
"      JAMP-Rizatriptan;",
"     </li>",
"     <li>",
"      Mar-Rizatriptan;",
"     </li>",
"     <li>",
"      Maxalt RPD&trade;;",
"     </li>",
"     <li>",
"      Maxalt&trade;;",
"     </li>",
"     <li>",
"      Mylan-Rizatriptan ODT;",
"     </li>",
"     <li>",
"      Sandoz-Rizatriptan ODT",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F219026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antimigraine Agent;",
"     </li>",
"     <li>",
"      Serotonin 5-HT",
"      <sub>",
"       1B, 1D",
"      </sub>",
"      Receptor Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F219001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     In patients with risk factors for coronary artery disease, following adequate evaluation to establish the absence of coronary artery disease, the initial dose should be administered in a setting where response may be evaluated (physician's office or similarly staffed setting). ECG monitoring may be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Migraine:",
"     </b>",
"     Oral: 5-10 mg, repeat after 2 hours if significant relief is not attained; maximum: 30 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Dose adjustment with concomitant propranolol therapy:",
"     </i>",
"     5 mg/dose (maximum: 15 mg/24 hours)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F14292543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/24/8581?source=see_link\">",
"      see \"Rizatriptan: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     In patients with risk factors for coronary artery disease, following adequate evaluation to establish the absence of coronary artery disease, the initial dose should be administered in a setting where response may be evaluated (physician's office or similarly staffed setting). ECG monitoring may be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Migraine:",
"     </b>",
"     Oral: Children 6-17 years:",
"     <b>",
"      Note:",
"     </b>",
"     Safety and efficacy of multiple rizatriptan doses in a 24-hour period have not been established for pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;40 kg: 5 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;40 kg: 10 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Dose adjustment with concomitant propranolol therapy:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;40 kg: Use not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;40 kg: 5 mg as a single dose (maximum: 5 mg/24 hours)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F219002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F14292541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling; however, the AUC was 44% greater in patients on hemodialysis.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14292542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling; however, plasma concentrations are increased by 30% in patients with moderate hepatic dysfunction.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F218975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maxalt&reg;: 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral: 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maxalt-MLT&reg;: 5 mg [contains phenylalanine 1.05 mg/tablet; peppermint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maxalt-MLT&reg;: 10 mg [contains phenylalanine 2.1 mg/tablet; peppermint flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F218961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F14292544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food. For orally-disintegrating tablets (Maxalt-MLT&reg;), patient should be instructed to place tablet on tongue and allow to dissolve. Dissolved tablet will be swallowed with saliva.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F218976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acute treatment of migraine with or without aura",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F219024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (&lt;2% to 3%), flushing (&gt;1%), palpitation (&gt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (4% to 9%), somnolence (4% to 8%), fatigue (adults 4% to 7%; children &gt;1%), pain (3%), headache (&le;2%), euphoria (&gt;1%), hypoesthesia (&gt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Skin flushing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (4% to 6%), xerostomia (3%), abdominal discomfort (children &gt;1%), diarrhea (&gt;1%), vomiting (&gt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (4% to 7%), paresthesia (3% to 4%); neck, throat, and jaw pain/tightness/pressure (&le;2%), tremor (&gt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (&gt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Feeling of heaviness (&lt;1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis/anaphylactoid reactions, angina, angioedema, blurred vision, bradycardia, confusion, edema, hallucination (children), hearing impairment, hypertensive crisis, memory impairment, MI, myocardial ischemia, pruritus, seizure, syncope, tachycardia, tinnitus, tongue edema, toxic epidermal necrolysis, vasospasm, vertigo, wheezing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F218980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to rizatriptan or any component of the formulation; documented ischemic heart disease or other significant cardiovascular disease; coronary artery vasospasm (including Prinzmetal's angina); history of stroke or transient ischemic attack; peripheral vascular disease; ischemic bowel disease; uncontrolled hypertension; basilar or hemiplegic migraine; during or within 2 weeks of MAO inhibitors; during or within 24 hours of treatment with another 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonist, or an ergot-containing or ergot-type medication (eg, methysergide, dihydroergotamine)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F218965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac events: Coronary artery vasospasm, transient ischemia, myocardial infarction, ventricular tachycardia/fibrillation, cardiac arrest, and death have been reported with 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonist administration. Patients who experience sensations of chest pain/pressure/tightness or symptoms suggestive of angina following dosing should be evaluated for coronary artery disease or Prinzmetal's angina before receiving additional doses; if dosing is resumed and similar symptoms recur, monitor with ECG.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cerebrovascular events: Cerebral/subarachnoid hemorrhage and stroke have been reported with 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonist administration. Use is contraindicated in patients with a history of stroke or transient ischemic attack",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elevated blood pressure: Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Headache exacerbation: Overuse of medications for acute migraine, including 5-HT1 agonists, may lead to headache exacerbation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vasospasm-related events: Peripheral vascular ischemia and colonic ischemia, gastrointestinal ischemia/infarction, splenic infarction, and Raynaud&rsquo;s syndrome have been reported with 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonist.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Visual effects: Rarely, partial vision loss and blindness (transient and permanent) have been reported with 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonist.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery disease: Should not be given to patients who have risk factors for CAD (eg, hypertension, hypercholesterolemia, smoker, obesity, diabetes, strong family history of CAD, menopause, male &gt;40 years of age) without adequate cardiac evaluation. Patients with suspected CAD should have cardiovascular evaluation to rule out CAD before considering use; if cardiovascular evaluation is &ldquo;satisfactory,&rdquo; first dose should be given in the healthcare provider's office (consider ECG monitoring). Periodic evaluation of cardiovascular status should be done in all patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; drug clearance may be reduced leading to increased plasma concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in dialysis patients (systemic exposure is increased).",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serotonin syndrome: Symptoms of agitation, confusion, hallucinations, hyper-reflexia, myoclonus, shivering, and tachycardia may occur with concomitant proserotonergic drugs (ie, SSRIs/SNRIs or triptans) or agents which reduce rizatriptan's metabolism. Concurrent use of serotonin precursors (eg, tryptophan) is not recommended.  If concomitant administration with SSRIs is warranted, monitor closely, especially at initiation and with dose increases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenylalanine: Maxalt-MLT&reg; tablets contain phenylalanine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Only indicated for treatment of acute migraine; not for the prevention of migraines or the treatment of cluster headache. If a patient does not respond to the first dose, the diagnosis of migraine should be reconsidered.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F218969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. Serotonin 5-HT1D Receptor Agonists may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May decrease the metabolism of Serotonin 5-HT1D Receptor Agonists. Management: If MAO inhibitor therapy is required, naratriptan, eletriptan or frovatriptan may be a suitable 5-HT1D agonist to employ.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propranolol: May increase the serum concentration of Rizatriptan. Management: Rizatriptan adult dose should be reduced to 5 mg in patients who are also being treated with propranolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F218994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Food delays absorption.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F218971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F218982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A pregnancy registry has been established to monitor outcomes of women exposed to rizatriptan during pregnancy (800-986-8999). Preliminary data from the pregnancy registry does not show an increased risk of congenital malformations (Fiore, 2005). In some animal studies, administration was associated with decreased weight gain, developmental toxicity and increased mortality in the offspring. Teratogenic effects were not observed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F219005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F218983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F218981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, orally-disintegrating",
"     </b>",
"     (Maxalt-MLT Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (3): $110.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (3): $110.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, orally-disintegrating",
"     </b>",
"     (Rizatriptan Benzoate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (3): $99.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (3): $99.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Maxalt Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (18): $665.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (18): $665.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Rizatriptan Benzoate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (18): $598.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (18): $598.52",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F218973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Headache severity, signs/symptoms suggestive of angina; consider monitoring blood pressure, heart rate, and/or ECG with first dose in patients with likelihood of unrecognized coronary disease, such as patients with significant hypertension, hypercholesterolemia, obese patients, patients with diabetes, smokers with other risk factors or strong family history of coronary artery disease",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F218984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Maxalt (AR, AT, AU, BE, BG, BR, CH, CN, CR, DE, DK, EE, ES, FI, GB, GR, GT, HN, HU, IT, MX, NL, NO, NZ, PA, PE, PL, PT, SE, SV);",
"     </li>",
"     <li>",
"      Maxalt RPD (CN, PE, VE);",
"     </li>",
"     <li>",
"      Migoff (TW);",
"     </li>",
"     <li>",
"      Ouliting (CL);",
"     </li>",
"     <li>",
"      Rizact (IN);",
"     </li>",
"     <li>",
"      Rizalt (IL);",
"     </li>",
"     <li>",
"      Rizamelt (NZ);",
"     </li>",
"     <li>",
"      Rizatan (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F218964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selective agonist for serotonin (5-HT",
"     <sub>",
"      1B",
"     </sub>",
"     and 5-HT",
"     <sub>",
"      1D",
"     </sub>",
"     receptors) in cranial arteries; causes vasoconstriction and reduces sterile inflammation associated with antidromic neuronal transmission correlating with relief of migraine",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F218979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Most patients have response to treatment within 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Females: 110 L; Males 140 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 14%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Via monoamine oxidase-A;  forms metabolites; significant first-pass metabolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~45%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Maxalt&reg;: 1-1.5 hours (delayed up to 0.7 hour with Maxalt-MLT&reg;)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (82%, 14% as unchanged drug); feces (12%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Boyer EW and Shannon M, &ldquo;The Serotonin Syndrome,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(11):1112-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/14/29925/abstract-text/15784664/pubmed\" id=\"15784664\" target=\"_blank\">",
"        15784664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fiore M, Shields KE, Santanello N, et al, \"Exposure to Rizatriptan During Pregnancy: Post-Marketing Experience Up to 30 June 2004,\"",
"      <i>",
"       Cephalalgia",
"      </i>",
"      , 2005, 25(9):685-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/14/29925/abstract-text/16109049/pubmed\" id=\"16109049\" target=\"_blank\">",
"        16109049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10243 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.81.197.98-4F96C3A324-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_14_29925=[""].join("\n");
var outline_f29_14_29925=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218997\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218998\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219026\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219001\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14292543\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219002\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14292541\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14292542\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218975\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218961\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14292544\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218976\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219024\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218980\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218965\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300011\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218969\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218994\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218971\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218982\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219005\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218983\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218981\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218973\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218984\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218964\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218979\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10243\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10243|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/47/37621?source=related_link\">",
"      Rizatriptan: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/24/8581?source=related_link\">",
"      Rizatriptan: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_14_29926="Microbiology, pathogenesis, and epidemiology of Streptococcus bovis infection";
var content_f29_14_29926=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Microbiology, pathogenesis, and epidemiology of Streptococcus bovis infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/14/29926/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/14/29926/contributors\">",
"     Howard S Gold, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/14/29926/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/14/29926/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/14/29926/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/14/29926/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/14/29926/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Streptococcus bovis is a gram-positive coccus that is an important cause of bacteremia and infective endocarditis in adults. Such infections have been associated with colonic neoplasia and other lesions of the gastrointestinal tract. Therefore, diagnostic evaluation of the gastrointestinal tract is important for patients with systemic infection due to this organism [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/1\">",
"     1",
"    </a>",
"    ]. Members of the S. bovis group include Streptococcus gallolyticus or Streptococcus infantarius [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. These species differ in their microbiology, pathogenesis, and epidemiology but are identified under the common name S. bovis by many laboratories [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The microbiology, pathogenesis, and epidemiology of S. bovis infection will be reviewed here. The clinical features, diagnosis, and treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22041?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of Streptococcus bovis infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;S. bovis is a catalase-negative, gram-positive coccus that usually expresses the Lancefield group D antigen. Colonies are typically small and non-hemolytic on blood agar. Both S. bovis and Enterococcus spp were originally classified as group D streptococci but are now considered separate genera. Enterococcus spp and most S. bovis grow in 40 percent bile and hydrolyze esculin [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/1,5,6\">",
"     1,5,6",
"    </a>",
"    ]. S. bovis can be distinguished from enterococci because S. bovis is PYR (pyrrolidonyl arylamidase) negative, fails to hydrolyze arginine, and is typically unable to grow in 6.5 percent salt broth [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/1,5,6\">",
"     1,5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is some phenotypic and genotypic variability among members of the S. bovis group (also referred to as the Streptococcus",
"    <span class=\"nowrap\">",
"     bovis/Streptococcus",
"    </span>",
"    equinus complex), which highlights the importance of precise nomenclature including the subspecies names [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/2,3,7,8\">",
"     2,3,7,8",
"    </a>",
"    ]. S. bovis may be subdivided into biotype I (S. bovis) and biotype II (S. bovis variant) based on biochemical reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/9\">",
"     9",
"    </a>",
"    ]. Occasionally, strains of Streptococcus salivarius are misidentified as S. bovis, but commercially available kits can be used to differentiate it from S. bovis and S. bovis variant in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These distinctions have clinical significance, as S. salivarius is not usually associated with neoplasia and is a relatively frequent blood culture contaminant. In one study of 68 patients with positive cultures growing S. bovis biotype I, S. bovis biotype II, and S. salivarius, the frequency of IE was 94, 18, and 10 percent respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/9\">",
"     9",
"    </a>",
"    ]. The incidence of malignant or premalignant colonic lesions was 71, 18, and 3 percent, respectively.",
"   </p>",
"   <p>",
"    S. bovis biotype II strains have been further subdivided into groups",
"    <span class=\"nowrap\">",
"     II/1",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     II/2",
"    </span>",
"    based on additional biochemical reactions and 16S rRNA gene sequencing [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Using this classification scheme, S. bovis biotype",
"    <span class=\"nowrap\">",
"     II/2",
"    </span>",
"    appears to be the most common S. bovis type isolated in blood cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/10,12,13\">",
"     10,12,13",
"    </a>",
"    ]. Other surveys including predominantly or exclusively endocarditis cases have noted biotype I to be most prevalent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/9,14\">",
"     9,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Members of the S. bovis group include Streptococcus gallolyticus and Streptococcus infantarius. S. gallolyticus includes some strains previously classified as S. bovis biotype I and",
"    <span class=\"nowrap\">",
"     II/2",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/15\">",
"     15",
"    </a>",
"    ]. S. infantarius includes strains identified as S. bovis biotype",
"    <span class=\"nowrap\">",
"     II/1.",
"    </span>",
"    Subspecies names include [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/2,3,16\">",
"     2,3,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      S. gallolyticus subspecies gallolyticus subsp. nov (includes strains identified as S. bovis biotype I)",
"     </li>",
"     <li>",
"      S. gallolyticus subsp. pasteurianus subsp. nov (includes strains identified as S. bovis biotype",
"      <span class=\"nowrap\">",
"       II/2)",
"      </span>",
"     </li>",
"     <li>",
"      S. gallolyticus subsp. macedonius subsp. nov",
"     </li>",
"     <li>",
"      S. infantarius subsp. infantarius subsp. nov",
"     </li>",
"     <li>",
"      S. infantarius subsp. coli subsp. nov",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A survey of 58 blood isolates of the S. bovis group identified to the subspecies level by 16S rRNA sequencing noted the following species breakdown [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      29 strains were S. gallolyticus subsp. gallolyticus (50 percent)",
"     </li>",
"     <li>",
"      12 strains were S. gallolyticus subsp. pasteurianus (21 percent)",
"     </li>",
"     <li>",
"      17 strains were S. infantarius subsp. coli (29 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Isolation of one of these three bacteria from blood was associated with altered liver parenchyma or gall bladder disease in 65 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/6\">",
"     6",
"    </a>",
"    ]. S. gallolyticus subsp. gallolyticus has the strongest association with colonic lesions and endocarditis; a meta-analysis has demonstrated that patients with infection due to this organism had a strongly increased risk of colorectal cancer (pooled odds ratio [OR] 7.26; 95 percent confidence interval [CI] 3.94-13.36) and endocarditis (pooled OR 16.61; 95 percent CI 2.03-6.81) compared with patients with S. bovis biotype II infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association between S. bovis and colonic malignancy is not fully understood. S. gallolyticus have fimbriae or pili, which may be used for adhesion to host cells [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. A number of S. gallolyticus Microbial Surface Component Recognizing Adhesive Matrix Molecules (MSCRAMMs) and pilus-related proteins have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/7,20\">",
"     7,20",
"    </a>",
"    ]. Neoplastic colonic epithelial cells appear to express distinctive surface markers that are bound by S. bovis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, patients with adenomas and carcinomas appear to have a distinct immune response to S. gallolyticus antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22041?source=see_link&amp;anchor=H24506924#H24506924\">",
"     \"Clinical manifestations, diagnosis, and treatment of Streptococcus bovis infection\", section on 'Association with colonic neoplasia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;S. bovis has been isolated in the stool of 2 to 12 percent of healthy individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/23-27\">",
"     23-27",
"    </a>",
"    ]. The organism is not generally considered to be part of the normal oral flora, although it has been identified in cultures of gingiva or throat in small numbers of individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/5\">",
"     5",
"    </a>",
"    ]. Two published studies used pulsed-field gel electrophoresis to demonstrate that S. bovis isolates were largely genetically diverse, even at the subspecies level [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Bacteremia and endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;S. bovis accounts for 2 to 6 percent of streptococcal bloodstream isolates among hospitalized patients and for 2 to 57 percent of organisms associated with infective endocarditis (IE) in various series [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/1,28-38\">",
"     1,28-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    S. bovis has emerged as an important etiologic agent of IE in some geographic areas [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/34-36,38,39\">",
"     34-36,38,39",
"    </a>",
"    ]. In one study, the proportion of streptococcal IE due to S. bovis increased from 11 to 23 percent prior to and after 1989 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/35\">",
"     35",
"    </a>",
"    ]. The proportion varied by region; S. bovis accounted for 57 percent of IE in France, 9 percent in the rest of Europe, and 6 percent in the United States. This disparity persisted in an analysis of a large database of IE isolates from 2000-2005, in which the proportion of IE caused by S. bovis in Europe was 10 percent, fivefold higher than in the US [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/36\">",
"     36",
"    </a>",
"    ]. In a population-based survey of French hospitals in 1999, S. bovis was the most common cause of IE (25 percent of cases), surpassing Staphylococcus aureus and oral streptococci [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/34\">",
"     34",
"    </a>",
"    ]. At a Spanish hospital, the proportion of IE cases due to S. bovis increased from 14 to 30 percent between 1988-1996 and 1997-2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/36\">",
"     36",
"    </a>",
"    ]. In other parts of Europe and in the United States, oral streptococci remain more common agents of streptococcal endocarditis than S. bovis, and staphylococci are more common pathogens than streptococci and enterococci [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/33,35,38\">",
"     33,35,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with S. bovis endocarditis are typically older than patients with IE due to other organisms (mean age 59 to 67 years versus to 46 to 59) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/1,5,30,35-37,39,40\">",
"     1,5,30,35-37,39,40",
"    </a>",
"    ]. Most series report a higher incidence in males [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/30,36,41,42\">",
"     30,36,41,42",
"    </a>",
"    ], although some showed more cases in females or neither sex [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/5,31\">",
"     5,31",
"    </a>",
"    ]. In one Spanish series of 55 cases, 93 percent of patients were men [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with S. bovis endocarditis are less likely to have risk factors that predispose to development of IE, such as intravenous drug use or structural heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/5,30,31,34-36,39,43\">",
"     5,30,31,34-36,39,43",
"    </a>",
"    ]. The incidence of S. bovis in prosthetic valve endocarditis is variable [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. S. bovis was the etiologic agent of late prosthetic valve endocarditis in 3 percent of cases in Barcelona over a 20-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/44\">",
"     44",
"    </a>",
"    ],",
"   </p>",
"   <p>",
"    There are a number of case reports describing S. bovis bacteremia and meningitis complicating Strongyloides stercoralis infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29926/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11193?source=see_link\">",
"     \"Strongyloidiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Association with colonic neoplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association between S. bovis bacteremia or endocarditis and colonic neoplasia has been appreciated for many years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22041?source=see_link&amp;anchor=H24506924#H24506924\">",
"     \"Clinical manifestations, diagnosis, and treatment of Streptococcus bovis infection\", section on 'Association with colonic neoplasia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Streptococcus bovis is a gram-positive coccus that is an important cause of bacteremia and infective endocarditis in adults. Such infections have been associated with colonic neoplasia and other lesions of the gastrointestinal tract. Therefore, diagnostic evaluation of the gastrointestinal tract is important for patients with systemic infection due to this organism. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22041?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of Streptococcus bovis infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      S. bovis is a catalase-negative, gram-positive coccus that usually express the Lancefield group D antigen. Colonies are typically small and non-hemolytic on blood agar. Both S. bovis and Enterococcus spp were originally classified as group D streptococci but are now considered separate genera. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      S. bovis may be subdivided into biotype I (S. bovis) and biotype II (S. bovis variant) based on biochemical reactions. Members of the S. bovis group include Streptococcus gallolyticus (some strains previously classified as S. bovis biotype I and",
"      <span class=\"nowrap\">",
"       II/2)",
"      </span>",
"      and Streptococcus infantarius (strains identified as S. bovis biotype",
"      <span class=\"nowrap\">",
"       II/1).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Occasionally strains of Streptococcus salivarius are misidentified as S. bovis. Unlike S. bovis, S. salivarius is not usually associated with neoplasia and is a relatively frequent blood culture contaminant. Commercially available kits can be used to differentiate it from S. bovis and S. bovis variant in most cases. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      S. bovis has been isolated in the stool of 2 to 12 percent of healthy individuals. The organism is not generally considered to be part of the normal oral flora, although it has been identified in cultures of gingiva or throat in small numbers of individuals. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      S. bovis accounts for 2 to 6 percent of streptococcal bloodstream isolates among hospitalized patients. S. bovis causes about 2 percent of IE cases in the US, but is more prominent in Europe (10 percent in a large series). Patients with S. bovis endocarditis are typically older than patients with IE due to other organisms and may lack risk factors that typically predispose to development of IE, such as intravenous drug use or structural heart disease. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Bacteremia and endocarditis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Roberts, RB. Streptococcal endocarditis: The viridans and beta hemolytic streptococci. In: Infective Endocarditis, Kaye, D (Ed), Raven Press, Ltd, New York, 1992. p.191.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/2\">",
"      Facklam R. What happened to the streptococci: overview of taxonomic and nomenclature changes. Clin Microbiol Rev 2002; 15:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/3\">",
"      Schlegel L, Grimont F, Ageron E, et al. Reappraisal of the taxonomy of the Streptococcus bovis/Streptococcus equinus complex and related species: description of Streptococcus gallolyticus subsp. gallolyticus subsp. nov., S. gallolyticus subsp. macedonicus subsp. nov. and S. gallolyticus subsp. pasteurianus subsp. nov. Int J Syst Evol Microbiol 2003; 53:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/4\">",
"      van't Wout JW, Bijlmer HA. Bacteremia due to Streptococcus gallolyticus, or the perils of revised nomenclature in bacteriology. Clin Infect Dis 2005; 40:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/5\">",
"      Moellering RC Jr, Watson BK, Kunz LJ. Endocarditis due to group D streptococci. Comparison of disease caused by streptococcus bovis with that produced by the enterococci. Am J Med 1974; 57:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/6\">",
"      Beck M, Frodl R, Funke G. Comprehensive study of strains previously designated Streptococcus bovis consecutively isolated from human blood cultures and emended description of Streptococcus gallolyticus and Streptococcus infantarius subsp. coli. J Clin Microbiol 2008; 46:2966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/7\">",
"      Sillanp&auml;&auml; J, Nallapareddy SR, Singh KV, et al. Adherence characteristics of endocarditis-derived Streptococcus gallolyticus ssp. gallolyticus (Streptococcus bovis biotype I) isolates to host extracellular matrix proteins. FEMS Microbiol Lett 2008; 289:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/8\">",
"      Tripodi MF, Fortunato R, Utili R, et al. Molecular epidemiology of Streptococcus bovis causing endocarditis and bacteraemia in Italian patients. Clin Microbiol Infect 2005; 11:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/9\">",
"      Ruoff KL, Miller SI, Garner CV, et al. Bacteremia with Streptococcus bovis and Streptococcus salivarius: clinical correlates of more accurate identification of isolates. J Clin Microbiol 1989; 27:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/10\">",
"      Clarridge JE 3rd, Attorri SM, Zhang Q, Bartell J. 16S ribosomal DNA sequence analysis distinguishes biotypes of Streptococcus bovis: Streptococcus bovis Biotype II/2 is a separate genospecies and the predominant clinical isolate in adult males. J Clin Microbiol 2001; 39:1549.",
"     </a>",
"    </li>",
"    <li>",
"     Ruoff KL, Whiley RA, Beighton D. Streptococcus. In: Manual of Clinical Microbiology, 7th ed, Murray PR, Baron EJ, Pfaller MA, et al (Eds), American Association for Microbiology, Washington, DC 1999. p.283.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/12\">",
"      Teng LJ, Hsueh PR, Ho SW, Luh KT. High prevalence of inducible erythromycin resistance among Streptococcus bovis isolates in Taiwan. Antimicrob Agents Chemother 2001; 45:3362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/13\">",
"      Lee RA, Woo PC, To AP, et al. Geographical difference of disease association in Streptococcus bovis bacteraemia. J Med Microbiol 2003; 52:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/14\">",
"      Herrero IA, Rouse MS, Piper KE, et al. Reevaluation of Streptococcus bovis endocarditis cases from 1975 to 1985 by 16S ribosomal DNA sequence analysis. J Clin Microbiol 2002; 40:3848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/15\">",
"      Corredoira JC, Alonso MP, Garc&iacute;a JF, et al. Clinical characteristics and significance of Streptococcus salivarius bacteremia and Streptococcus bovis bacteremia: a prospective 16-year study. Eur J Clin Microbiol Infect Dis 2005; 24:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/16\">",
"      Schlegel L, Grimont F, Collins MD, et al. Streptococcus infantarius sp. nov., Streptococcus infantarius subsp. infantarius subsp. nov. and Streptococcus infantarius subsp. coli subsp. nov., isolated from humans and food. Int J Syst Evol Microbiol 2000; 50 Pt 4:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/17\">",
"      Boleij A, van Gelder MM, Swinkels DW, Tjalsma H. Clinical Importance of Streptococcus gallolyticus infection among colorectal cancer patients: systematic review and meta-analysis. Clin Infect Dis 2011; 53:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/18\">",
"      Vanrobaeys M, De Herdt P, Ducatelle R, et al. Extracellular proteins and virulence in Streptococcus bovis isolates from pigeons. Vet Microbiol 1997; 59:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/19\">",
"      Telford JL, Barocchi MA, Margarit I, et al. Pili in gram-positive pathogens. Nat Rev Microbiol 2006; 4:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/20\">",
"      Sillanp&auml;&auml; J, Nallapareddy SR, Qin X, et al. A collagen-binding adhesin, Acb, and ten other putative MSCRAMM and pilus family proteins of Streptococcus gallolyticus subsp. gallolyticus (Streptococcus bovis Group, biotype I). J Bacteriol 2009; 191:6643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/21\">",
"      Boleij A, Schaeps RM, de Kleijn S, et al. Surface-exposed histone-like protein a modulates adherence of Streptococcus gallolyticus to colon adenocarcinoma cells. Infect Immun 2009; 77:5519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/22\">",
"      Tjalsma H, Sch&ouml;ller-Guinard M, Lasonder E, et al. Profiling the humoral immune response in colon cancer patients: diagnostic antigens from Streptococcus bovis. Int J Cancer 2006; 119:2127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/23\">",
"      Klein RS, Recco RA, Catalano MT, et al. Association of Streptococcus bovis with carcinoma of the colon. N Engl J Med 1977; 297:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/24\">",
"      Klein RS, Warman SW, Knackmuhs GG, et al. Lack of association of Streptococcus bovis with noncolonic gastrointestinal carcinoma. Am J Gastroenterol 1987; 82:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/25\">",
"      Burns CA, McCaughey R, Lauter CB. The association of Streptococcus bovis fecal carriage and colon neoplasia: possible relationship with polyps and their premalignant potential. Am J Gastroenterol 1985; 80:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/26\">",
"      Hoen B, Brian&ccedil;on S, Delahaye F, et al. Tumors of the colon increase the risk of developing Streptococcus bovis endocarditis: case-control study. Clin Infect Dis 1994; 19:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/27\">",
"      Norfleet RG, Mitchell PD. Streptococcus bovis does not selectively colonize colorectal cancer and polyps. J Clin Gastroenterol 1993; 17:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/28\">",
"      Pfaller MA, Jones RN, Marshall SA, et al. Nosocomial streptococcal blood stream infections in the SCOPE Program: species occurrence and antimicrobial resistance. The SCOPE Hospital Study Group. Diagn Microbiol Infect Dis 1997; 29:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/29\">",
"      Eggers S, Beuth J. Etiology and antibiotic susceptibility of bloodstream Streptococcus sp. Zentralbl Bakteriol 1992; 276:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/30\">",
"      Ballet M, Gevigney G, Gar&eacute; JP, et al. Infective endocarditis due to Streptococcus bovis. A report of 53 cases. Eur Heart J 1995; 16:1975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/31\">",
"      Murray HW, Roberts RB. Streptococcus bovis bacteremia and underlying gastrointestinal disease. Arch Intern Med 1978; 138:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/32\">",
"      Selton-Suty C, Hoen B, Delahaye F, et al. Comparison of infective endocarditis in patients with and without previously recognized heart disease. Am J Cardiol 1996; 77:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/33\">",
"      Cabell CH, Jollis JG, Peterson GE, et al. Changing patient characteristics and the effect on mortality in endocarditis. Arch Intern Med 2002; 162:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/34\">",
"      Hoen B, Alla F, Selton-Suty C, et al. Changing profile of infective endocarditis: results of a 1-year survey in France. JAMA 2002; 288:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/35\">",
"      Hoen B, Chirouze C, Cabell CH, et al. Emergence of endocarditis due to group D streptococci: findings derived from the merged database of the International Collaboration on Endocarditis. Eur J Clin Microbiol Infect Dis 2005; 24:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/36\">",
"      Corredoira J, Alonso MP, Coira A, et al. Characteristics of Streptococcus bovis endocarditis and its differences with Streptococcus viridans endocarditis. Eur J Clin Microbiol Infect Dis 2008; 27:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/37\">",
"      Durante-Mangoni E, Bradley S, Selton-Suty C, et al. Current features of infective endocarditis in elderly patients: results of the International Collaboration on Endocarditis Prospective Cohort Study. Arch Intern Med 2008; 168:2095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/38\">",
"      Murdoch DR, Corey GR, Hoen B, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med 2009; 169:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/39\">",
"      Tripodi MF, Adinolfi LE, Ragone E, et al. Streptococcus bovis endocarditis and its association with chronic liver disease: an underestimated risk factor. Clin Infect Dis 2004; 38:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/40\">",
"      Pergola V, Di Salvo G, Habib G, et al. Comparison of clinical and echocardiographic characteristics of Streptococcus bovis endocarditis with that caused by other pathogens. Am J Cardiol 2001; 88:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/41\">",
"      Zarkin BA, Lillemoe KD, Cameron JL, et al. The triad of Streptococcus bovis bacteremia, colonic pathology, and liver disease. Ann Surg 1990; 211:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/42\">",
"      Duval X, Papastamopoulos V, Longuet P, et al. Definite streptococcus bovis endocarditis: characteristics in 20 patients. Clin Microbiol Infect 2001; 7:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/43\">",
"      McKinsey DS, Ratts TE, Bisno AL. Underlying cardiac lesions in adults with infective endocarditis. The changing spectrum. Am J Med 1987; 82:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/44\">",
"      Tornos P, Almirante B, Olona M, et al. Clinical outcome and long-term prognosis of late prosthetic valve endocarditis: a 20-year experience. Clin Infect Dis 1997; 24:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/45\">",
"      Jain AK, Agarwal SK, el-Sadr W. Streptococcus bovis bacteremia and meningitis associated with Strongyloides stercoralis colitis in a patient infected with human immunodeficiency virus. Clin Infect Dis 1994; 18:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29926/abstract/46\">",
"      Linder JD, M&ouml;nkem&uuml;ller KE, Lazenby AJ, Wilcox CM. Streptococcus bovis bacteremia associated with Strongyloides stercoralis colitis. Gastrointest Endosc 2000; 52:796.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3159 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-863E2EFFA9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_14_29926=[""].join("\n");
var outline_f29_14_29926=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Bacteremia and endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Association with colonic neoplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22041?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of Streptococcus bovis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11193?source=related_link\">",
"      Strongyloidiasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_14_29927="Treatment of hearing impairment in children";
var content_f29_14_29927=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of hearing impairment in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/14/29927/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/14/29927/contributors\">",
"     Richard JH Smith, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/14/29927/contributors\">",
"     Adrian Gooi, MD, FRCS(C)",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/14/29927/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/14/29927/contributors\">",
"     Glenn C Isaacson, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/14/29927/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/14/29927/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/14/29927/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of hearing impairment in children is reviewed here. The etiology and evaluation of hearing loss in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19050?source=see_link\">",
"     \"Etiology of hearing impairment in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=see_link\">",
"     \"Evaluation of hearing impairment in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hearing loss in children is often a silent and hidden handicap. Children with hearing loss frequently appear to be normal, and often their handicaps are not apparent. Hearing loss that is undetected and untreated can result in speech, language, and cognitive delays. Early identification and effective treatment of hearing loss improves language, communication, and cognitive skills [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29927/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment options for children with hearing loss depend upon the etiology. The underlying cause is addressed whenever possible. As examples, acute otitis media is treated with antibiotics, impacted cerumen is removed, and ototoxic drugs that cause reversible hearing loss are stopped if alternate therapy is available. Surgical intervention is necessary for some conditions. Amplification devices are recommended for children with bilateral sensorineural hearing loss or long-term conductive hearing loss. Cochlear implants are an option for children with profound bilateral hearing loss who do not benefit from traditional amplification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MULTIDISCIPLINARY TEAM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally, all children with permanent hearing loss should be managed by a multidisciplinary team that includes audiologists, otolaryngologists, speech pathologists, geneticists, and educational specialists. In addition, these children should be referred to a pediatric ophthalmologist, because they rely on sight for communication and learning [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29927/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hearing-impaired child should also be referred to the appropriate educational agency. In some states, referral is mandatory within a limited time after identification. The local school district or early childhood intervention agency is equipped to provide educational guidance for the special needs of hearing-impaired children. This may include preferential seating or the use of frequency modulated (FM) systems at school (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Assistive listening devices'",
"    </a>",
"    below). Educational options vary according to the degree of hearing loss and cognitive ability of the child. Development of communication skills is the basic goal of early education programs for hearing-impaired children. Most agencies work with the team of professionals to establish an individual treatment plan for each child.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SURGICAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step is to treat underlying etiology if possible. Some conditions associated with hearing loss are amenable to surgical intervention:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pressure equalization tubes for the tympanic membrane may improve hearing for children with middle ear effusion, eustachian tube dysfunction, or recurrent acute otitis media. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/56/3978?source=see_link\">",
"       \"Overview of tympanostomy tube placement and medical care of children with tympanostomy tubes\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42857?source=see_link&amp;anchor=H21#H21\">",
"       \"Acute otitis media in children: Prevention of recurrence\", section on 'Tympanostomy tubes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tumors and cholesteatomas require surgical excision or mastoidectomy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42808?source=see_link\">",
"       \"Cholesteatoma in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children with fluctuating or progressive sensorineural hearing loss may occasionally benefit from surgical exploration for and repair of a perilymph fistula. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/38/17001?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathophysiology, etiology, and differential diagnosis of vertigo\", section on 'Perilymphatic fistula'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some conditions that cause conductive hearing loss can be treated with either surgery or amplification (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12055?source=see_link\">",
"     \"Congenital anomalies of the ear\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Otosclerosis or other ossicular chain abnormalities",
"     </li>",
"     <li>",
"      Stenosis of the external auditory canal",
"     </li>",
"     <li>",
"      Some cases of atresia of the external auditory canal [",
"      <a class=\"abstract\" href=\"UTD.htm?29/14/29927/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     HEARING AIDS AND ASSISTIVE DEVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The next step in the management of hearing impairment, after the underlying etiology is addressed when possible, is hearing amplification. The initial stage in providing successful hearing amplification is for the audiologist and the parents, child, and other family members to agree that the child has hearing loss and will benefit from a hearing aid. A second opinion is sometimes necessary to convince the parents of this fact. Parents should know that hearing aids do not necessarily restore hearing to normal, but improved hearing is expected. Amplification before the age of six months improves language outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29927/abstract/1,8\">",
"     1,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hearing aids",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A range of hearing aid styles, types, and costs is available. The choice of a hearing aid for each child is made on an individual basis in consultation with an audiologist and the parents. The best hearing aid for the child is determined by the results of the formal audiologic evaluation, the age of the child, the level and type of hearing loss, and",
"    <span class=\"nowrap\">",
"     patient/family",
"    </span>",
"    preference.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Fitting",
"    </span>",
"    &nbsp;&mdash;&nbsp;In young children, it may be difficult to know whether a hearing aid is correctly fit or too loud. Measurement of sound intensity in the ear canal with a tiny microphone (Real Ear&trade;) can address this problem. Computer programs are available that use real ear measurements or simulated real ear measurements to help the audiologist determine whether a particular device is appropriate for a given child. The desired sensation level (DSL) approach estimates a frequency gain target that amplifies speech to audible levels across a broad frequency range and is beneficial in fitting hearing aids for very young children [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29927/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Style",
"    </span>",
"    &nbsp;&mdash;&nbsp;The styles of hearing aids available include bone conduction, behind-the-ear, in-the-ear, and completely-in-the-canal instruments. Bone conduction hearing aids are used for children who have atretic ears or chronic otorrhea. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Bone conduction hearing devices'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Most hearing aids fit for children are behind-the-ear instruments, because the ear mold that is coupled to the ear is easily remade as the child grows. In-the-ear and in-the-canal instruments are more cosmetically appealing to teenagers; these devices are appropriate only for hearing loss less than 60 dB.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Electronic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electronic circuitry and signal processing options also must be considered when selecting a hearing aid. Circuitry can be analog, digital, or digitally programmable. The advantages of digital and programmable hearing aids over conventional analog hearing aids include better sound quality, increased precision, improved speech recognition [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29927/abstract/11,12\">",
"     11,12",
"    </a>",
"    ], and flexibility of settings; the disadvantage is higher cost. Most digital hearing aids are not appropriate for children with profound hearing loss; however, several programmable aids provide adequate gain for children with severe to profound losses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Assistive listening devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assistive listening systems are designed to improve hearing perception, especially in noisy environments. They consist of a microphone for the speaker, a frequency modulated (FM) transmitter, and a receiver worn by the listener. These are available as stand-alone units, or the FM receiver can be attached to a hearing aid [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29927/abstract/13\">",
"     13",
"    </a>",
"    ]. Assistive listening systems provide gain (amplification) and improve signal-to-noise ratio by eliminating background noise. Most FM assistive devices are used for educational purposes, but they can help in other listening situations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Counseling and education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parents should be encouraged to purchase an extended warranty or insurance plan for hearing aids. Most manufacturers offer extended warranties at reasonable prices. Some insurance companies specialize in coverage for hearing aids.",
"   </p>",
"   <p>",
"    The fitting of hearing aids and assistive devices can be a stressful time for parents of hearing-impaired children. They may need counseling and support in addition to written information on hearing loss, hearing aids, and troubleshooting tips. Regular follow-up sessions with the audiologist are necessary to establish aided benefit and to check the fit of the hearing aids and ear mold.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     BONE CONDUCTION HEARING DEVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients who are unable to benefit from a standard air conduction device (a conventional hearing aid) may benefit from a device that transmits sound directly through the skull. Bone conduction hearing aids can be held against the skull with a steel-spring or soft headband. Improvements in design have led to instruments that are more comfortable and provide better sound. However, an implantable bone conduction hearing aid still has significant advantages [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29927/abstract/14-18\">",
"     14-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main implantable system available is a bone-anchored implantable hearing aid system, known as BAHA. A small titanium screw is inserted and osseointegrates with the bone of the skull over several months. An abutment is attached to the screw such that a small portion of the abutment sticks out through the skin and forms an attachment point for a removable bone-conduction hearing aid. The sound quality is superior to that of traditional bone conduction hearing aids. Other implantable systems that directly vibrate the ossicles in the middle ear have become available [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29927/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential indications for an implantable system include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Congenital atresia of the ear canal such that it does not exist or cannot accommodate a standard hearing aid (provided that the nerve is functional) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/14/29927/abstract/21-23\">",
"       21-23",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12055?source=see_link&amp;anchor=H11#H11\">",
"       \"Congenital anomalies of the ear\", section on 'Aural atresia'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Chronic infection of the middle or outer ear that is exacerbated by a standard hearing aid",
"     </li>",
"     <li>",
"      Allergic reactions to standard hearing aids",
"     </li>",
"     <li>",
"      Single-sided deafness as may occur after removal of a vestibular schwannoma (acoustic neuroma), from trauma, or from a viral or vascular insult [",
"      <a class=\"abstract\" href=\"UTD.htm?29/14/29927/abstract/24\">",
"       24",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children are typically about six years of age before BAHA is feasible, because 3 to 4 mm of bone is needed to ensure osseointegration [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29927/abstract/25\">",
"     25",
"    </a>",
"    ]. The BAHA may be implanted either unilaterally or bilaterally [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29927/abstract/26\">",
"     26",
"    </a>",
"    ]. A systematic review of observational studies of BAHA in both children and adults found greater audiologic benefits (eg, hearing sensitivity in quiet, speech perception in quiet and in noise, and",
"    <span class=\"nowrap\">",
"     localization/lateralization)",
"    </span>",
"    in patients with bilateral compared with unilateral placement [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29927/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     COCHLEAR IMPLANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cochlear implants are surgically implanted prosthetic devices that electrically stimulate the cochlear nerve to provide hearing. The device consists of a battery-powered external processor (that looks like a hearing aid), a receiver coil implanted below the scalp, and an electrode inserted directly into the cochlea through a surgical opening.",
"   </p>",
"   <p>",
"    The criteria for selecting cochlear implantation include severe to profound bilateral sensorineural hearing loss and little or no benefit from hearing aid use after six months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29927/abstract/28-30\">",
"     28-30",
"    </a>",
"    ] in patients who desire access to audition and spoken language.",
"   </p>",
"   <p>",
"    Cochlear implant devices (including those from Advanced Bionics, Med-El, and Clarion) are approved by the US Food and Drug Administration (FDA) for use in children as young as 12 months, although off-label use has occurred for infants less than 12 months old [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29927/abstract/31\">",
"     31",
"    </a>",
"    ]. A meta-analysis suggests the role of cochlear implantation in children less than 12 months of age remains unclear, since the literature is lacking in prospective studies or long-term follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29927/abstract/32\">",
"     32",
"    </a>",
"    ]. The advantage of early auditory stimulation during the \"critical period\" of hearing development needs to be balanced against the risks of the procedure. As an example, meningitis may cause labyrinthitis ossificans (bony filling of the cochlear duct), and may necessitate consideration for earlier cochlear implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29927/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bilateral cochlear implants have been advocated as they allow a child to hear better in conditions with background noise (such as restaurants), localize sound, and hear sound coming from either side without having to turn the head [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29927/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. Arguments against bilateral implantation have included increased surgical and anesthetic risk, risk to residual hearing, and saving one ear for future technologies. If chosen, bilateral implants are either performed simultaneously in the same operation, or sequentially in separate surgeries. Studies demonstrate benefit from bilateral implantation with any length of time between surgeries [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29927/abstract/37\">",
"     37",
"    </a>",
"    ]; however, improved response at the brainstem and greater expressive language development is noted in patients with minimized duration between implants, with the greatest response seen in patients with simultaneous implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29927/abstract/34,38,39\">",
"     34,38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Preoperative evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative evaluation for a cochlear implant includes computed tomography (CT) or magnetic resonance imaging (MRI) of the temporal bone to evaluate the patency of the cochlea, identify congenital malformations, and assess surgical anatomy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29927/abstract/40\">",
"     40",
"    </a>",
"    ]. Audiometric testing should be well documented. Other important prerequisites include access to an education program that stresses auditory and verbal skills and highly motivated parents who have realistic expectations. Because of the increased risk of meningitis in children with cochlear implants, immunization again",
"    <em>",
"     Streptococcus pneumoniae",
"    </em>",
"    and",
"    <em>",
"     Haemophilus influenza",
"    </em>",
"    is recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35913?source=see_link\">",
"     \"Cochlear implant infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cochlear implantation in children provides auditory detection over much of the speech signal and results in improved auditory discrimination and speech production [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29927/abstract/40\">",
"     40",
"    </a>",
"    ]. In one study, the language achievement of 29 prelingually deaf children three or more years after cochlear implantation was compared with the achievement of 29 prelingually deaf children who were treated with hearing aids [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29927/abstract/41\">",
"     41",
"    </a>",
"    ]. The children with cochlear implants had better language comprehension and production skills.",
"   </p>",
"   <p>",
"    Children whose deafness occurs after age two years, who are deaf for short periods of time, who use oral communication,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    who are implanted at an earlier age have the best language outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29927/abstract/40,42-45\">",
"     40,42-45",
"    </a>",
"    ]. As an example, the speech perception and production skills of three groups of children were analyzed after cochlear implantation: 70 children who were congenitally deaf, 22 children who were deafened by meningitis before two years of age, and 14 children who were deafened by meningitis after two years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29927/abstract/46\">",
"     46",
"    </a>",
"    ]. The speech perception skills of the groups of children who were deafened after age two were better than those of the other two groups; no difference was found in speech perception or production skills between the two groups of children whose deafness began before age two years.",
"   </p>",
"   <p>",
"    Speech perception was measured three, four, and five years after cochlear implantation in 40 children who were born deaf or who became deaf before three years of age and who had no measurable speech perception before implantation with the most powerful hearing aids [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29927/abstract/47\">",
"     47",
"    </a>",
"    ]. Speech perception improved with time (27, 35, and 45 mean words per minute at three, four, and five years of follow-up, respectively). Improvement in speech perception was greater for children who were younger at the time of implantation and who used oral, rather than total, communication (eg, including signing).",
"   </p>",
"   <p>",
"    The language outcome may be poorer in children with underlying motor",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cognitive disabilities, such as those with congenital cytomegalovirus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29927/abstract/48\">",
"     48",
"    </a>",
"    ], and in those with hypoplastic inner ear malformations",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cochlear nerve deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29927/abstract/49\">",
"     49",
"    </a>",
"    ]. Severe inner ear dysplasia is also associated with a poorer audiologic outcome and increased surgical difficulty, including a higher rate of intraoperative cerebrospinal fluid gushers [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29927/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Educational and employment achievements were examined in a series of 100 prelingually deaf children who received cochlear implants before six years of age and were followed for at least four years after implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29927/abstract/52\">",
"     52",
"    </a>",
"    ]. Most children without additional disabilities were in mainstream schools. About one-quarter experienced delayed reading and writing skills and approximately one-half repeated a grade. Despite this, the educational and employment levels ultimately achieved in this group were comparable to that of their peers with normal hearing.",
"   </p>",
"   <p>",
"    Cochlear implant failure, due to medical (infection or wound dehiscence) or device failure, is rare and is associated with a history of meningitis as the cause of deafness [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29927/abstract/53-57\">",
"     53-57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Risk of meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with cochlear implants are at increased risk for meningitis, particularly pneumococcal meningitis. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35913?source=see_link\">",
"     \"Cochlear implant infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     RESOURCES FOR FAMILIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Choices for Parents is an Illinois coalition that provides information for parents of children with hearing loss (",
"    <a class=\"external\" href=\"file://www.choicesforparents.org/\">",
"     www.choicesforparents.org",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hearing loss that is undetected and untreated can result in speech, language, and cognitive delays. Early identification and effective treatment of hearing loss improves language, communication, and cognitive skills. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment options for children with hearing loss depend upon the etiology. The underlying cause is addressed whenever possible. Some underlying conditions are amenable to surgical intervention. Amplification devices are recommended for children with bilateral sensorineural hearing loss or long-term conductive hearing loss. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with permanent hearing loss should be managed by a multidisciplinary team that includes audiologists, otolaryngologists, speech pathologists, geneticists, and educational specialists. They should also be referred to a pediatric ophthalmologist because they rely on sight for communication and learning. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Multidisciplinary team'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical intervention is indicated for some conditions associated with hearing loss (eg, tumors, cholesteatomas). Some conditions that cause conductive hearing loss can be treated with either surgery or amplification (eg, otosclerosis, ossicular chain abnormalities, or stenosis or atresia of the external auditory canal). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Surgical management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hearing aids are the primary form of amplification devices used. Hearing aids improve hearing, but do not necessarily restore it to normal. Amplification before the age of six months improves language outcome. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Hearing aids and assistive devices'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bone conduction hearing aids are devices that transmit sound directly through the skull. Bone conduction hearing aids are used in certain patients who are unable to benefit from a standard air conduction device (a conventional hearing aid), such as those with congenital aural atresia. These devices are held against the skull or bone-anchored. The latter method is preferred in most cases, although children are typically about six years of age before the bone-anchored hearing aid (BAHA) is feasible because 3 to 4 mm of bone is needed to ensure osseointegration. The BAHA may be implanted either unilaterally or bilaterally. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Bone conduction hearing devices'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cochlear implants electrically stimulate the cochlear nerve to provide hearing. We recommend cochlear implants for patients with profound bilateral sensorineural hearing loss who have had little or no benefit from hearing aid use after six months (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We also suggest bilateral, rather than unilateral, implantation and decreasing the time between implants (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Cochlear implants'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/1\">",
"      Yoshinaga-Itano C, Sedey AL, Coulter DK, Mehl AL. Language of early- and later-identified children with hearing loss. Pediatrics 1998; 102:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/2\">",
"      Watkin P, McCann D, Law C, et al. Language ability in children with permanent hearing impairment: the influence of early management and family participation. Pediatrics 2007; 120:e694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/3\">",
"      Downs MP, Yoshinaga-Itano C. The efficacy of early identification and intervention for children with hearing impairment. Pediatr Clin North Am 1999; 46:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/4\">",
"      Yoshinaga-Itano C. Benefits of early intervention for children with hearing loss. Otolaryngol Clin North Am 1999; 32:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/5\">",
"      Vohr B, Jodoin-Krauzyk J, Tucker R, et al. Early language outcomes of early-identified infants with permanent hearing loss at 12 to 16 months of age. Pediatrics 2008; 122:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/6\">",
"      Callison DM. Audiologic evaluation of hearing-impaired infants and children. Otolaryngol Clin North Am 1999; 32:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/7\">",
"      Jahrsdoerfer R. Congenital malformations of the ear. Analysis of 94 operations. Ann Otol Rhinol Laryngol 1980; 89:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/8\">",
"      Yoshinaga-Itano C. Efficacy of early identification and early intervention. Semin Hear 1995; 16:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/9\">",
"      Seewald RC. The desired sensation level method for fitting children. Hear J 1992; 45:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/10\">",
"      Winter M, Eisenberg L. Amplification for infants: selection and verification. Otolaryngol Clin North Am 1999; 32:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/11\">",
"      Bamford J, McCracken W, Peers I, Grayson P. Trial of a two-channel hearing aid (low-frequency compression-high-frequency linear amplification) with school age children. Ear Hear 1999; 20:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/12\">",
"      Kuk FK, Kollofski C, Brown S, et al. Use of a digital hearing aid with directional microphones in school-aged children. J Am Acad Audiol 1999; 10:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/13\">",
"      Madell JR. FM systems as primary amplification for children with profound hearing loss. Ear Hear 1992; 13:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/14\">",
"      Lloyd S, Almeyda J, Sirimanna KS, et al. Updated surgical experience with bone-anchored hearing aids in children. J Laryngol Otol 2007; 121:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/15\">",
"      Snik A, Leijendeckers J, Hol M, et al. The bone-anchored hearing aid for children: recent developments. Int J Audiol 2008; 47:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/16\">",
"      Hol MK, Kunst SJ, Snik AF, et al. Bone-anchored hearing aids in patients with acquired and congenital unilateral inner ear deafness (Baha CROS): clinical evaluation of 56 cases. Ann Otol Rhinol Laryngol 2010; 119:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/17\">",
"      Saliba I, Woods O, Caron C. BAHA results in children at one year follow-up: a prospective longitudinal study. Int J Pediatr Otorhinolaryngol 2010; 74:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/18\">",
"      Ricci G, Della Volpe A, Faralli M, et al. Results and complications of the Baha system (bone-anchored hearing aid). Eur Arch Otorhinolaryngol 2010; 267:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/19\">",
"      Chen DA, Backous DD, Arriaga MA, et al. Phase 1 clinical trial results of the Envoy System: a totally implantable middle ear device for sensorineural hearing loss. Otolaryngol Head Neck Surg 2004; 131:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/20\">",
"      Snik AF, Cremers CW. First audiometric results with the Vibrant soundbridge, a semi-implantable hearing device for sensorineural hearing loss. Audiology 1999; 38:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/21\">",
"      Mazita A, Fazlina WH, Abdullah A, et al. Hearing rehabilitation in congenital canal atresia. Singapore Med J 2009; 50:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/22\">",
"      Ricci G, Volpe AD, Faralli M, et al. Bone-anchored hearing aids (Baha) in congenital aural atresia: personal experience. Int J Pediatr Otorhinolaryngol 2011; 75:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/23\">",
"      Fuchsmann C, Tringali S, Disant F, et al. Hearing rehabilitation in congenital aural atresia using the bone-anchored hearing aid: audiological and satisfaction results. Acta Otolaryngol 2010; 130:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/24\">",
"      Bishop CE, Eby TL. The current status of audiologic rehabilitation for profound unilateral sensorineural hearing loss. Laryngoscope 2010; 120:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/25\">",
"      Federspil PA, Tretbar SH, B&ouml;hlen FH, et al. Measurement of skull bone thickness for bone-anchored hearing aids: an experimental study comparing both a novel ultrasound system (SonoPointer) and computed tomographic scanning to mechanical measurements. Otol Neurotol 2010; 31:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/26\">",
"      de Wolf MJ, Hol MK, Mylanus EA, et al. Benefit and quality of life after bone-anchored hearing aid fitting in children with unilateral or bilateral hearing impairment. Arch Otolaryngol Head Neck Surg 2011; 137:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/27\">",
"      Janssen RM, Hong P, Chadha NK. Bilateral bone-anchored hearing aids for bilateral permanent conductive hearing loss: a systematic review. Otolaryngol Head Neck Surg 2012; 147:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/28\">",
"      Rizer FM, Burkey JM. Cochlear implantation in the very young child. Otolaryngol Clin North Am 1999; 32:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/29\">",
"      NIH consensus conference. Cochlear implants in adults and children. JAMA 1995; 274:1955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/30\">",
"      Peters BR, Wyss J, Manrique M. Worldwide trends in bilateral cochlear implantation. Laryngoscope 2010; 120 Suppl 2:S17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/31\">",
"      Colletti L, Mandal&agrave; M, Colletti V. Cochlear implants in children younger than 6 months. Otolaryngol Head Neck Surg 2012; 147:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/32\">",
"      Vlastarakos PV, Proikas K, Papacharalampous G, et al. Cochlear implantation under the first year of age--the outcomes. A critical systematic review and meta-analysis. Int J Pediatr Otorhinolaryngol 2010; 74:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/33\">",
"      Young NM, Tan TQ. Current techniques in management of postmeningitic deafness in children. Arch Otolaryngol Head Neck Surg 2010; 136:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/34\">",
"      Papsin BC, Gordon KA. Bilateral cochlear implants should be the standard for children with bilateral sensorineural deafness. Curr Opin Otolaryngol Head Neck Surg 2008; 16:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/35\">",
"      Balkany T, Hodges A, Telischi F, et al. William House Cochlear Implant Study Group: position statement on bilateral cochlear implantation. Otol Neurotol 2008; 29:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/36\">",
"      Basura GJ, Eapen R, Buchman CA. Bilateral cochlear implantation: current concepts, indications, and results. Laryngoscope 2009; 119:2395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/37\">",
"      Smulders YE, Rinia AB, Rovers MM, et al. What is the effect of time between sequential cochlear implantations on hearing in adults and children? A systematic review of the literature. Laryngoscope 2011; 121:1942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/38\">",
"      Zeitler DM, Kessler MA, Terushkin V, et al. Speech perception benefits of sequential bilateral cochlear implantation in children and adults: a retrospective analysis. Otol Neurotol 2008; 29:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/39\">",
"      Boons T, Brokx JP, Frijns JH, et al. Effect of pediatric bilateral cochlear implantation on language development. Arch Pediatr Adolesc Med 2012; 166:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/40\">",
"      Kveton J, Balkany TJ. Status of cochlear implantation in children. American Academy of Otolaryngology-Head and Neck Surgery Subcommittee on Cochlear implants. J Pediatr 1991; 118:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/41\">",
"      Tomblin JB, Spencer L, Flock S, et al. A comparison of language achievement in children with cochlear implants and children using hearing aids. J Speech Lang Hear Res 1999; 42:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/42\">",
"      Manrique M, Cervera-Paz FJ, Huarte A, Molina M. Advantages of cochlear implantation in prelingual deaf children before 2 years of age when compared with later implantation. Laryngoscope 2004; 114:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/43\">",
"      Niparko JK, Tobey EA, Thal DJ, et al. Spoken language development in children following cochlear implantation. JAMA 2010; 303:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/44\">",
"      Zeitler DM, Anwar A, Green JE, et al. Cochlear implantation in prelingually deafened adolescents. Arch Pediatr Adolesc Med 2012; 166:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/45\">",
"      Ahmad FI, Demason CE, Teagle HF, et al. Cochlear implantation in children with postlingual hearing loss. Laryngoscope 2012; 122:1852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/46\">",
"      Mitchell TE, Psarros C, Pegg P, et al. Performance after cochlear implantation: a comparison of children deafened by meningitis and congenitally deaf children. J Laryngol Otol 2000; 114:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/47\">",
"      O'Donoghue GM, Nikolopoulos TP, Archbold SM. Determinants of speech perception in children after cochlear implantation. Lancet 2000; 356:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/48\">",
"      Malik V, Bruce IA, Broomfield SJ, et al. Outcome of cochlear implantation in asymptomatic congenital cytomegalovirus deafened children. Laryngoscope 2011; 121:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/49\">",
"      Buchman CA, Teagle HF, Roush PA, et al. Cochlear implantation in children with labyrinthine anomalies and cochlear nerve deficiency: implications for auditory brainstem implantation. Laryngoscope 2011; 121:1979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/50\">",
"      Pakdaman MN, Herrmann BS, Curtin HD, et al. Cochlear implantation in children with anomalous cochleovestibular anatomy: A systematic review. Otolaryngol Head Neck Surg 2012; 146:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/51\">",
"      Pakdaman MN, Herrmann BS, Curtin HD, et al. Cochlear implantation in children with anomalous cochleovestibular anatomy. Otolaryngol Head Neck Surg 2012; 146:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/52\">",
"      Venail F, Vieu A, Artieres F, et al. Educational and employment achievements in prelingually deaf children who receive cochlear implants. Arch Otolaryngol Head Neck Surg 2010; 136:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/53\">",
"      Parisier SC, Chute PM, Popp AL, Suh GD. Outcome analysis of cochlear implant reimplantation in children. Laryngoscope 2001; 111:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/54\">",
"      Lassig AA, Zwolan TA, Telian SA. Cochlear implant failures and revision. Otol Neurotol 2005; 26:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/55\">",
"      Fayad JN, Eisenberg LS, Gillinger M, et al. Clinical performance of children following revision surgery for a cochlear implant. Otolaryngol Head Neck Surg 2006; 134:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/56\">",
"      Eskander A, Gordon KA, Kadhim L, et al. Low pediatric cochlear implant failure rate: contributing factors in large-volume practice. Arch Otolaryngol Head Neck Surg 2011; 137:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29927/abstract/57\">",
"      Roby BB, Ferrello M, Huang TC, et al. Symptom timeline preceding cochlear implant failure: an institutional experience. Otolaryngol Head Neck Surg 2012; 146:782.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6298 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-109.230.63.219-37932DBF7B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_14_29927=[""].join("\n");
var outline_f29_14_29927=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MULTIDISCIPLINARY TEAM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SURGICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HEARING AIDS AND ASSISTIVE DEVICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hearing aids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Fitting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Style",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Electronic features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Assistive listening devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Counseling and education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      BONE CONDUCTION HEARING DEVICES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      COCHLEAR IMPLANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Preoperative evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Risk of meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      RESOURCES FOR FAMILIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42857?source=related_link\">",
"      Acute otitis media in children: Prevention of recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42808?source=related_link\">",
"      Cholesteatoma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35913?source=related_link\">",
"      Cochlear implant infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12055?source=related_link\">",
"      Congenital anomalies of the ear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19050?source=related_link\">",
"      Etiology of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=related_link\">",
"      Evaluation of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/56/3978?source=related_link\">",
"      Overview of tympanostomy tube placement and medical care of children with tympanostomy tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/38/17001?source=related_link\">",
"      Pathophysiology, etiology, and differential diagnosis of vertigo",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_14_29928="Varus stress test";
var content_f29_14_29928=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69222%7EEM%2F77592%7EPC%2F73257&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69222%7EEM%2F77592%7EPC%2F73257&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Varus stress test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 354px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The varus stress test is used to determine the integrity of the lateral collateral ligament. One hand is placed above the knee medially and one hand is placed along the lateral gastrocnemius muscle. The upper hand is used to stabilize the thigh while the lower hand places inward pressure on the calf. Pain, movement of the lateral joint space, and the elasticity of the ligament are noted.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Valgus stress test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 347px; height: 290px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The valgus stress test is used to determine the integrity of the medial collateral ligament. One hand is placed above the knee along the lateral thigh and one hand is placed along the medial gastrocnemius muscle. The upper hand is used to stabilize the thigh while the lower hand places outward pressure on the calf. Pain, movement of the medial joint space, and elasticity of the ligament are noted.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anterior drawer test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 349px; height: 292px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The anterior drawer test is used to assess the integrity of the anterior cruciate ligament. With the knee flexed to 90&ordm;, the foot is stabilized by sitting on it. The proximal tibia is grasped firmly with both hands, and the tibia is forcibly pulled anteriorly, noting any pain, laxity, or abnormal movement compared with the opposite side.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_14_29928=[""].join("\n");
var outline_f29_14_29928=null;
var title_f29_14_29929="Clinical presentation and diagnosis of urinary incontinence";
var content_f29_14_29929=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical presentation and diagnosis of urinary incontinence",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/14/29929/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/14/29929/contributors\">",
"     Catherine E DuBeau, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/14/29929/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/14/29929/contributors\">",
"     Linda Brubaker, MD, FACS, FACOG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/14/29929/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/14/29929/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/14/29929/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/14/29929/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 28, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary incontinence, the complaint of involuntary leakage of urine [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/1\">",
"     1",
"    </a>",
"    ], often remains undetected and undertreated by health care personnel worldwide despite its substantial impact upon affected individuals and health care systems [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In a US survey of a multiethnic population, only 45 percent of women who reported urinary incontinence occurring at least once a week ever sought care for their incontinence symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/4\">",
"     4",
"    </a>",
"    ]. This leaves incontinent individuals with unresolved physical, functional, and psychological morbidity, and diminished quality of life, both at home and at work [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms of incontinence may herald a serious underlying condition (eg, neurologic disease such as multiple sclerosis, or malignancy) and should never be dismissed as an age-related inconvenience. Primary care clinicians are able to identify the appropriate causes of incontinence sufficient to initiate management in many patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Specialized testing and referral are required initially in only a minority of cases.",
"   </p>",
"   <p>",
"    This topic will review the clinical presentation and diagnosis of urinary incontinence primarily in women. Urinary incontinence in men, as well as the epidemiology, pathogenesis, and treatment in women, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/1/7192?source=see_link\">",
"     \"Epidemiology, risk factors, and pathogenesis of urinary incontinence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=see_link\">",
"     \"Treatment of urinary incontinence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11290?source=see_link\">",
"     \"Lower urinary tract symptoms in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because many patients are reluctant to initiate a discussion about their incontinence, and because of the high prevalence of incontinence among women across the lifespan, it is recommended that all women be specifically screened for urinary incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. This is particularly important for women who have had children, have comorbid conditions associated with increased risk for urinary incontinence (ie, diabetes, neurologic disease), and who are over 65 years of age.",
"   </p>",
"   <p>",
"    Such screening has been incorporated into health care quality process measures in the US [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/9\">",
"     9",
"    </a>",
"    ]. The following screening questions have been suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Do you ever leak",
"      <span class=\"nowrap\">",
"       urine/water",
"      </span>",
"      when you don't want to?",
"     </li>",
"     <li>",
"      Do you ever leak urine when you cough, laugh, or exercise?",
"     </li>",
"     <li>",
"      Do you ever leak urine on the way to the bathroom?",
"     </li>",
"     <li>",
"      Do you ever use pads, tissue, or cloth in your underwear to catch urine?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Screening can also be done using short standardized questionnaires. The ICIQ questionnaire is a validated instrument for severity of incontinence, assessing frequency and volume of leakage, circumstances of leakage, and interference with everyday life&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urine leakage may present with a variety of specific symptoms. These symptoms, however, do not imply specific pathophysiology. The following standardized terminology should be used in describing a patient's symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urgency is the complaint of a sudden and compelling desire to pass urine that is difficult to defer.",
"     </li>",
"     <li>",
"      Urge incontinence is the complaint of involuntary leakage accompanied by urgency, an often sudden, compelling desire to pass urine which is difficult to deter. Leakage may range from drops to a soaking. Commonly reported precipitants include running water, hand washing, going out in the cold, and even the sight of the garage or trying to unlock the door when returning home. The need to &ldquo;rush to the toilet&rdquo; and length of time one can forestall an urgency episode are less useful symptoms because they reflect cognition, mobility, toilet availability, and sphincter control as well as bladder function.",
"     </li>",
"     <li>",
"      Stress incontinence is the complaint of involuntary leakage with effort, exertion, sneezing, or coughing. Leakage, however, may be provoked by minimal or no activity when there is severe sphincter damage.",
"      <br/>",
"      <br/>",
"      We find it useful to establish whether leakage occurs coincident with or after a several-second delay following cough. Immediate leakage suggests failure of sphincter mechanisms, while delayed leakage that is difficult to stop suggests a cough-induced uninhibited detrusor (bladder muscle) contraction.",
"     </li>",
"     <li>",
"      Mixed incontinence is the complaint of involuntary leakage associated with urgency and also with exertion, effort, sneezing, or coughing. Patients vary in the predominance, severity,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bother of urge versus stress leakage.",
"     </li>",
"     <li>",
"      \"Overactive bladder\" is a symptom syndrome (not a specific pathological condition) consisting of urgency, frequency, and nocturia, with or without urge incontinence.",
"     </li>",
"     <li>",
"      Continuous urinary incontinence is the complaint of continuous leakage, usually dribbling of small amounts of urine.",
"     </li>",
"     <li>",
"      Daytime frequency is the complaint of needing to void too often during the day, as defined by the patient.",
"     </li>",
"     <li>",
"      Nocturia is the complaint of waking at night one or more times to void. If these voids are associated with incontinence, the term \"nocturnal enuresis\" may be used.",
"     </li>",
"     <li>",
"      Slow stream is the perception of reduced urine flow, usually compared to previous performance.",
"     </li>",
"     <li>",
"      Intermittent stream (intermittency) is urine flow which stops and starts on one or more occasions during voiding.",
"     </li>",
"     <li>",
"      Hesitancy describes difficulty in initiating voiding, resulting in a delay in the onset of voiding after the individual feels ready to pass urine.",
"     </li>",
"     <li>",
"      Straining to void is the muscular effort used either to initiate, maintain, or improve the urinary stream.",
"     </li>",
"     <li>",
"      Incomplete emptying is the sensation that the bladder is not empty after voiding.",
"     </li>",
"     <li>",
"      In men, post-void dribbling may be another symptom associated with leakage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TYPES OF URINARY INCONTINENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Terminology regarding urinary incontinence can be confusing, as the same terms are used to describe symptoms and the common clinical types of incontinence, despite the lack of many of the symptoms. At the same time, classification of incontinence into a relatively small number of clinical types is useful in diagnosis and planning treatment. However, it should be noted that for a large proportion of patients, several urinary symptoms coexist [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/12\">",
"     12",
"    </a>",
"    ], and patterns of incontinence (stress, urge, or mixed) do not correlate precisely with an underlying pathophysiology. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Classifying type of incontinence from symptoms'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Lower urinary tract causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four major clinical types of urinary incontinence associated with lower urinary tract dysfunction: urge incontinence, stress incontinence, mixed incontinence, and \"overflow incontinence.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Urge incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of urge urinary incontinence and the overactive bladder syndrome is presumed to be uninhibited bladder contractions (called detrusor overactivity, DO) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/13\">",
"     13",
"    </a>",
"    ]. Detrusor overactivity, however, may also be found in healthy, continent elderly individuals, suggesting that overactivity alone is not sufficient to cause incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/14\">",
"     14",
"    </a>",
"    ]. Research suggests an important role of afferent sensory nerve pathways in the development of detrusor overactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Urge leakage symptoms may also be due to factors outside of the lower urinary tract. Failure of compensatory mechanisms in the lower urinary tract, and impairments in the functional requirements for continence may be important. In many cases, detrusor overactivity may be idiopathic. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Incontinence related to potentially reversible conditions'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/1/7192?source=see_link\">",
"     \"Epidemiology, risk factors, and pathogenesis of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urge urinary incontinence in younger women may be due to interstitial cystitis, also known as painful bladder syndrome. This condition is characterized by urgency and frequent voiding of small amounts of urine, often with dysuria or pain that is relieved by voiding; not all affected persons are incontinent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/16\">",
"     16",
"    </a>",
"    ]. Treatment is hampered by an incomplete understanding of its pathophysiology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8330?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of interstitial cystitis/bladder pain syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43369?source=see_link\">",
"     \"Management of interstitial cystitis/bladder pain syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urge urinary incontinence in frail older persons frequently coexists with impaired detrusor contractility, a condition termed detrusor hyperactivity with impaired contractility (DHIC). (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Incomplete emptying (overflow incontinence)'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Stress incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress leakage occurs when an increase in intraabdominal pressure overcomes sphincter closure mechanisms in the absence of a bladder contraction. Stress urinary incontinence is the most common cause of urinary incontinence in younger women, and is the second most common cause in older women [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/17\">",
"     17",
"    </a>",
"    ]. Stress incontinence often coexists with urge incontinence in middle-aged and older women. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Mixed incontinence'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Mixed incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mixed incontinence is the combination of urge and stress incontinence, and the most common type of urinary incontinence in women. Although generally thought to represent the overlap of two mechanisms, detrusor overactivity and impaired urethral sphincter function, the precise pathophysiology of mixed urinary incontinence is still under investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Incomplete emptying (overflow incontinence)",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Overflow incontinence\" is a term used to describe the dribbling",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    continuous leakage associated with incomplete bladder emptying, due to impaired detrusor contractility",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bladder outlet obstruction. This term is felt to be confusing and lacks a precise definition. A preferred term is \"incomplete bladder emptying\" and the description optimally should list the specific symptoms and any known associated pathophysiology (such as bladder outlet obstruction) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other associated symptoms may include weak urinary stream, dribbling, intermittency, hesitancy, frequency, and nocturia. Stress-related leakage may be apparent, reflecting an otherwise intact sphincter mechanism overwhelmed by the large bladder volume.",
"   </p>",
"   <p>",
"    Bladder outlet obstruction is common in men but uncommon in women, occurring in approximately 3 percent of a referral population of incontinent women [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11290?source=see_link&amp;anchor=H6#H6\">",
"     \"Lower urinary tract symptoms in men\", section on 'Bladder outlet obstruction (BOO)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Obstruction in women may be caused by scarring from prior anti-incontinence surgery or significant pelvic organ prolapse, when the prolapsed bladder or uterus kinks the urethra. Patients with suprasacral spinal cord injury can develop neurological obstruction from detrusor-sphincter dyssynergia, in which interruption of spinal pathways leads to sphincter contraction during bladder contraction; these patients are at high risk for hydronephrosis.",
"   </p>",
"   <p>",
"    Detrusor underactivity sufficient to cause overflow urinary incontinence and urinary retention occurs in about 5 to 10 percent of older persons and is less frequent in younger individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/19\">",
"     19",
"    </a>",
"    ]. Etiologies of detrusor underactivity include smooth muscle damage, fibrosis, low estrogen, aging, peripheral neuropathy (due to diabetes mellitus, vitamin B12 deficiency, Parkinson disease, alcoholism, tabes dorsalis), and damage to the spinal detrusor efferents by disc herniation, spinal stenosis, tumor, or congenital abnormalities.",
"   </p>",
"   <p>",
"    \"Detrusor hyperactivity with impaired contractility\" (DHIC), representing incontinence due to a combination of detrusor underactivity and overactivity, may occur in frail elderly persons [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/20\">",
"     20",
"    </a>",
"    ]. DHIC is characterized by urgency and an &ldquo;elevated&rdquo; postvoiding residual in the absence of outlet obstruction. It is not clear that the research definition of DHIC (postvoiding volume &gt;50 ml) is clinically relevant, especially as there is no consensus on the definition of elevated postvoiding volumes. DHIC can be misdiagnosed as stress urinary incontinence if DO is triggered by a stress maneuver, or as outlet obstruction and detrusor weakness, since it shares the same symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    \"Neurogenic bladder\" is a nonspecific term used to refer to conditions ranging from areflexic noncontractile bladder to detrusor overactivity; we prefer to avoid this terminology. Neurogenic lower urinary tract dysfunction can be diagnosed only in the presence of neurological pathology, and the type of dysfunction should be specified (",
"    <a class=\"graphic graphic_figure graphicRef52890 \" href=\"UTD.htm?21/36/22095\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Incontinence related to potentially reversible conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continence depends not only on the integrity of the lower urinary tract and its neurological control, but also on cognition, mobility, manual dexterity, environmental factors, and the absence of medical factors that affect these components",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    urine output (",
"    <a class=\"graphic graphic_table graphicRef82618 graphicRef60839 \" href=\"UTD.htm?13/61/14301\">",
"     table 1A-B",
"    </a>",
"    ). Therefore, particularly in older persons, a proportion of urinary incontinence is due to or exacerbated by such factors, resulting in incontinence even when lower urinary tract function is normal. Such urinary incontinence has been referred to elsewhere as \"transient\" or, when primarily due to impaired mobility or cognition, \"functional\" incontinence. There has been no consensus on the definitions of these terms, and we prefer to call this \"incontinence related to potentially reversible conditions.\"",
"   </p>",
"   <p>",
"    Little is known about the prevalence of this type of incontinence, alone or in combination with other types, although older studies suggest that it occurs in up to one-third of community-dwelling older persons and in up to one-half of hospitalized individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Identification of potentially reversible medical and functional conditions is important in all clinical settings, because they may be readily treatable and may contribute to morbidity beyond urinary incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/6\">",
"     6",
"    </a>",
"    ]. Chief among these factors are medications, which often precipitate or worsen urinary incontinence in older individuals (",
"    <a class=\"graphic graphic_table graphicRef80413 \" href=\"UTD.htm?3/11/3261\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Uncommon causes of incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other types of urinary incontinence, such as extraurethral incontinence (eg, from vesico-vaginal fistula) and impaired detrusor compliance (excessive pressure response to filling, usually due to spinal cord injury), are rare in developed countries. However, vesico-vaginal fistula remains a significant and often devastating problem in less developed nations, where women do not have ready access to obstetrical care for obstructed labor [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history, physical examination, and urinalysis are sufficient to guide initial therapy based on a working diagnosis of the type and etiology of urinary incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/6\">",
"     6",
"    </a>",
"    ]. Not all components of the evaluation have to be done in a single visit. The initial visit can be used to classify the type of incontinence, evaluate for potentially reversible conditions, and obtain a urinalysis. These evaluations can be used to initiate",
"    <span class=\"nowrap\">",
"     treatment/investigation",
"    </span>",
"    of comorbid conditions and initiate lifestyle and behavioral treatments as appropriate. In the subsequent visit (within one to two months) outcome from initial management can be assessed and more detailed examination completed.",
"   </p>",
"   <p>",
"    Patients may have had prior negative experiences with clinicians who provided either perfunctory or nihilistic urinary incontinence care. An empathic approach with a commitment to devote effort to the problem is an important aspect of care. Specialized testing and referral are not necessary for initial evaluation and treatment for most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Specialist referral'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Providers must initiate the discussion of voiding symptoms with their patients because less than one-half of incontinent individuals report the problem to healthcare personnel [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Key components of the history include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The onset and course of incontinence and associated lower urinary tract symptoms. Lower urinary tract symptoms which occur suddenly, in the absence of symptoms of an acute urinary tract infection, may indicate neurological or neoplastic causes, and should prompt further investigation (evaluation of neurological symptoms, neurological examination, urine cytology, specialist referral).",
"     </li>",
"     <li>",
"      Leakage frequency, volume, timing, and associated symptoms (eg, urgency, effort maneuvers, urinary frequency, nocturia, hesitancy, interrupted voiding, incomplete emptying, straining to empty, sense of warning). The severity of incontinence can be determined using standardized questionnaires, such as the Sandvik Severity Index, that determines a score based on the frequency of episodes and amount of urine leaked (",
"      <a class=\"graphic graphic_figure graphicRef55412 \" href=\"UTD.htm?28/12/28878\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/28,29\">",
"       28,29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Precipitants (eg, caffeinated beverages, alcohol, physical activity, cough, laughing, sound of water, placing hands in water).",
"     </li>",
"     <li>",
"      Bowel and sexual function (impaction can cause impaired bladder emptying; bowel control and sexual function share the same sacral cord innervation as the bladder; fecal incontinence is more common in people with urinary incontinence).",
"     </li>",
"     <li>",
"      Status of other medical conditions and symptoms, parity, and prescribed and over-the-counter medications, along with their temporal relationship to urinary incontinence onset or worsening (eg, a stroke of several years' duration is unlikely to be responsible for new onset urinary incontinence).",
"     </li>",
"     <li>",
"      Previous types of continence treatment and its outcome should be reviewed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Classifying type of incontinence from symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little is known about how factors such as age,",
"    <span class=\"nowrap\">",
"     race/ethnicity,",
"    </span>",
"    and comorbidity affect the reliability and validity of specific urinary symptoms in predicting the type of incontinence. However, several generalization can be made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urgency symptoms (eg \"Do you experience such a strong and sudden urge to void that you leak before reaching the toilet?\") are sensitive and specific for the diagnosis of urge incontinence (positive likelihood ratio (LR) 4.2, 95% CI 2.3-7.6; negative LR 0.48, 0.36-0.62) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/30\">",
"       30",
"      </a>",
"      ]. A report of such symptoms is also a reliable diagnostic tool, with approximately a 90 percent agreement between two interviews [",
"      <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Leakage with stress maneuvers (coughing, laughing, bending over, running, changing position) has the same reliability as urgency symptoms and is highly sensitive but has lower specificity [",
"      <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/30\">",
"       30",
"      </a>",
"      ]. \"Stress\" leakage can occur with detrusor overactivity, DHIC, and incomplete bladder emptying.",
"     </li>",
"     <li>",
"      Frequency, nocturia, slow urine stream, hesitancy, interrupted voiding, straining, and terminal dribbling are commonly associated with urinary incontinence. These symptoms lack diagnostic specificity and may occur with detrusor overactivity, DHIC, outlet obstruction, detrusor underactivity, fluid intake, medications, and many medical conditions.",
"     </li>",
"     <li>",
"      Nocturia may be related to nocturnal polyuria (eg, from late evening beverages, pedal edema, congestive heart failure, or sleep apnea), sleep disturbance (eg, from depression, pain, or medication), or from the lower urinary tract (detrusor overactivity, eg, benign prostatic enlargement). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28122?source=see_link\">",
"       \"Nocturia: Clinical presentation, diagnosis, and treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Symptom diagnostic tool",
"    </span>",
"    &nbsp;&mdash;&nbsp;A brief questionnaire, the 3IQ, has been developed to categorize incontinence (urge, stress, other, or mixed urinary incontinence) and guide the primary care clinician toward an initial treatment plan [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/32\">",
"     32",
"    </a>",
"    ]. A multicenter study of 300 middle aged women with moderate incontinence evaluated the performance of the 3IQ tool, using the results of a specialist urogynecologic workup as the \"gold standard\". For urge incontinence, the tool had a sensitivity of 0.75 and specificity of 0.77; sensitivity was greater for stress incontinence (0.86) but specificity was lower (0.60). Performance of this tool in older women, those with coexistent pelvic organ prolapse, and in other racial and ethnic groups needs to be established (",
"    <a class=\"graphic graphic_form graphicRef72319 \" href=\"UTD.htm?15/13/15571\">",
"     form 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Bother and impact on quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary incontinence has a profound effect on many domains of quality of life, and is associated with depression, work impairment, and sexual dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/33\">",
"     33",
"    </a>",
"    ]. Incontinence in frail older persons is also associated with increased caregiver burdens.",
"   </p>",
"   <p>",
"    Patients and clinicians often diverge in their assessment of the impact of urinary incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/34\">",
"     34",
"    </a>",
"    ] and interpatient variability is common [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/33\">",
"     33",
"    </a>",
"    ]. Therefore, it is important to explore the extent of bother and degree to which incontinence impacts the life of the patient",
"    <span class=\"nowrap\">",
"     (and/or",
"    </span>",
"    caregiver).",
"   </p>",
"   <p>",
"    Patients should be questioned about impact on work, activities of daily living, sleep, sexual activity, recreational activity, social interactions, interpersonal relationship, self-concept and perceptions, emotional coping, and general perception of health. Patients who report no bother should be questioned further as some patients, especially older patients, may assume that incontinence symptoms are normal or that treatment would be ineffective.",
"   </p>",
"   <p>",
"    A number of well-validated instruments are available for evaluating incontinence-specific quality of life (",
"    <a class=\"graphic graphic_table graphicRef71639 \" href=\"UTD.htm?13/46/14060\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Determining the most bothersome aspect may help target management. As an example, treatment that only relieves daytime incontinence might be considered a failure if the patient is mainly concerned about nocturia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Bladder diary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bladder diaries (also called frequency-volume charts) are patient recordings of the time and volume of all continent and incontinent voids. Diaries provide a reproducible and reliable measure of incontinence frequency before and after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/7,35\">",
"     7,35",
"    </a>",
"    ]. Reliability is greatest with seven-day diaries [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/36\">",
"     36",
"    </a>",
"    ]. However, these are burdensome and two- or three-day diaries are commonly used in both clinical and research settings.",
"   </p>",
"   <p>",
"    Diaries provide information on the usual timing and circumstances of urinary incontinence, modal voided volume (amount of urine per void, a proxy for functional bladder volume), voiding and urinary incontinence frequency, and total daytime and nocturnal urine output (",
"    <a class=\"graphic graphic_figure graphicRef69130 \" href=\"UTD.htm?4/30/4591\">",
"     figure 3",
"    </a>",
"    ). However, basic diary parameters such as frequency and volume are neither sensitive nor specific for determining the urodynamic cause of incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/30,37\">",
"     30,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most specialists have all patients complete a diary. However, this approach is often impractical in primary care, and its utility is unproven. Specific situations in which bladder diaries can be clinically helpful and should be considered include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nocturia &mdash; A bladder diary can help determine whether nocturia is due to an intrinsic problem (such as detrusor overactivity) or nocturnal polyuria. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28122?source=see_link\">",
"       \"Nocturia: Clinical presentation, diagnosis, and treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      High urinary frequency",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      incontinence frequency &mdash; Diaries can help confirm patient reports of very frequent urination or leakage, and assess whether frequency is associated with high urine output (eg, high fluid intake or the rare case of diabetes insipidus).",
"     </li>",
"     <li>",
"      Unclear history &mdash; Diaries can help determine incontinence severity by quantifying incontinence frequency and volume when patients or caretaker have difficulty giving a consistent description of leakage episodes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To complete a diary, patients (or caretakers) are instructed to record the time and volume of every continent and incontinent void over at least 48 to 72 hours (",
"    <a class=\"graphic graphic_figure graphicRef69130 \" href=\"UTD.htm?4/30/4591\">",
"     figure 3",
"    </a>",
"    ). Toilet inserts with volume markings (commonly called \"hats\") are helpful. Other information that should be recorded in the bladder diary includes pertinent associated activities (eg, coffee drinking, exercise) and hours of sleep. Urinary incontinence volumes can be estimated as drops, small, medium, and soaking. In institutional settings, the staff should check the continence status (eg, dry, damp, or soaked) every two hours if they cannot monitor urine output.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;All women presenting with incontinence should have a pelvic examination. However, a comprehensive examination extending \"above the waistline\" is often necessary to detect contributory factors and underlying serious conditions, especially in older persons. Urinary incontinence may be the only presenting symptom of morbid and sometimes life-threatening disease in both young and older persons. Thus, the evaluation should consider neurologic conditions (eg, multiple sclerosis, cord lesions), bladder and prostate neoplasms (especially if risk factors are present), and sleep apnea in persons with nocturia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28122?source=see_link\">",
"     \"Nocturia: Clinical presentation, diagnosis, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The key points in the detailed physical examination are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The cardiovascular examination should look for evidence of volume overload (eg, rales, pedal edema).",
"     </li>",
"     <li>",
"      The abdomen should be palpated for masses and tenderness, although the abdominal exam is an insensitive test for bladder distention.",
"     </li>",
"     <li>",
"      The extremities should be examined for joint mobility, function, and peripheral edema.",
"     </li>",
"     <li>",
"      The genital examination in women should include inspection of the vaginal mucosa for atrophy (thinning, pallor, loss of rugae), narrowing of the introitus by a posterior synechia, vault stenosis, and inflammation (erythema, petechiae, telangiectasia, friability). A bimanual examination should be done to evaluate for masses or tenderness. The adequacy of pelvic support may be assessed by a split-speculum exam, removing the top blade of the speculum and holding the bottom blade firmly against the posterior vaginal wall for support. Ask the woman to cough, looking for whether the urethra remains firmly fixed or swings quickly forward (urethral hypermobility) and for bulging of the anterior vaginal wall either to or through the level of the hymenal ring (anterior wall support defect, or cystocoele). Check for a posterior wall support defect (rectocele) by turning the single blade of the speculum to support the anterior vaginal wall and having the patient cough again.",
"     </li>",
"     <li>",
"      In men, the digital rectal exam should be performed to estimate prostate size and detect any abnormalities suggestive of prostate cancer.",
"     </li>",
"     <li>",
"      A detailed neurologic examination is not necessary in the initial evaluation of incontinence, but should be considered for patients with sudden onset of incontinence (especially urge), known neurological disease, or new onset of neurological symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/6\">",
"       6",
"      </a>",
"      ]. The testing should include an evaluation of sacral root integrity, including perineal sensation, resting and volitional tone of the anal sphincter, anal wink (visual or palpated anal contraction in response to a light scratch of the perineal skin lateral to the anus), and the bulbocavernosus reflex (similar anal contraction in response to a light squeeze of the clitoris or glans penis). In addition, vibration and peripheral sensation should be evaluated in testing for peripheral neuropathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=see_link\">",
"       \"The detailed neurologic examination in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Evaluation in older persons should include screening for depression, assessment of functional status, and (for treatment planning) evaluation of cognitive function [",
"      <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/38\">",
"       38",
"      </a>",
"      ]. Specific comorbidities may also indicate need for targeted evaluation. For patients with extensive osteoarthritis, the examination should include assessment of neck movement (lateral rotation and flexion) and evaluation for interosseous muscle wasting of the hands. These changes, especially if a Babinski reflex is also present, suggest cervical spondylosis or stenosis causing interruption of inhibitory tracts to the detrusor and thus detrusor overactivity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;A urinalysis should be performed in all patients, with urine culture if infection is suspected. In older women, the interpretation of the urinalysis must take into account the high prevalence of asymptomatic bacteriuria, which is not a cause of incontinence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/19/42295?source=see_link\">",
"     \"Approach to the adult with asymptomatic bacteriuria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Current guidelines do not recommend routine testing of renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/22\">",
"     22",
"    </a>",
"    ]. Serum calcium and glucose testing may be considered in patients with frequency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an increased urine volume as recorded in a bladder diary. Vitamin B12 level may be considered in older persons with an elevated PVR. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=see_link\">",
"     \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urine cytology is indicated only if there is hematuria or pelvic pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Clinical testing",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Stress test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expert opinion recommends a clinical bladder stress test for persons with stress incontinence symptoms who are being evaluated in specialist care settings. The utility of stress testing in primary care is less certain [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/22\">",
"     22",
"    </a>",
"    ]. Testing in primary care to confirm stress leakage may be helpful before recommending intensive pelvic muscle exercise programs, or when patients fail to respond to empiric therapy based on incontinence symptoms.",
"   </p>",
"   <p>",
"    In women, a positive bladder stress test is helpful in confirming stress leakage in patients with stress or mixed incontinence symptoms, although a negative test is less useful because it may result from a small urine volume in the bladder or patient inhibition [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/30\">",
"     30",
"    </a>",
"    ]. However, a positive bladder stress test does not necessitate treatment unless the patient indicates sufficient bother related to stress leakage.",
"   </p>",
"   <p>",
"    The test is performed by asking the patient, with a full bladder, to stand, relax, and give a single vigorous cough (determining whether leakage is instantaneous or delayed is difficult with multiple coughs). A chux or pad is held underneath the perineum or on the floor and the clinician observes directly whether there is leakage from the urethra.",
"   </p>",
"   <p>",
"    Leakage instantaneous with cough suggests stress incontinence, while delayed leakage suggests cough-induced detrusor overactivity, especially if there is large volume leakage that is difficult to stop.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Postvoid residual volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postvoid residual (PVR) testing, by catheterization or ultrasound, is recommended in current guidelines for evaluation of incontinence. However, high quality evidence from randomized trials is not available to support this recommendation, which is based on expert opinion [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. The 4",
"    <sup>",
"     th",
"    </sup>",
"    International Consultation on Incontinence recommends against PVR testing as part of the initial evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Parameters for interpreting the results of PVR testing are neither standardized nor well evaluated. The prevalence of elevated PVR is generally low even in symptomatic populations, and results might not change overall management. Additionally, it may not be practical to perform PVR measurement by catheterization or ultrasound in the primary care setting. The inability to perform PVR testing in primary care settings should not preclude the evaluation and management of the majority of patients with incontinence.",
"   </p>",
"   <p>",
"    Expert opinion suggests that a PVR should be performed in patients with incontinence who have higher risk for an elevated PVR [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Indications include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women who develop recurrent or a new type of incontinence after anti-incontinence surgery or who have significant pelvic organ prolapse",
"     </li>",
"     <li>",
"      Persons with specific neurological disease (eg, spinal cord injury, Parkinson disease)",
"     </li>",
"     <li>",
"      Persons who have failed empiric antimuscarinic drug therapy",
"     </li>",
"     <li>",
"      Persons with recurrent urinary tract infections",
"     </li>",
"     <li>",
"      Persons with detrusor underactivity or bladder outlet obstruction determined by previous urodynamic testing",
"     </li>",
"     <li>",
"      Persons with prior episodes of urinary retention",
"     </li>",
"     <li>",
"      Persons with severe constipation",
"     </li>",
"     <li>",
"      Persons on high doses or multiple agents that can suppress detrusor contractility or increase sphincter tone (",
"      <a class=\"graphic graphic_table graphicRef82618 graphicRef60839 \" href=\"UTD.htm?13/61/14301\">",
"       table 1A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Persons with diabetes mellitus with peripheral neuropathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, a PVR of less than 50 mL is considered adequate emptying, and a PVR greater than 200 mL is considered inadequate and suggestive of either detrusor weakness or obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/17\">",
"     17",
"    </a>",
"    ]. However, a PVR greater than 200 to 300 mL in women does not in itself require treatment in the absence of symptoms or recurrent infection. Treatment of coexisting conditions (eg, treatment of constipation, stopping medications with antimuscarinic action) may reduce PVR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Urine flow rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine measurement of the peak urine flow rate with a flowmeter is not recommended, especially in women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Urodynamic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine urodynamic testing in the evaluation of urinary incontinence is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/43\">",
"     43",
"    </a>",
"    ]. Urodynamics are the physiological diagnostic \"gold standard\", but are invasive, expensive, require special equipment and training, are not usually necessary to make the diagnosis, and have not been found to affect outcome.",
"   </p>",
"   <p>",
"    Urodynamics can correlate poorly with symptoms. Lower urinary tract pathology is rarely the only etiologic factor due to the multifactorial nature of urinary incontinence; misplaced focus upon a urodynamic diagnosis may detract from more relevant precipitants. Adverse effects of urodynamics primarily involve minor patient discomfort and a 2 percent rate of urinary tract infection. The precise diagnosis offered by urodynamic testing is most important when invasive therapy is planned [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=see_link\">",
"     \"Treatment of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Options for using specialized diagnostic tests are demonstrated in the table (",
"    <a class=\"graphic graphic_table graphicRef69931 \" href=\"UTD.htm?34/60/35788\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Clinicians should be aware of what diagnostic information urodynamic tests can and cannot provide [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fluid cystometry provides information on bladder proprioception (sensation), capacity, the presence of detrusor overactivity (uninhibited contractions), contractility, and voiding efficacy. Carbon dioxide cystometry is unreliable because the gas is compressible and can irritate the bladder.",
"     </li>",
"     <li>",
"      Simultaneous measurement of abdominal pressure during cystometry is necessary to exclude the effects of abdominal straining and detect DHIC.",
"     </li>",
"     <li>",
"      Fluoroscopy, abdominal leak-point pressure, or profilometry is required for the urodynamic diagnosis of stress urinary incontinence. Abdominal leak-point pressure is the intravesical pressure at which urine leakage occurs in the absence of a detrusor contraction [",
"      <a class=\"abstract\" href=\"UTD.htm?29/14/29929/abstract/1\">",
"       1",
"      </a>",
"      ], determined by measurement of detrusor pressure while the patient strains and noting (visually or fluoroscopically) the pressure at which urine passes into the urethra in the absence of a phasic detrusor contraction. Profilometry is the measurement of urethral pressure, generally along the length of the urethra.",
"     </li>",
"     <li>",
"      Pressure-flow studies (analysis of the relation between detrusor pressure and urethral flow during voiding) has been the gold standard for the urodynamic diagnosis of outlet obstruction; reliability has been questioned by more recent studies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bedside cystometric testing was popularized to detect detrusor overactivity and measure bladder capacity and postvoid residual in frail older persons. This study should no longer be used because of lack of sensitivity and specificity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Specialist referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for specialist referral are:",
"   </p>",
"   <p>",
"    <strong>",
"     Immediate specialist referral",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Incontinence with abdominal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pelvic pain",
"     </li>",
"     <li>",
"      Hematuria in the absence of a urinary tract infection",
"     </li>",
"     <li>",
"      Suspected fistula",
"     </li>",
"     <li>",
"      Complex neurological conditions (eg Parkinson disease, spinal cord injury, possible normal pressure hydrocephalus [cognitive impairment, wide-based gait, urinary incontinence])",
"     </li>",
"     <li>",
"      Abnormal findings (pelvic mass or symptomatic organ prolapse beyond the hymen in women)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     All patients - Elective referral",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Persistent symptoms after adequate therapeutic trial, especially severe urge incontinence unresponsive to several antimuscarinic medication trials",
"     </li>",
"     <li>",
"      Uncertainty in diagnosis and inability to develop a reasonable treatment plan based on the evaluation",
"     </li>",
"     <li>",
"      Significantly elevated PVR that does not resolve after treatment of possible precipitants (eg, medications, stool impaction)",
"     </li>",
"     <li>",
"      Prior pelvic surgery, prostatectomy, or pelvic irradiation",
"     </li>",
"     <li>",
"      Desiring surgical treatment for bothersome stress incontinence",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     IMPROVING QUALITY OF CARE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Performance measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several organizations and government agencies in the United States have developed quality performance measures of screening and evaluation of urinary incontinence (",
"    <a class=\"graphic graphic_table graphicRef59932 \" href=\"UTD.htm?26/17/26909\">",
"     table 5",
"    </a>",
"    ). These measures are not treatment guidelines, but rather tools which can be used to assess the quality of care, identify areas needing improvement for individual clinicians, and facilitate practice-based learning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/8/22658?source=see_link\">",
"       \"Patient information: Urinary incontinence (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/0/16386?source=see_link\">",
"       \"Patient information: Neurogenic bladder in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/36/43586?source=see_link\">",
"       \"Patient information: Treatments for urge incontinence in women (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/16/9474?source=see_link\">",
"       \"Patient information: Urinary incontinence in women (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/19/19764?source=see_link\">",
"       \"Patient information: Urinary incontinence treatments for women (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Patient advocacy groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients can be referred to incontinence patient advocacy groups. These groups can supply additional information about incontinence and its management, including links to product suppliers. Some useful resources are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      National Association for Continence:",
"      <a class=\"external\" href=\"file://www.nafc.org/\">",
"       www.NAFC.org",
"      </a>",
"      ; 1-800-BLADDER (252-3337)",
"     </li>",
"     <li>",
"      Simon Foundation for Continence:",
"      <a class=\"external\" href=\"file://www.simonfoundation.org/\">",
"       www.simonfoundation.org",
"      </a>",
"      ; 1-800-23SIMON (237-4666).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urinary incontinence, the complaint of involuntary leakage of urine, often remains undetected and undertreated; less than one-half of incontinent individuals report the problem to their providers. Clinicians must initiate screening for incontinence with all patients, especially women and older adults. A history and physical examination along with urinalysis are often sufficient to provide a working diagnosis to initiate treatment. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major clinical types of urinary incontinence are: urge incontinence (leakage with sudden urgency), stress incontinence (leakage with maneuvers that increase intraabdominal pressure), mixed incontinence (urge and stress leakage), and incomplete bladder emptying (resulting in an elevated postvoid residual volume, often associated with weak stream, hesitancy, frequency and nocturia). Urinary incontinence may also be due to reversible medical factors (",
"      <a class=\"graphic graphic_table graphicRef82618 graphicRef60839 \" href=\"UTD.htm?13/61/14301\">",
"       table 1A-B",
"      </a>",
"      ), particularly in older patients. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Types of urinary incontinence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An incontinence history should include questions about onset, course of symptoms, frequency of leakage, associated symptoms, precipitants, bowel and sexual function, other medical conditions, prescription and nonprescription medications, and prior therapy. It is particularly important to determine the bothersomeness of symptoms and their impact on quality of life, both for patient and caregiver when applicable. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'History'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Bother and impact on quality of life'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A bladder diary can be a valuable tool both for diagnosis (especially for nocturia) and to follow response to treatment (",
"      <a class=\"graphic graphic_figure graphicRef69130 \" href=\"UTD.htm?4/30/4591\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Bladder diary'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A physical examination for incontinence should include a pelvic examination and also extend \"above the waistline.\" Urinary incontinence may be the only presenting symptom of life-threatening disease; the evaluation should consider neurologic conditions (eg, multiple sclerosis, cord lesions) and bladder and prostate neoplasms, especially if risk factors are present. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A urinalysis should be obtained in all patients, with urine culture if infection is suspected. Urine cytology is indicated only if there is hematuria or pelvic pain. Renal function should be measured, if not known. Tests for glucose and calcium and vitamin B12 should be considered. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Laboratory tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postvoid residual testing is not necessary in most patients, but should be done either by catheterization or ultrasound in patients at high risk. Routine urodynamic testing is not recommended and is mainly of value when invasive treatment is being considered. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Postvoid residual volume'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Urodynamic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The likely cause or causes of urinary incontinence can be identified in a primary care setting for most individuals; only a minority of patients require initial referral. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Specialist referral'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29929/abstract/1\">",
"      Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29929/abstract/2\">",
"      Mardon RE, Halim S, Pawlson LG, Haffer SC. Management of urinary incontinence in Medicare managed care beneficiaries: results from the 2004 Medicare Health Outcomes Survey. Arch Intern Med 2006; 166:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29929/abstract/3\">",
"      Griffiths AN, Makam A, Edwards GJ. Should we actively screen for urinary and anal incontinence in the general gynaecology outpatients setting?--A prospective observational study. J Obstet Gynaecol 2006; 26:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29929/abstract/4\">",
"      Harris SS, Link CL, Tennstedt SL, et al. Care seeking and treatment for urinary incontinence in a diverse population. J Urol 2007; 177:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29929/abstract/5\">",
"      Irwin DE, Milsom I, Kopp Z, et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int 2006; 97:96.",
"     </a>",
"    </li>",
"    <li>",
"     Staskin D, Hilton P, Emmanuel A, et al. Initial assessment of incontinence. In: Incontinence: 3rd International Consultation on Incontinence, Abrams P, Cardozo L, Khoury S, Wein A (Eds), Health Publications Ltd, 2005. p.485.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29929/abstract/7\">",
"      Wyman JF, Choi SC, Harkins SW, et al. The urinary diary in evaluation of incontinent women: a test-retest analysis. Obstet Gynecol 1988; 71:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29929/abstract/8\">",
"      Goode PS, Burgio KL, Richter HE, Markland AD. Incontinence in older women. JAMA 2010; 303:2172.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Medicare and Medicaid Services. Available at: www.cms.hhs.gov/pqri (Accessed on September 24, 2007).",
"    </li>",
"    <li>",
"     Association of Women's Health, Obstetric and Neonatal Nurses (AWHONN). Continence for Women - Evidence-based practice guideline. Washington (DC). AWHONN; 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29929/abstract/11\">",
"      Avery K, Donovan J, Peters TJ, et al. ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn 2004; 23:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29929/abstract/12\">",
"      Barry MJ, Link CL, McNaughton-Collins MF, et al. Overlap of different urological symptom complexes in a racially and ethnically diverse, community-based population of men and women. BJU Int 2008; 101:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29929/abstract/13\">",
"      Nygaard I. Clinical practice. Idiopathic urgency urinary incontinence. N Engl J Med 2010; 363:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29929/abstract/14\">",
"      Resnick, NM, Elbadawi, A, Yalla, SV. Age and the lower urinary tract: What is normal? Neurourol Urodyn 1995; 14:577.",
"     </a>",
"    </li>",
"    <li>",
"     Morrison J, Steers WD, Brading AF, et al. Neurophysiology and neuropharmacology. In: Incontinence, 2nd ed, Abrams P, Cardozo L, Khoury S, Wein A (Eds), Health Publications, Plymouth, UK 2002. p.86.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29929/abstract/16\">",
"      Bogart LM, Berry SH, Clemens JQ. Symptoms of interstitial cystitis, painful bladder syndrome and similar diseases in women: a systematic review. J Urol 2007; 177:450.",
"     </a>",
"    </li>",
"    <li>",
"     Fantl JA, Newman DK, Colling J, et al.. Urinary Incontinence in Adults: Acute and Chronic Management, Clinical Practice Guideline, No. 2. AHCPR Publication No. 96-0682, Public Health and Human Service, Agency for Health Care Policy and Research, Rockville, MD 1966.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29929/abstract/18\">",
"      Massey JA, Abrams PH. Obstructed voiding in the female. Br J Urol 1988; 61:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29929/abstract/19\">",
"      Taylor JA 3rd, Kuchel GA. Detrusor underactivity: Clinical features and pathogenesis of an underdiagnosed geriatric condition. J Am Geriatr Soc 2006; 54:1920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29929/abstract/20\">",
"      Resnick NM, Yalla SV. Detrusor hyperactivity with impaired contractile function. An unrecognized but common cause of incontinence in elderly patients. JAMA 1987; 257:3076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29929/abstract/21\">",
"      Resnick NM, Brandeis GH, Baumann MM, et al. Misdiagnosis of urinary incontinence in nursing home women: prevalence and a proposed solution. Neurourol Urodyn 1996; 15:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29929/abstract/22\">",
"      Abrams P, Andersson KE, Birder L, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn 2010; 29:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29929/abstract/23\">",
"      St&ouml;hrer M, Goepel M, Kondo A, et al. The standardization of terminology in neurogenic lower urinary tract dysfunction: with suggestions for diagnostic procedures. International Continence Society Standardization Committee. Neurourol Urodyn 1999; 18:139.",
"     </a>",
"    </li>",
"    <li>",
"     Wyndaele, JJ, Castro, D, Madersbacher, H, et al. Neurologic Urinary and Fecal Incontinence, In: Abrams, P, Cardozo, L, Khoury, S, Wien, A (Eds), Incontinence, 2nd ed, Health Publications Ltd, Plymouth, UK 2002. p.697.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29929/abstract/25\">",
"      Resnick NM. Noninvasive diagnosis of the patient with complex incontinence. Gerontology 1990; 36 Suppl 2:8.",
"     </a>",
"    </li>",
"    <li>",
"     Resnick, NM. Voiding dysfunction in the elderly. In: Neurourology and Urodynamics: Principles and Practice. Yalla, SV, McGuire, EJ, Elbadawi, A, Blaivas JG (Eds), MacMillan Publishing Company, New York 1984. p.303.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29929/abstract/27\">",
"      Wall LL. Obstetric vesicovaginal fistula as an international public-health problem. Lancet 2006; 368:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29929/abstract/28\">",
"      Sandvik H, Hunskaar S, Seim A, et al. Validation of a severity index in female urinary incontinence and its implementation in an epidemiological survey. J Epidemiol Community Health 1993; 47:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29929/abstract/29\">",
"      Hanley J, Capewell A, Hagen S. Validity study of the severity index, a simple measure of urinary incontinence in women. BMJ 2001; 322:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29929/abstract/30\">",
"      Holroyd-Leduc JM, Tannenbaum C, Thorpe KE, Straus SE. What type of urinary incontinence does this woman have? JAMA 2008; 299:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29929/abstract/31\">",
"      Rohr G, Christensen K, Ulstrup K, Kragstrup J. Reproducibility and validity of simple questions to identify urinary incontinence in elderly women. Acta Obstet Gynecol Scand 2004; 83:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29929/abstract/32\">",
"      Brown JS, Bradley CS, Subak LL, et al. The sensitivity and specificity of a simple test to distinguish between urge and stress urinary incontinence. Ann Intern Med 2006; 144:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29929/abstract/33\">",
"      Coyne KS, Sexton CC, Irwin DE, et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 2008; 101:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29929/abstract/34\">",
"      DuBeau CE, Levy B, Mangione CM, Resnick NM. The impact of urge urinary incontinence on quality of life: importance of patients' perspective and explanatory style. J Am Geriatr Soc 1998; 46:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29929/abstract/35\">",
"      Martin JL, Williams KS, Abrams KR, et al. Systematic review and evaluation of methods of assessing urinary incontinence. Health Technol Assess 2006; 10:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29929/abstract/36\">",
"      Locher JL, Goode PS, Roth DL, et al. Reliability assessment of the bladder diary for urinary incontinence in older women. J Gerontol A Biol Sci Med Sci 2001; 56:M32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29929/abstract/37\">",
"      Parsons M, Amundsen CL, Cardozo L, et al. Bladder diary patterns in detrusor overactivity and urodynamic stress incontinence. Neurourol Urodyn 2007; 26:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29929/abstract/38\">",
"      DuBeau CE, Kuchel GA, Johnson T 2nd, et al. Incontinence in the frail elderly: report from the 4th International Consultation on Incontinence. Neurourol Urodyn 2010; 29:165.",
"     </a>",
"    </li>",
"    <li>",
"     United Kingdom National Institute for Health and Clinical Excellence. www.nice.org.uk/nicemedia/pdf/CG40NICEguideline.pdf.",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists (ACOG). Urinary incontinence in women. Washington, DC. ACOG; Clinical management guidelines for obstetrician-gynecologists number 63, June 2005.",
"    </li>",
"    <li>",
"     Staskin D, Hilton P, Emmanuel A, et al.. Initial assessment of incontinence. In: Incontinence, 3rd ed., Abrams P, Cardozo L, Khoury S, Wein A. (Eds), Health Publications, Plymouth, UK 2005. p.485.",
"    </li>",
"    <li>",
"     Fonda, D, DuBeau, C, Harari, D, et al. Incontinence in the Frail Elderly. In: Incontinence, 3rd edition. Abrams, P, Cardozo, L, Khoury, S, Wein, A, ed. Plymouth UK. Health PUblication LTD 2005 (pp 1163-1239).",
"    </li>",
"    <li>",
"     Griffiths D, Kondo, Bauer S, et al.. Dynamic testing. In: Incontinence, 3rd ed., Abrams P, Cardozo L, Khoury S, Wein A. (Eds), Health Publications, Plymouth, UK 2005. p.587.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29929/abstract/44\">",
"      Weidner AC, Myers ER, Visco AG, et al. Which women with stress incontinence require urodynamic evaluation? Am J Obstet Gynecol 2001; 184:20.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6874 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-641A5F4110-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_14_29929=[""].join("\n");
var outline_f29_14_29929=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TYPES OF URINARY INCONTINENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Lower urinary tract causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Urge incontinence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Stress incontinence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Mixed incontinence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Incomplete emptying (overflow incontinence)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Incontinence related to potentially reversible conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Uncommon causes of incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Classifying type of incontinence from symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Symptom diagnostic tool",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Bother and impact on quality of life",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Bladder diary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Clinical testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Stress test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Postvoid residual volume",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Urine flow rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Urodynamic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Specialist referral",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      IMPROVING QUALITY OF CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Performance measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Patient advocacy groups",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6874\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6874|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/36/22095\" title=\"figure 1\">",
"      Neurogenic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/12/28878\" title=\"figure 2\">",
"      Sandvik Severity Score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/30/4591\" title=\"figure 3\">",
"      Voiding diary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6874|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?15/13/15571\" title=\"form 1\">",
"      The 3 incontinence questions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6874|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/13/41179\" title=\"table 1A\">",
"      Reversible cause incontinence A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/55/10108\" title=\"table 1B\">",
"      Reversible cause incontinence B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/11/3261\" title=\"table 2\">",
"      Meds that worsen UI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/46/14060\" title=\"table 3\">",
"      Quality of life measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/60/35788\" title=\"table 4\">",
"      Urodynamic test options",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/17/26909\" title=\"table 5\">",
"      Quality measures scrn eval",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/19/42295?source=related_link\">",
"      Approach to the adult with asymptomatic bacteriuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/1/7192?source=related_link\">",
"      Epidemiology, risk factors, and pathogenesis of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=related_link\">",
"      Etiology and clinical manifestations of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11290?source=related_link\">",
"      Lower urinary tract symptoms in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43369?source=related_link\">",
"      Management of interstitial cystitis/bladder pain syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28122?source=related_link\">",
"      Nocturia: Clinical presentation, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8330?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of interstitial cystitis/bladder pain syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/0/16386?source=related_link\">",
"      Patient information: Neurogenic bladder in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/36/43586?source=related_link\">",
"      Patient information: Treatments for urge incontinence in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/8/22658?source=related_link\">",
"      Patient information: Urinary incontinence (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/16/9474?source=related_link\">",
"      Patient information: Urinary incontinence in women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/19/19764?source=related_link\">",
"      Patient information: Urinary incontinence treatments for women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=related_link\">",
"      The detailed neurologic examination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=related_link\">",
"      Treatment of urinary incontinence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_14_29930="Aplastic anemia: Prognosis and treatment";
var content_f29_14_29930=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Aplastic anemia: Prognosis and treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/14/29930/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/14/29930/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/14/29930/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/14/29930/contributors\">",
"     William C Mentzer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/14/29930/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/14/29930/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/14/29930/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aplastic anemia (AA) is a disorder of stem cell failure, leading to pancytopenia in the absence of splenomegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/1\">",
"     1",
"    </a>",
"    ]. Affected patients typically present with recurrent infections due to neutropenia, bleeding episodes due to thrombocytopenia, and, less often, fatigue due to anemia. AA can be induced by a variety of disorders, but immune mechanisms with local activation of interferon gamma may be a common etiologic pathway.",
"   </p>",
"   <p>",
"    The diagnosis of AA is established following bone marrow aspiration and biopsy. The characteristic findings include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The marrow is profoundly hypocellular with a decrease in all elements; the marrow space is composed of fat cells and marrow stroma (",
"      <a class=\"graphic graphic_picture graphicRef63867 \" href=\"UTD.htm?34/43/35513\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef68384 \" href=\"UTD.htm?27/53/28500\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The residual hematopoietic cells are morphologically normal",
"     </li>",
"     <li>",
"      Malignant infiltrates or fibrosis is absent",
"     </li>",
"     <li>",
"      Hematopoiesis is non-megaloblastic",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prognosis and treatment of AA will be discussed here [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Other aspects of AA are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/586?source=see_link\">",
"     \"Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18217?source=see_link\">",
"     \"Hematopoietic cell transplantation in aplastic anemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3738?source=see_link\">",
"     \"Acquired aplastic anemia in children and young adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11562?source=see_link\">",
"     \"Hematopoietic cell transplantation for idiopathic severe aplastic anemia and Fanconi anemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Disease severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical outcome in AA is dependent upon the severity of the pancytopenia and patient age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Moderate AA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The criteria for moderate AA include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Marrow cellularity &lt;30 percent",
"     </li>",
"     <li>",
"      Absence of severe pancytopenia",
"     </li>",
"     <li>",
"      Depression of at least two of three blood elements below normal",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Severe AA (SAA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The criteria for severe aplastic anemia (SAA) include [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A marrow biopsy showing &lt;25 percent of normal cellularity,",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      A marrow showing &lt;50 percent normal cellularity in which &lt;30 percent of the cells are hematopoietic and at least two of the following are present: absolute reticulocyte count",
"      <span class=\"nowrap\">",
"       &lt;40,000/microL;",
"      </span>",
"      absolute neutrophil count (ANC)",
"      <span class=\"nowrap\">",
"       &lt;500/microL",
"      </span>",
"      (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?12/1/12305?source=see_link\">",
"       calculator 1",
"      </a>",
"      ); or platelet count",
"      <span class=\"nowrap\">",
"       &lt;20,000/microL.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Very severe AA (vSAA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient is considered to have very severe aplastic anemia (vSAA) if the criteria for SAA are met and the ANC is",
"    <span class=\"nowrap\">",
"     &lt;200/microL",
"    </span>",
"    (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?12/1/12305?source=see_link\">",
"     calculator 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Unless patients with SAA or vSAA are successfully treated, over 70 percent will be dead within one year [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/1\">",
"     1",
"    </a>",
"    ]. In a retrospective review from the European Group for Blood and Marrow Transplantation (EBMT), the relative risk for a poor outcome following immunosuppressive treatment was 3.4 for patients with an ANC",
"    <span class=\"nowrap\">",
"     &lt;200/microL",
"    </span>",
"    (vSAA) and 1.5 in those with an ANC between 200 and",
"    <span class=\"nowrap\">",
"     500/microL",
"    </span>",
"    (SAA) compared with patients with higher ANCs [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Patient age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of AA is influenced by patient age. The above report from the EBMT evaluated the effectiveness of immunosuppressive therapy in 810 patients with AA reported to the registry between 1974 and 1997 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/5\">",
"     5",
"    </a>",
"    ]. The response rate at 12 months was 62 percent. The response to therapy, relapse rate, and risk of clonal complications were similar in all three age groups studied (&lt;49 years, 50 to 59 years, and &gt;60 years). However, the five-year survival rate varied inversely and significantly with age, being 72, 57, and 50 percent, respectively, in the three groups. The increase in mortality in the older patients was mainly due to infection or bleeding. Most infections were acquired from endogenous microbial flora of the skin and gastrointestinal tract.",
"   </p>",
"   <p>",
"    At any degree of severity of the AA in the EBMT review, the outcome was worse in older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/5\">",
"     5",
"    </a>",
"    ]. Among those with vSAA, the five-year survival rates for the three age groups mentioned above were 49, 40, and 21 percent, respectively; among those with moderate aplasia, the respective values were 86, 72, and 54 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other predictive factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single institution retrospective analysis of 316 patients with SAA treated with horse ATG-based immunosuppressive therapy indicated the following predictors for treatment response at six months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Younger age",
"     </li>",
"     <li>",
"      Higher baseline absolute reticulocyte count (ARC)",
"     </li>",
"     <li>",
"      Higher baseline absolute lymphocyte count (ALC)",
"     </li>",
"     <li>",
"      Higher baseline absolute neutrophil count (ANC)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with an ARC",
"    <span class=\"nowrap\">",
"     &ge;25,000/microL",
"    </span>",
"    and an ALC",
"    <span class=\"nowrap\">",
"     &ge;1000/microL,",
"    </span>",
"    the response rate at six months was 83 percent. For those with an ARC &lt;25,000 and an ALC &lt;1000, the response rate was significantly lower at 41 percent. Five-year survivals for the two groups were 92 and 53 percent, respectively.",
"   </p>",
"   <p>",
"    A study of 2163 patients with severe AA from the EBMT Working Party assessed the impact of the etiology of AA (eg, idiopathic, post-hepatitis, drug-associated) on treatment outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/7\">",
"     7",
"    </a>",
"    ]. While significant differences were found in age, sex, and disease severity, these differences did not affect the overall outcome of patients treated with bone marrow transplantation or immunosuppressive therapy. While it is important to discontinue all drugs that may suppress the bone marrow, particularly cancer-chemotherapy agents, there is no evidence that withdrawal of the offending agent alone will be sufficient treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of AA should include a combination of withdrawal of potentially offending agents (",
"    <a class=\"graphic graphic_table graphicRef70072 \" href=\"UTD.htm?7/49/7964\">",
"     table 1",
"    </a>",
"    ), supportive care (eg, transfusion, antibiotics), and some form of definitive therapy (eg, hematopoietic cell transplantation (HCT), immunosuppressive regimens) for patients with severe or very severe AA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Blood and platelet transfusions should be used selectively in patients who are candidates for HCT in order to avoid sensitization.",
"   </p>",
"   <p>",
"    For patients with moderate AA, treatment recommendations are unclear. With progressive cytopenias, particularly severe neutropenia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    transfusion dependence, treatment with HCT or immunosuppression should be considered.",
"   </p>",
"   <p>",
"    In view of the devastating outlook for SAA and vSAA, a long-term approach is required [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/11\">",
"     11",
"    </a>",
"    ]. HCT is the most effective therapy, but its usefulness declines with age because of fatal complications; as a result, other therapies have usually been used in patients over the age of 20 years. However, because of continual improvements in the outcome of patients undergoing HCT, this procedure could be the first choice up to age 40 to 45 if the patient is in otherwise excellent health and has a fully HLA-matched sibling donor [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, a large retrospective study from Seattle assessed the outcomes of 395 patients with SAA who received either HCT (168 patients) or immunosuppressive drugs (227 patients) as primary therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/12\">",
"     12",
"    </a>",
"    ]. The mean patient age was 22 and 25 years in the two groups but some patients were transplanted as late as age 53. Actuarial survival at 15 years was significantly higher in the HCT group (69 versus 38 percent with immunosuppressive therapy) (",
"    <a class=\"graphic graphic_figure graphicRef75806 \" href=\"UTD.htm?33/20/34125\">",
"     figure 1",
"    </a>",
"    ). The relative survival benefit of HCT was greatest in children but disappeared in patients over age 40. In addition to HCT, the factors that predicted improved outcome were younger age, no prior history of transfusions, and a higher absolute neutrophil count.",
"   </p>",
"   <p>",
"    A number of drugs have been used as treatments for aplastic anemia in the past, including corticosteroids and androgens. Their role as supplementary therapy for aplastic anemia is not clear, but they should not be used alone as definitive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/13\">",
"     13",
"    </a>",
"    ]. At present, the combination of antithymocyte globulin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    appears to be most effective immunosuppressive regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Under age 20",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients under age 20, allogeneic HCT is the treatment of choice and should be performed promptly if a fully HLA-matched sibling donor is available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11562?source=see_link&amp;anchor=H2#H2\">",
"     \"Hematopoietic cell transplantation for idiopathic severe aplastic anemia and Fanconi anemia in children\", section on 'Idiopathic severe aplastic anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transfusion of platelets and red cells should be minimized and family blood donors should be scrupulously avoided to minimize sensitization. Approximately 60 to 70 percent of such patients may be cured despite complications such as graft-versus-host disease (GVHD) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Patient survival following HCT has improved over time, due primarily to reduced mortality in the first three months post-transplantation; the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    to prevent severe GVHD accounts for most of the improved outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/17\">",
"     17",
"    </a>",
"    ]. In a review of 1305 HLA-identical sibling transplants performed in 179 centers, patient survival improved from 48 percent in the 1976 to 1980 cohort to 66 percent in the 1988 to 1992 cohort [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10425?source=see_link\">",
"     \"Prevention and treatment of acute graft-versus-host disease: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another series of 212 patients from Seattle found that chronic GVHD was a major determinant of long-term survival [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/18\">",
"     18",
"    </a>",
"    ]. The survival probability at 20 years was much lower in those with this complication (69 versus 89 percent). The majority of patients who survived two years returned to a fully functional life.",
"   </p>",
"   <p>",
"    Unfortunately, only 25 to 30 percent of potential recipients with AA have HLA-matched siblings who can act as donors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/19\">",
"     19",
"    </a>",
"    ]. Patients who do not have a matched sibling donor should receive immunosuppressive therapy as used in patients over age 45, although matched unrelated transplants have been tried in younger patients with resistant disease (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Relapsing or resistant disease'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Ages 20 to 45",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to these patients is changing, because current transplantation programs appear to be capable of reducing the incidence and severity of GVHD. Preliminary studies suggest an improved outcome with",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"      cyclophosphamide",
"     </a>",
"     /antithymocyte",
"    </span>",
"    globulin conditioning prior to HCT to prevent rejection and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    to reduce the incidence of acute or chronic GvHD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/14\">",
"     14",
"    </a>",
"    ]. Therefore, if a patient in this age group is in otherwise excellent health and has a fully HLA-matched sibling donor, allogeneic HCT could be the first choice [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/1,11\">",
"     1,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18217?source=see_link\">",
"     \"Hematopoietic cell transplantation in aplastic anemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immunosuppressive therapy, as described in the next section, should be given to patients without such a donor. The use of more aggressive regimens has led to an improvement in survival over time. In the 568 patients in the EBMT review who were &lt;49 years of age, the five-year survival rate increased significantly from 56 to 69 to 89 percent in the period of 1974-1979, 1980-1989, and 1990-1997, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is limited experience with the use of umbilical cord blood transplantation for SAA in patients who do not have fully HLA matched sibling donors. In one study, six adults were transplanted using umbilical cord blood; three received one unit of cord cells, while the other three received two units of cord cells each [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/20\">",
"     20",
"    </a>",
"    ]. Of the nine units employed, only one was HLA identical; a single or double antigen mismatch was present in seven and one units, respectively. At a median follow-up of 20 months following transplantation, four of the six patients were alive and free of disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Over age 45",
"    </span>",
"    &nbsp;&mdash;&nbsp;GVHD is thought to be a very difficult problem for patients with AA over the age of 45 who receive hematopoietic cell transplantation; for these patients immunosuppressive therapy (IST) is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/11,12,21\">",
"     11,12,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Older adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients over the age of 60 have a poorer response to IST. Treatment needs to be based upon the presence or absence of co-morbidities, risk for infection, and ability to tolerate ATG, as well as the patient&rsquo;s own values and preferences [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/22\">",
"     22",
"    </a>",
"    ]. In a single center study of 24 consecutive patients over the age of 60 (range: 61 to 78) with AA, the two-year cumulative incidence of response was 42 percent, with a three-year overall survival of 49 percent and an incidence of early death (ie, within three months of starting IST) of 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/23\">",
"     23",
"    </a>",
"    ]. Moderate or severe comorbidities were associated with significantly inferior overall survival.",
"   </p>",
"   <p>",
"    In this report, seven patients received standard IST consisting of standard dose antithymocyte globulin (ATG; horse ATG 160",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    divided over 4 to 10 days, or rabbit ATG 18.75",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    divided over 5 days) with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (CsA, 2.5 to 5.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 12 hours), and 17 patients received attenuated IST consisting of a 50 percent or more dose reduction of ATG with CsA or CsA alone [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/23\">",
"     23",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     Granulocyte colony-stimulating factor",
"    </a>",
"    was not part of the planned IST. Nine of 14 patients (64 percent) receiving attenuated IST had durable responses, suggesting that patients not deemed suitable for standard IST can benefit from attenuated treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     IMMUNOSUPPRESSIVE REGIMENS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     ATG alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial regimens often consisted of antithymocyte globulin (ATG) alone. According to one report, the response is dependent upon disease severity, with six-year survival rates of 71, 48, and 38 percent for patients with moderate AA, SAA, and vSAA, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/16\">",
"     16",
"    </a>",
"    ]. Similar results were noted in the EBMT review with five-year survival rates of 79, 69, and 45 percent in these three groups [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/5\">",
"     5",
"    </a>",
"    ]. The somewhat better outcomes in this report may result from the inclusion of some patients under the age of 45. Within each of these groups of severity, the outcome was inversely related to age (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Patient age'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Another report compared lower and higher doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    in 68 patients (not all of whom were over age 45) who were also treated with ATG and the androgen",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/39/10868?source=see_link\">",
"     oxymetholone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/13\">",
"     13",
"    </a>",
"    ]. The actuarial four-year survival was similar in both groups (47 versus 43 percent); most of these patients had SAA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     ATG and cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A more intensive regimen including ATG and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    appears to provide superior results compared with treatment with ATG alone in patients with SAA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/1,21,24-26\">",
"     1,21,24-26",
"    </a>",
"    ]. In our practice, we prefer the shorter, higher dose regimen described below, primarily because it reduces the length of hospitalization needed to infuse the ATG preparations. These are reviewed below.",
"   </p>",
"   <p>",
"    A German trial randomly assigned patients with AA to receive ATG and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    with or without cyclosporin A [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/26\">",
"     26",
"    </a>",
"    ]. Patients receiving the three-drug regimen responded more rapidly, often following a single course of treatment, and had a higher response rate after four months than those treated with ATG and steroids alone (70 versus 41 percent). Although failure-free survival favored the group receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , relapse rates at 11 years were similar in the two treatment arms (38 percent), as was overall survival.",
"   </p>",
"   <p>",
"    In another study of 122 patients with SAA, 31 of whom were &le;18 years of age, the following regimen was used [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/24,27\">",
"     24,27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Horse ATG at a dose 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in 500 mL of saline given over four to six hours for four consecutive days. A skin test for hypersensitivity to horse serum is given before the first dose.",
"     </li>",
"     <li>",
"      Premedication before each ATG dose with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      is conventional, and common infusion reactions are managed symptomatically with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"       meperidine",
"      </a>",
"      (rigors), intravenous hydration (hypotension), and supplemental oxygen (hypoxemia) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      is given in divided doses of 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, as prophylaxis for serum sickness. Steroids were given for two weeks, with the dose tapered so that the corticosteroids were discontinued by day 30.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      , at a starting dose of 10 to 12",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, is given in two equal divided doses, aiming for trough levels of approximately 200 to 400",
"      <span class=\"nowrap\">",
"       ng/mL.",
"      </span>",
"      This usually requires some reduction in cyclosporine dosing to 5 to 7",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day. Most authors prefer to measure levels in whole blood [",
"      <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/3,28\">",
"       3,28",
"      </a>",
"      ], while some institutions offer only serum level measurements. Cyclosporine levels, renal function (ie, serum creatinine levels), signs of neurotoxicity, and the patient&rsquo;s blood pressure should be checked frequently for possible toxicity. This medication is generally continued for about six months, although the dose may be tapered after one month to trough serum or whole blood levels in the range of 200 to 250",
"      <span class=\"nowrap\">",
"       ng/mL.",
"      </span>",
"     </li>",
"     <li>",
"      However, these suggested",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      levels are method-, specimen-, disease-, and investigator-dependent; accordingly, therapeutic trough ranges have not been absolutely defined. As an example, there are six analytical techniques in common use for the measurement of cyclosporine, and several more are in development. These analytical methods differ in their accuracy and specificity for the measurement of the parent cyclosporine molecule in any one sample, and the average difference between two methods can be as much as 57 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/29\">",
"       29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link&amp;anchor=H9#H9\">",
"       \"Pharmacology and side effects of cyclosporine and tacrolimus\", section on 'Pharmacokinetics'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other routine procedures utilized in these patients include platelet transfusions to keep the platelet count",
"      <span class=\"nowrap\">",
"       &gt;20,000/microL",
"      </span>",
"      during treatment with ATG, and the use of leukoreduced irradiated blood products. Insertion of a double lumen central line is most helpful for blood drawing and infusion of blood products and other fluids [",
"      <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Using this approach, improvement in blood counts occurred in 60 percent of patients after three months. The actuarial risk of relapse was 35 percent at five years. Most of the relapsing patients responded to additional courses of immunosuppression, and relapse was not associated with a significant survival disadvantage.",
"   </p>",
"   <p>",
"    Evolution to a new hematologic diagnosis, most commonly monosomy 7, occurred in 13 patients. Sixty percent of evolving patients were dead within three years of the event; all had monosomy 7. Actuarial overall survival for the entire group was 55 percent at seven years, and was higher for responders at three months (86 versus 40 percent) as well as those &lt;50 years of age (66 versus 38 percent).",
"   </p>",
"   <p>",
"    Combination therapy may also be beneficial in patients with nonsevere AA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/26\">",
"     26",
"    </a>",
"    ]. This approach was evaluated in a prospective trial in which 115 such patients were randomly assigned to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (CSA), alone or in combination with horse ATG [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/30\">",
"     30",
"    </a>",
"    ]. Combination therapy was associated with a significantly higher overall response (74 percent, 57 percent complete responses) than CSA alone (46 percent, 23 percent complete) and a lower rate of disease progression requiring further therapy in six months (6 versus 25 percent). At 180 days, the prevalence of patients surviving free of transfusions was 67 percent in the CSA group and 90 percent in the ATG plus CSA group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Addition of G-CSF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two studies have evaluated the combined use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , ATG, glucocorticoids, and G-CSF in patients with aplastic anemia.",
"   </p>",
"   <p>",
"    The first report evaluated results in 24 patients with previously untreated aplastic anemia who received (initial doses): rabbit ATG (3.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for five doses),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day orally for six months), steroids (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day tapered off over one month), and G-CSF. The overall response rate was 64 percent, with a median time to response of three months and no early deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/31\">",
"     31",
"    </a>",
"    ]. In this small study, the addition of G-CSF provided no advantage to the larger horse",
"    <span class=\"nowrap\">",
"     ATG/cyclosporine",
"    </span>",
"    study cited below.",
"   </p>",
"   <p>",
"    The second, non-randomized study evaluated 100 patients (mean age 16 years) who were treated with (initial doses): horse antilymphocyte globulin (15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for five days),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for five days), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for six months) plus recombinant human",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF, 5",
"    <span class=\"nowrap\">",
"     microg/kg",
"    </span>",
"    per day SQ for 90 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/25,32\">",
"     25,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tri-lineage recovery at a median of three months occurred in 77 patients (48 complete responses) after one or more courses of therapy. Among the 23 nonresponders, 11 died at a median interval of three months; six were considered treatment failures and underwent HCT. The actuarial survival was 87 percent at five years (98 versus 76 percent in those with neutrophil counts greater than or less than",
"    <span class=\"nowrap\">",
"     200/microL",
"    </span>",
"    at presentation, and 92 versus 72 percent for age &lt;36 or &ge;36); relapse occurred in 9 percent. Overall, 11 percent of evaluable patients developed a cytogenetic abnormality (eg, monosomy 7) and 8 percent developed clonal disease (see",
"    <a class=\"local\" href=\"#H28\">",
"     'Occurrence of clonal disorders'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    In this study, the response to G-CSF appeared to have prognostic value; patients who did not achieve a white blood cell count of at least",
"    <span class=\"nowrap\">",
"     5000/microL",
"    </span>",
"    had a low probability of response (37 percent) and a high mortality (42 percent).",
"   </p>",
"   <p>",
"    There is no evidence that the use of G-CSF corrects the underlying defect; its use as primary therapy will only delay the onset of effective therapy (eg, immunosuppressive therapy, HCT) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/33\">",
"     33",
"    </a>",
"    ], and may be associated with an increased incidence of",
"    <span class=\"nowrap\">",
"     MDS/AML",
"    </span>",
"    as well as a worse outcome in relapsing patients who had prior treatment with G-CSF (see",
"    <a class=\"local\" href=\"#H29\">",
"     'Development of MDS/AML'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/34\">",
"     34",
"    </a>",
"    ]. In one study, use of a higher dose of G-CSF (ie, 10",
"    <span class=\"nowrap\">",
"     microg/kg",
"    </span>",
"    per day rather than 5",
"    <span class=\"nowrap\">",
"     microgram/kg",
"    </span>",
"    per day) in a standard immunosuppressive program may have actually reduced the overall response rate, without improving blood counts or survival [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized studies of the value of adding G-CSF to immunosuppressive therapy have resulted in varying conclusions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report in children, addition of G-CSF to a regimen of ATG,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"       danazol",
"      </a>",
"      did not result in a reduction in the incidence of febrile episodes or documented infections or an improvement in the hematologic response rate at six months [",
"      <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 102 patients with severe aplastic anemia, the addition of lenograstim to standard therapy resulted in an increased proportion of patients showing a complete neutrophil response but no difference in terms of overall hematologic response or survival [",
"      <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a Japanese study in 101 adults with severe AA, addition of G-CSF did not result in a reduced incidence of infections or febrile episodes [",
"      <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/38\">",
"       38",
"      </a>",
"      ]. While the overall hematologic response rate at one year and four-year survivals were not improved by the addition of G-CSF, the four-year relapse rate was lower in the G-CSF-treated group (15 versus 42 percent).",
"     </li>",
"     <li>",
"      The largest trial to date on this question was a randomized EBMT trial comparing ATG plus CsA with or without G-CSF in 192 patients with newly diagnosed severe AA [",
"      <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/39\">",
"       39",
"      </a>",
"      ]. While patients randomly assigned to treatment with G-CSF had fewer infectious episodes and fewer hospitalization days compared with patients not receiving G-CSF, no differences in overall survival, event-free survival, remission rates, relapse rates, or mortality were seen between the two study arms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on these and other studies, it has been concluded that, while the addition of G-CSF may reduce infectious episodes, it has no discernible effect on remission or survival [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one study in 104 consecutive patients with SAA, addition of the immunosuppressive agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil to a standard regimen containing horse-ATG,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    <span class=\"nowrap\">",
"     (h-ATG/CsA)",
"    </span>",
"    did not result in an improvement in response or relapse rates in comparison to the historical standard",
"    <span class=\"nowrap\">",
"     h-ATG/CsA",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Complications of ATG and cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects of ATG are the manifestations of horse serum sickness, while",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    can cause renal impairment, hypertension, hemolysis, tremor, vitiligo, gingival hyperplasia, and hypertrichosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14441?source=see_link\">",
"     \"Acute cardiac allograft rejection: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8842?source=see_link\">",
"     \"Serum sickness and serum sickness-like reactions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fever associated with the administration of ATG in patients with aplastic anemia typically develops on the first day of treatment and lasts from one to six days [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/42\">",
"     42",
"    </a>",
"    ]. In one study of 39 such patients, positive blood cultures were obtained from only four and the organism in each case was a coagulase-negative Staphylococcus [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/43\">",
"     43",
"    </a>",
"    ]. Twenty-two patients had neutrophil counts",
"    <span class=\"nowrap\">",
"     &lt;200/microL,",
"    </span>",
"    only one of whom had a positive blood culture. This was in striking contrast to patients with acute leukemia admitted for chemotherapy in whom blood cultures were positive in 57 of 66 patients with fever.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8466382\">",
"    <span class=\"h3\">",
"     Horse versus rabbit ATG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two studies have concluded that horse ATG is more effective that rabbit ATG in previously untreated",
"    <strong>",
"     adults",
"    </strong>",
"    with aplastic anemia.",
"   </p>",
"   <p>",
"    Rabbit ATG in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    was evaluated prospectively in a multicenter phase II pilot study in 35 patients with aplastic anemia, and was compared with results in 105 age- and disease severity-matched historical controls treated with horse ATG and cyclosporine. Results included [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/44\">",
"     44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Overall response rates were 60 and 67 percent for the rabbit ATG- and horse ATG-containing regimens, respectively.",
"     </li>",
"     <li>",
"      Overall two-year survivals were 68 and 86 percent for the rabbit ATG- and horse ATG-containing regimens, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A single center randomized trial compared horse ATG (ATGAM, 40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for four days) with rabbit ATG (Thymoglobulin, 3.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for five days) in 120 consecutive patients with severe aplastic anemia, who were also treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day given in divided doses every day from day 1 and continued for at least six months; dose adjusted to maintain trough blood levels of 200 to 400",
"    <span class=\"nowrap\">",
"     ng/mL).",
"    </span>",
"    The primary study endpoint was hematologic response at six months. Results, which showed clear superiority of the horse ATG preparation, included the following [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hematologic response at six months was 68 (95% CI: 56 to 80) versus 37 (95% CI: 24 to 49) percent for those treated with horse versus rabbit ATG, respectively.",
"     </li>",
"     <li>",
"      Overall survival, when censored at the time of stem cell transplantation, also strongly favored use of horse ATG, with three-year overall survivals of 96 (95% CI: 90 to 100) versus 76 (95% CI: 61 to 95) percent, respectively.",
"     </li>",
"     <li>",
"      At a median follow-up of 28 months, there were no significant differences between the two regimens in terms of the cumulative incidences of relapse or clonal evolution.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two retrospective reports have indicated the superiority of horse ATG over rabbit ATG for induction of remission in",
"    <strong>",
"     children",
"    </strong>",
"    with aplastic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     High dose cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another possible approach in the treatment of AA is the administration of high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    as used for conditioning for HCT, but without the infusion of hematopoietic stem cells [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/47-50\">",
"     47-50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A total of 44 treatment-naive patients with SAA or VSAA have been reported who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    alone (200",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in divided doses over four days) and followed for a median period of 58 months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/49\">",
"     49",
"    </a>",
"    ]. Toxicity of this regimen was appreciable, requiring hospitalization for febrile neutropenia, severe fungal infection,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prolonged transfusional support with red cells and platelets. Complete remission was attained in 19 patients (43 percent), with estimated 10-year failure-free and overall survivals of 58 and 88 percent, respectively. Thus far, two patients have developed myelodysplastic syndrome and two others have more than 20 percent GPI anchor-deficient granulocytes but as yet without clinical symptoms of PNH. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Occurrence of clonal disorders'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    These provocative reports from a single institution required confirmation to determine if the outcome after treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    justified its routine use in the treatment of SAA. A randomized phase III study of 182 patients with SAA, comparing cyclophosphamide (50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV per day for four days) plus cyclosporine versus ATG and cyclosporine was initiated in 1997. This study was terminated in March 2000 after accrual of only 31 patients, because of an increase in invasive fungal infections as well as excess deaths in the group receiving cyclophosphamide [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given these results, the use of high-dose intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (total dose 200",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    given over four days), with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , cannot be recommended as",
"    <strong>",
"     initial",
"    </strong>",
"    treatment for SAA, and must still be considered as experimental [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/3,52,53\">",
"     3,52,53",
"    </a>",
"    ]. However, use of this approach has been reported in patients with SAA who had not responded to one or more cycles of immunosuppressive therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study in 17 such patients treated with this regimen, 9 (53 percent) were in complete or partial remission at a median follow-up of 29 months [",
"      <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second study in 23 patients with refractory SAA or VSAA, high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      resulted in complete and partial remission in 11 patients (48 percent) and a 10-year failure-free survival rate of 27 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/49\">",
"       49",
"      </a>",
"      ]. Toxicity was appreciable, with an early mortality of 17 percent secondary to bacterial or fungal sepsis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3908418\">",
"    <span class=\"h3\">",
"     Modified high dose cyclophosphamide plus cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the above reports of toxicity, 48 patients with SAA or VSAA were treated with a modified high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    regimen consisting of cyclophosphamide (CTX, 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously over one hour each day for four consecutive days) plus oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (CsA, 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day starting on day 11, adjusted to maintain trough and peak blood levels of 150 to 250",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    and 700 to 1000",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    respectively, for at least 180 days). Results were compared with a contemporaneous group of 73 patients with SAA or VSAA who did not select the modified CTX trial and were treated with rabbit ATG (3.75",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for five consecutive days) plus CsA (dosing as above) starting on day 1. Results included the following [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/55\">",
"     55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete remission rates for those in the",
"      <span class=\"nowrap\">",
"       CTX/CsA",
"      </span>",
"      group at 3, 6, and 12 months were 54, 65, and 73 percent, respectively. CR rates for those treated with",
"      <span class=\"nowrap\">",
"       ATG/CsA",
"      </span>",
"      were 58, 73, and 78 percent, respectively, for the same time intervals. Five-year overall survivals were 81 percent for both treatment groups.",
"     </li>",
"     <li>",
"      The early death rate was similar in the two treatment groups: 4.2 percent in those receiving",
"      <span class=\"nowrap\">",
"       CTX/CsA",
"      </span>",
"      and 8.2 percent in those receiving",
"      <span class=\"nowrap\">",
"       ATG/CsA.",
"      </span>",
"      There was one death from bacterial sepsis in the",
"      <span class=\"nowrap\">",
"       CTX/CsA",
"      </span>",
"      group and three deaths from infection (two pulmonary, one invasive fungal) in the",
"      <span class=\"nowrap\">",
"       ATG/CsA",
"      </span>",
"      group.",
"     </li>",
"     <li>",
"      High medical costs for rabbit ATG and unavailability of horse ATG were apparently the driving forces for treatment selection in this Chinese study, and were 55 percent lower for those treated with the",
"      <span class=\"nowrap\">",
"       CTX/CsA",
"      </span>",
"      combination.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While these results were based upon a single study, in countries where ATG is unavailable because of costs or other issues, this combination of modified high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    appears to offer an effective alternative to the use of ATG plus cyclosporine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"   </p>",
"   <p>",
"    <strong>",
"     Anti-IL-2 receptor antibody",
"    </strong>",
"    &mdash; In a small study, patients with moderate AA (ie, marrow cellularity &lt;30 percent, absence of severe pancytopenia, depression of at least two of three blood elements below normal) were treated with a recombinant humanized anti-IL-2 receptor antibody (daclizumab, 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every other week for a total of five doses) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/56\">",
"     56",
"    </a>",
"    ]. There were 6 responses among the 16 evaluable patients (38 percent), two of whom reverted to completely normal blood counts which were sustained for more than two years following treatment. A later report from the same authors indicated that 7 of 28 patients (25 percent) with moderate AA who were treated with this agent achieved long-term red cell transfusion independence [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/57\">",
"     57",
"    </a>",
"    ].Toxicity was minimal. Randomized controlled studies will be required to validate this approach in patients with only moderate degrees of aplasia, who otherwise might not have been treated.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"     Arsenic trioxide",
"    </a>",
"    <strong>",
"     plus",
"    </strong>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    &mdash; Ten Chinese patients with severe aplastic anemia were treated with a combination of cyclosporine (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally daily, adjusted to achieve a whole blood trough level of 100 to 200",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    plus one or two courses of arsenic trioxide (ATO, 0.15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously daily for five days each week for 8 weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/58\">",
"     58",
"    </a>",
"    ]. Overall and complete response rates at 8 weeks were 100 and 30 percent, respectively, and were 100 and 80 percent, respectively, at 17 weeks. Toxicity of ATO was modest and did not compromise overall treatment. Since the rationale for the use of ATO in this setting is unclear and the number of patients treated is small, this treatment combination requires verification from a well-designed research trial and cannot be recommended at this time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Viral reactivation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral reactivation is common in patients with AA treated with immunosuppressive agents, although symptomatic clinical disease is uncommon. As an example, in a study of antibody-based immunosuppressive regimens in patients with severe AA, reactivation of EBV occurred in 82 of 94 courses in EBV seropositive patients and reactivation of CMV occurred in 19 of 57 courses in CMV seropositive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/59\">",
"     59",
"    </a>",
"    ]. However, there were no cases of symptomatic EBV or CMV infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     RELAPSING OR RESISTANT DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Retreatment with ATG",
"    </span>",
"    &nbsp;&mdash;&nbsp;The therapeutic response to immunosuppressive therapy in AA is not a \"cure,\" as is allogeneic HCT, and the responses are incomplete. Many of these patients continue to have marginal cytopenias, and 9 to 35 percent relapse with AA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/16,25,60,61\">",
"     16,25,60,61",
"    </a>",
"    ]. A review of 719 patients treated with immunosuppressive therapy noted an actuarial relapse rate of 35 percent at 14 years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/61\">",
"     61",
"    </a>",
"    ]. Relapse was not predicted by age or severity of disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 50 to 65 percent of patients who relapse following a first successful course of ATG (with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ) respond to additional courses of immunosuppression (either repeated horse ATG or rabbit ATG) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/25,62\">",
"       25,62",
"      </a>",
"      ]. Although serum sickness occurs earlier with repeated courses of horse ATG, such regimens are generally well tolerated.",
"     </li>",
"     <li>",
"      The response rate to additional courses of immunosuppression for those who failed to respond to a first course of horse ATG has varied widely, from 10 to 77 percent in various studies [",
"      <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/63-66\">",
"       63-66",
"      </a>",
"      ], and was 30 percent in 22 patients who failed treatment with horse ATG and were subsequently treated with rabbit ATG [",
"      <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In an uncontrolled trial, 30 patients with SAA who failed to respond to a schedule of horse ATG,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , and G-CSF were treated with the following regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/65\">",
"     65",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rabbit ATG (3.5",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      diluted in isotonic saline, IV over 6 to 8 hours, days 1 through 5)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       Methylprednisolone",
"      </a>",
"      2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV days 1 through 5 and 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV on days 6 through 10, tapered within 30 days",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      PO days 1 to 180, slowly tapered thereafter",
"     </li>",
"     <li>",
"      G-CSF 5",
"      <span class=\"nowrap\">",
"       microg/kg",
"      </span>",
"      SQ days 1 to 90 (24 patients)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Transfusion independence was achieved in 23 of the 30 patients (77 percent) after a median time of 95 days, and 9 patients achieved complete remission. Overall survival rate was 93 percent at a median follow-up of 2.5 years, with no relapses to date. No anaphylaxis or major symptoms of allergic reaction were noted; female gender was the only factor predicting failure.",
"   </p>",
"   <p>",
"    In the above review of 719 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/61\">",
"     61",
"    </a>",
"    ], those who responded to a second course of immunosuppressive therapy had an actuarial survival of 80 percent; this value was similar to that in patients who did not relapse (86 percent) and significantly better than that in patients not achieving a second response (49 percent). Other studies have confirmed the lack of survival disadvantage in relapsers who responded to a second course of immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/24,64\">",
"     24,64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only a fraction of patients with severe aplastic anemia in first or second complete remission are able to mobilize sufficient stem cells to undergo autologous hematopoietic cell transplantation (HCT) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/67\">",
"     67",
"    </a>",
"    ]. Accordingly, patients with relapsing or resistant disease, who have even fewer mobilizable stem cells than those in remission, are not candidates for autologous HCT.",
"   </p>",
"   <p>",
"    An approach that has been evaluated in children and young adults with relapsing or resistant disease and no matched sibling donor is the use of matched unrelated donor HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/11,19,66\">",
"     11,19,66",
"    </a>",
"    ]. Patient survivals with this procedure have ranged from 43 percent at 1.2 years to as high as 84 percent at five years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/66\">",
"     66",
"    </a>",
"    ]. The use of umbilical cord blood as a stem cell source is also an option. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link\">",
"     \"Donor selection for hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18217?source=see_link&amp;anchor=H8#H8\">",
"     \"Hematopoietic cell transplantation in aplastic anemia\", section on 'Matched unrelated donor HCT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Resistant disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unless patients with SAA or vSAA are successfully treated, over 70 percent will be dead within one year. For patients who do not respond to a repeat course of immunosuppressive therapy with ATG and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and are not candidates for HCT, options include high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Single-agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    was employed in three separate randomized research protocols at the National Institutes of Health, with these results for the alemtuzumab treatment arms (eg, hematologic response at six months) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/70\">",
"     70",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For 16 treatment-na&iuml;ve subjects ��� 19 percent (95% CI 0-40 percent); this arm was discontinued early",
"     </li>",
"     <li>",
"      For 27 subjects with refractory disease ��� 37 percent (95% CI 18-57 percent); three-year survival 83 percent",
"     </li>",
"     <li>",
"      For 25 subjects with relapsed disease ��� 56 percent (95% CI 35-77 percent); three-year survival 86 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Enrollment in a well-conducted experimental protocol is strongly encouraged [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/15\">",
"     15",
"    </a>",
"    ]. The ex vivo and in vivo use of recombinant transcription factors that govern stem and progenitor cell fate decisions in patients with marrow failure syndromes is being explored [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Alemtuzumab plus cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early trials in small numbers of patients with AA employing the anti-CD52 antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    in conjunction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    have reported overall response rates as high as 70 percent, with some complete responses being reported [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. Use of this agent has been associated with serious bacterial, viral, fungal, and protozoan infections. Monitoring for reactivation of CMV and EBV",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prophylactic use of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    and cotrimoxazole have been employed when alemtuzumab was used in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/59,72\">",
"     59,72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16503636\">",
"    <span class=\"h3\">",
"     Use of a thrombopoietin mimetic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knockout mice deficient in expression of the thrombopoietin (TPO) receptor MPL and subjects with congenital amegakaryocytic thrombocytopenia and MPL mutations can both develop aplastic anemia. Similarly, both TPO and c-Mpl appear to play an important role in the regulation of the growth of the pluripotent stem cell. These observations have suggested that stimulation of c-Mpl-signaling pathways might overcome the depletion of hematopoietic stem and progenitor cells seen in patients with aplastic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/75\">",
"     75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16680?source=see_link&amp;anchor=H8#H8\">",
"     \"Biology and physiology of thrombopoietin\", section on 'Effects on bone marrow precursor cells'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/586?source=see_link&amp;anchor=H13878780#H13878780\">",
"     \"Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis\", section on 'Absent or abnormal thrombopoietin receptor'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This hypothesis was tested in a phase II trial of the TPO mimetic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"     eltrombopag",
"    </a>",
"    (starting dose 50",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    maximum dose 150",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for a total of 12 weeks) in patients with aplastic anemia refractory to immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Eleven of the 25 patients (44 percent) had significant increases in at least one lineage at 12 weeks, with minimal toxic effects. Serial bone marrow biopsies showed normalization of trilineage hematopoiesis in responders, without increased fibrosis. Additional experience with this investigational treatment approach is eagerly awaited [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     OCCURRENCE OF CLONAL DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an appreciable risk of progression to a clonal disorder (eg, myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), paroxysmal nocturnal hemoglobinuria (PNH)) following treatment for AA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/24,60\">",
"     24,60",
"    </a>",
"    ]. A report from the European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party estimated a 10-year incidence of malignancy of 19 percent in 860 patients treated with immunosuppression (5.2 times the overall cancer risk in an age-matched population), mostly MDS or AML [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/60\">",
"     60",
"    </a>",
"    ]. A much lower risk, 3 percent (consisting primarily of solid tumors), was seen after HCT. The incidence of solid tumors was similar with the two procedures but hematologic malignancy was much less common following HCT. Similar findings have been noted in other series in which clonal disorders occurred in 8 to 12 percent of patients followed for more than two years after ATG therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/16,77\">",
"     16,77",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18217?source=see_link\">",
"     \"Hematopoietic cell transplantation in aplastic anemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Development of MDS/AML",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is controversial whether long-term administration of G-CSF in combination with immunosuppressive therapy to patients with AA increases the risk of MDS or acute leukemia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 72 adults with AA, MDS developed in 1 of 47 patients treated without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or ATG compared to 4 of 25 treated with one or other of these agents [",
"      <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/77\">",
"       77",
"      </a>",
"      ]. All four acquired monosomy 7 and had received long-term G-CSF at a higher cumulative dose than those who did not develop MDS; administration for more than one year was the single most important risk factor for MDS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39594?source=see_link&amp;anchor=H21#H21\">",
"       \"Cytogenetics in acute myeloid leukemia\", section on 'del(7q)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Similar results were noted in another study in which MDS or acute leukemia developed in 11 of 50 children with acquired AA who were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      and G-CSF compared to none of 41 treated with either agent alone, or none of 48 who underwent HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/78\">",
"       78",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16890?source=see_link&amp;anchor=H15#H15\">",
"       \"Introduction to recombinant hematopoietic growth factors\", section on 'Possible stimulation of malignancy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      One study evaluated 144 patients with SAA treated with immunosuppressive agents (eg, antilymphocyte globulin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ) with (n = 87) or without (n = 57) G-CSF; all had normal cytogenetics before or immediately after treatment with antilymphocyte globulin [",
"      <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/79\">",
"       79",
"      </a>",
"      ]. At five years, the incidence of cytogenetic abnormalities was 14 and 11 percent, and the risk of developing a second malignancy was 9 and 7 percent for patients receiving or not receiving G-CSF, respectively.",
"     </li>",
"     <li>",
"      A large retrospective survey from the EBMT included 840 patients who received first line immunosuppressive therapy for severe aplastic anemia, with (43 percent) or without (57 percent) G-CSF [",
"      <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/34\">",
"       34",
"      </a>",
"      ]. Use of G-CSF was associated with a higher incidence of",
"      <span class=\"nowrap\">",
"       MDS/AML",
"      </span>",
"      (10.9 versus 5.8 percent, hazard ratio 1.9; 95% CI 1.0-3.5).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Development of PNH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 15 to 40 percent of patients with AA treated with immunotherapy will have evidence of paroxysmal nocturnal hemoglobinuria (PNH) that may be mild, transient, or progress to full-blown disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/80-82\">",
"     80-82",
"    </a>",
"    ]. Why this occurs is not known. An unproven hypothesis is that a small population of PNH cells, which lack GPI-anchored proteins, is relatively common in this disorder; this population remains small because of a proliferative disadvantage relative to normal clones.",
"   </p>",
"   <p>",
"    It is postulated that the process(es) involved in aplastic anemia may suppress GPI-negative cells to a lesser degree than GPI-positive cells. When the degree of suppression is reduced following therapy, the GPI-negative clone is able to emerge, since it now has a relative proliferative advantage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14121?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical manifestations of paroxysmal nocturnal hemoglobinuria\", section on 'Diminished hematopoiesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/586?source=see_link&amp;anchor=H3#H3\">",
"     \"Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis\", section on 'Causes and mechanisms of stem cell failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one series of 100 patients with AA, 22 percent of whom had evidence for PNH before treatment, the response to ATG in those with normal or GPI-anchored protein-deficient granulocytes was 71 percent and 82 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/83\">",
"     83",
"    </a>",
"    ]. No statistically significant evidence of expansion in the size of the PNH clone was seen during long-term follow-up of these patients.",
"   </p>",
"   <p>",
"    In a longitudinal study of 97 patients treated with combinations of corticosteroids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , and ATG, at a median follow-up of five years, no differences in survival or time to transfusion independence were seen among the subgroup without clonal hematopoiesis (73 percent), versus those who subsequently developed chromosomal abnormalities (13 percent)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the presence of GPI-negative cells (16 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Other clonal changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a longitudinal study of 30 patients with AA and a normal karyotype at presentation, clonal karyotypic evolution occurred at a constant rate, with 50 percent developing within the first 30 months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/85\">",
"     85",
"    </a>",
"    ]. The most common patterns were structural and numerical abnormalities of chromosome seven (40 percent) and trisomy eight (23 percent), with the following clinical outcomes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chromosome seven abnormalities were seen most often in patients with refractory disease; survival was poor and most deaths related to leukemic transformation occurred in this group.",
"     </li>",
"     <li>",
"      Trisomy eight developed in patients with good hematologic responses to immunosuppressive agents; survival was excellent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     HEPATITIS-ASSOCIATED APLASTIC ANEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis-associated AA most often affects boys and young men. Immune mechanisms appear to be involved and, in one report of 10 cases, seven responded to a regimen of antithymocyte globulin (40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily intravenously for four days) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (12 to 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for six months with the dose adjusted to maintain a blood level of 200 to 400",
"    <span class=\"nowrap\">",
"     ng/mL);",
"    </span>",
"    the three nonresponders died [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/42\">",
"     42",
"    </a>",
"    ]. The authors suggested that, in patients without an HLA-identical donor, this regimen can be safely started after diagnosis, allowing time to search for an alternative donor.",
"   </p>",
"   <p>",
"    In patients with a suitable donor, the nature and severity of the hepatitis should be investigated, with consideration given to antiviral treatment in an attempt to prevent posttransplant progression of hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/86\">",
"     86",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=see_link\">",
"     \"Overview of the management of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     PREGNANCY FOLLOWING TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation has reported on pregnancy outcomes in 36 women who had received prior immunosuppressive therapy for AA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/14/29930/abstract/87\">",
"     87",
"    </a>",
"    ]. Compared with prepregnancy values, in the first and",
"    <span class=\"nowrap\">",
"     second/third",
"    </span>",
"    trimesters median hemoglobin fell 9 and 19 percent, respectively, while neutrophil counts increased 45 and 36 percent, respectively. Platelet counts progressively fell by 20 percent in the first trimester and by 40 percent in the third.",
"   </p>",
"   <p>",
"    Obstetrical outcomes were generally good. Of 36 first pregnancies, there were 34 live births (one set of twins), two elective abortions, and one spontaneous abortion. Postnatal physical examination and development were normal in all infants. Complications included two cases of eclampsia; two cases of excessive bleeding at delivery associated with severe thrombocytopenia; nine women without excessive bleeding but requiring transfusion; and five preterm deliveries (three in women who relapsed or had progressive thrombocytopenia during pregnancy).",
"   </p>",
"   <p>",
"    Fourteen of the 36 pregnancies had associated medical complications, including relapse of AA in seven (two of whom had been in complete remission, four in partial remission, and one with PNH), and worsening thrombocytopenia requiring transfusion in an additional five. After delivery, six of the seven patients who relapsed recovered--three spontaneously, and three after additional immunosuppressive therapy.",
"   </p>",
"   <p>",
"    Each of the four patients with clinical PNH had a complicated course, including (one patient each): relapse of AA, increased transfusion requirement, eclampsia, and death due to cerebral thrombosis one month following delivery. Of nine women with subsequent pregnancies, only one had relapse of AA during pregnancy, but underwent spontaneous remission postpartum.",
"   </p>",
"   <p>",
"    In summary, more than one-half of the pregnancies were uneventful and all of the infants were normal. Maternal outcome was best in women who began pregnancy in remission with normal platelet counts and without PNH, but these criteria did not guarantee a normal outcome. One-third of mothers required transfusions. The rate of relapse of AA during pregnancy (19 percent) was higher than would be expected over a nine-month period (2 percent); however, most of these women went into remission postpartum with or without treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/4/30785?source=see_link\">",
"       \"Patient information: Aplastic anemia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of aplastic anemia (AA) depends upon two factors, disease severity and patient age.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disease severity &mdash; Depending on the degree of reduction of marrow cellularity and the amount and degree of cytopenia (eg, anemia, thrombocytopenia, neutropenia), AA is graded from moderate to severe (SAA) to very severe (vSAA). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Disease severity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Effect of age &mdash; There is a strong inverse relation between patient age and five-year survival in patients with AA. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Patient age'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unless patients with SAA or vSAA are successfully treated, over 70 percent will be dead within one year. At any degree of severity of AA, the outcome is worse in older patients. For patients with moderate AA, treatment recommendations are unclear. With progressive cytopenias, particularly severe neutropenia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    transfusion dependence, treatment with HCT or immunosuppression should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of AA includes withdrawal of potentially offending agents (",
"    <a class=\"graphic graphic_table graphicRef70072 \" href=\"UTD.htm?7/49/7964\">",
"     table 1",
"    </a>",
"    ), supportive care (eg, transfusion, antibiotics), and some form of definitive therapy (eg, hematopoietic cell transplantation, immunosuppressive regimens). Blood and platelet transfusions should be used selectively in patients who are candidates for HCT to avoid sensitization.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hematopoietic cell transplantation &mdash; Allogeneic hematopoietic cell transplantation (HCT) is curative in AA, but is limited by the availability of an HLA-matched sibling as well as by the potentially fatal consequences of graft versus host disease in patients over the age of 40 to 45. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18217?source=see_link\">",
"       \"Hematopoietic cell transplantation in aplastic anemia\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunosuppressive regimens &mdash; Immunosuppressive regimens are not curative, but can be associated with long-term survival. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Immunosuppressive regimens'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Under age 20",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with SAA or vSAA &lt;20 years of age with an HLA-matched sibling, we recommend treatment with allogeneic HCT over treatment with an immunosuppressive regimen (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). For those who do not have a matched sibling donor we suggest the use of immunosuppressive therapy over the use of matched unrelated, mismatched related, or mismatched unrelated HCT (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18217?source=see_link&amp;anchor=H6#H6\">",
"     \"Hematopoietic cell transplantation in aplastic anemia\", section on 'Comparison with immunosuppression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Age 20 to 45 years",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with SAA or vSAA 20 to 45 years of age in otherwise excellent health with a fully HLA-matched sibling donor, we recommend treatment with allogeneic HCT over treatment with an immunosuppressive regimen (",
"    <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"     Grade 1C",
"    </a>",
"    ). For those without a matched sibling donor, we suggest the use of immunosuppressive therapy over the use of matched unrelated, mismatched related, or mismatched unrelated HCT (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Age over 45",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with SAA or vSAA over the age of 45, we suggest the use of immunosuppressive therapy over HCT because of the very high risk of graft versus host disease in patients &gt;45 (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Treatment overview'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;For immunosuppression in patients with moderate AA, SAA, or vSAA we recommend the combined use of anti-thymocyte globulin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , and corticosteroids, without granulocyte-colony stimulating factor, over the use of less intensive regimens (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H16\">",
"     'ATG and cyclosporine'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend the use of horse ATG over rabbit ATG for this purpose (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8466382\">",
"       'Horse versus rabbit ATG'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients relapsing after successful treatment can be re-treated with this regimen with excellent results and no survival disadvantage.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/1\">",
"      Young NS. Aplastic anaemia. Lancet 1995; 346:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/2\">",
"      Marsh JC, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol 2009; 147:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/3\">",
"      Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood 2012; 120:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/4\">",
"      Rozman C, Mar&iacute;n P, Nomdedeu B, Montserrat E. Criteria for severe aplastic anaemia. Lancet 1987; 2:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/5\">",
"      Tichelli A, Soci&eacute; G, Henry-Amar M, et al. Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party. Ann Intern Med 1999; 130:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/6\">",
"      Scheinberg P, Wu CO, Nunez O, Young NS. Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol 2009; 144:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/7\">",
"      Bacigalupo A. Aetiology of severe aplastic anaemia and outcome after allogeneic bone marrow transplantation or immunosuppression therapy. Working Party on Severe Aplastic Anaemia of the European Blood and Marrow Transplantation Group. Eur J Haematol Suppl 1996; 60:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/8\">",
"      Brodsky RA, Jones RJ. Aplastic anaemia. Lancet 2005; 365:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/9\">",
"      Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006; 108:2509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/10\">",
"      H&ouml;chsmann B, Moicean A, Risitano A, et al. Supportive care in severe and very severe aplastic anemia. Bone Marrow Transplant 2013; 48:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/11\">",
"      Marsh JC, Ball SE, Darbyshire P, et al. Guidelines for the diagnosis and management of acquired aplastic anaemia. Br J Haematol 2003; 123:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/12\">",
"      Doney K, Leisenring W, Storb R, Appelbaum FR. Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy. Seattle Bone Marrow Transplant Team. Ann Intern Med 1997; 126:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/13\">",
"      Doney K, Pepe M, Storb R, et al. Immunosuppressive therapy of aplastic anemia: results of a prospective, randomized trial of antithymocyte globulin (ATG), methylprednisolone, and oxymetholone to ATG, very high-dose methylprednisolone, and oxymetholone. Blood 1992; 79:2566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/14\">",
"      Storb R, Etzioni R, Anasetti C, et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 1994; 84:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/15\">",
"      Risitano AM. Immunosuppressive therapies in the management of immune-mediated marrow failures in adults: where we stand and where we are going. Br J Haematol 2011; 152:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/16\">",
"      Paquette RL, Tebyani N, Frane M, et al. Long-term outcome of aplastic anemia in adults treated with antithymocyte globulin: comparison with bone marrow transplantation. Blood 1995; 85:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/17\">",
"      Passweg JR, Soci&eacute; G, Hinterberger W, et al. Bone marrow transplantation for severe aplastic anemia: has outcome improved? Blood 1997; 90:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/18\">",
"      Deeg HJ, Leisenring W, Storb R, et al. Long-term outcome after marrow transplantation for severe aplastic anemia. Blood 1998; 91:3637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/19\">",
"      Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993; 328:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/20\">",
"      Mao P, Wang S, Wang S, et al. Umbilical cord blood transplant for adult patients with severe aplastic anemia using anti-lymphocyte globulin and cyclophosphamide as conditioning therapy. Bone Marrow Transplant 2004; 33:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/21\">",
"      Dufour C, Svahn J, Bacigalupo A, Severe Aplastic Anemia&ndash;Working Party of the EBMT. Front-line immunosuppressive treatment of acquired aplastic anemia. Bone Marrow Transplant 2013; 48:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/22\">",
"      Tichelli A, Marsh JC. Treatment of aplastic anaemia in elderly patients aged &gt;60 years. Bone Marrow Transplant 2013; 48:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/23\">",
"      Kao SY, Xu W, Brandwein JM, et al. Outcomes of older patients (&gt; or = 60 years) with acquired aplastic anaemia treated with immunosuppressive therapy. Br J Haematol 2008; 143:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/24\">",
"      Rosenfeld SJ, Kimball J, Vining D, Young NS. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood 1995; 85:3058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/25\">",
"      Bacigalupo A, Bruno B, Saracco P, et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood 2000; 95:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/26\">",
"      Frickhofen N, Heimpel H, Kaltwasser JP, et al. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 2003; 101:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/27\">",
"      Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA 2003; 289:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/28\">",
"      Scheinberg P, Nunez O, Weinstein B, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med 2011; 365:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/29\">",
"      Holt DW, Johnston A, Kahan BD, et al. New approaches to cyclosporine monitoring raise further concerns about analytical techniques. Clin Chem 2000; 46:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/30\">",
"      Marsh J, Schrezenmeier H, Marin P, et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood 1999; 93:2191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/31\">",
"      Kadia TM, Borthakur G, Garcia-Manero G, et al. Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol 2012; 157:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/32\">",
"      Bacigalupo A, Broccia G, Corda G, et al. Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EBMT SAA Working Party. Blood 1995; 85:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/33\">",
"      Marsh JC, Socie G, Schrezenmeier H, et al. Haemopoietic growth factors in aplastic anaemia: a cautionary note. European Bone Marrow Transplant Working Party for Severe Aplastic Anaemia. Lancet 1994; 344:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/34\">",
"      Socie G, Mary JY, Schrezenmeier H, et al. Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood 2007; 109:2794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/35\">",
"      Locasciulli A, Bruno B, Rambaldi A, et al. Treatment of severe aplastic anemia with antilymphocyte globulin, cyclosporine and two different granulocyte colony-stimulating factor regimens: a GITMO prospective randomized study. Haematologica 2004; 89:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/36\">",
"      Kojima S, Hibi S, Kosaka Y, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood 2000; 96:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/37\">",
"      Gluckman E, Rokicka-Milewska R, Hann I, et al. Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia. Br J Haematol 2002; 119:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/38\">",
"      Teramura M, Kimura A, Iwase S, et al. Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan. Blood 2007; 110:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/39\">",
"      Tichelli A, Schrezenmeier H, Soci&eacute; G, et al. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. Blood 2011; 117:4434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/40\">",
"      Deyell RJ, Shereck EB, Milner RA, Schultz KR. Immunosuppressive therapy without hematopoietic growth factor exposure in pediatric acquired aplastic anemia. Pediatr Hematol Oncol 2011; 28:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/41\">",
"      Scheinberg P, Nunez O, Wu C, Young NS. Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetil. Br J Haematol 2006; 133:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/42\">",
"      Brown KE, Tisdale J, Barrett AJ, et al. Hepatitis-associated aplastic anemia. N Engl J Med 1997; 336:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/43\">",
"      Dearden C, Foukaneli T, Lee P, et al. The incidence and significance of fevers during treatment with antithymocyte globulin for aplastic anaemia. Br J Haematol 1998; 103:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/44\">",
"      Marsh JC, Bacigalupo A, Schrezenmeier H, et al. Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. Blood 2012; 119:5391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/45\">",
"      Yoshimi A, Niemeyer CM, F&uuml;hrer MM, Strahm B. Comparison of the efficacy of rabbit and horse antithymocyte globulin for the treatment of severe aplastic anemia in children. Blood 2013; 121:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/46\">",
"      Takahashi Y, Muramatsu H, Sakata N, et al. Rabbit antithymocyte globulin and cyclosporine as first-line therapy for children with acquired aplastic anemia. Blood 2013; 121:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/47\">",
"      Brodsky RA, Sensenbrenner LL, Jones RJ. Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation. Blood 1996; 87:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/48\">",
"      Brodsky RA, Sensenbrenner LL, Smith BD, et al. Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia. Ann Intern Med 2001; 135:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/49\">",
"      Brodsky RA, Chen AR, Dorr D, et al. High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood 2010; 115:2136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/50\">",
"      DeZern AE, Petri M, Drachman DB, et al. High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases. Medicine (Baltimore) 2011; 90:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/51\">",
"      Tisdale JF, Dunn DE, Geller N, et al. High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial. Lancet 2000; 356:1554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/52\">",
"      Abkowitz JL. Aplastic anemia: which treatment?. Ann Intern Med 2001; 135:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/53\">",
"      Soci&eacute; G. Cyclophosphamide in aplastic anemia? Blood 2010; 115:2120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/54\">",
"      Brodsky RA, Chen AR, Brodsky I, Jones RJ. High-dose cyclophosphamide as salvage therapy for severe aplastic anemia. Exp Hematol 2004; 32:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/55\">",
"      Zhang F, Zhang L, Jing L, et al. High-dose cyclophosphamide compared with antithymocyte globulin for treatment of acquired severe aplastic anemia. Exp Hematol 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/56\">",
"      Maciejewski JP, Sloand EM, Nunez O, et al. Recombinant humanized anti-IL-2 receptor antibody (daclizumab) produces responses in patients with moderate aplastic anemia. Blood 2003; 102:3584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/57\">",
"      Sloand EM, Olnes MJ, Weinstein B, et al. Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab. Haematologica 2010; 95:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/58\">",
"      Song Y, Li N, Liu Y, Fang B. Improved outcome of adults with aplastic anaemia treated with arsenic trioxide plus ciclosporin. Br J Haematol 2013; 160:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/59\">",
"      Scheinberg P, Fischer SH, Li L, et al. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood 2007; 109:3219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/60\">",
"      Soci&eacute; G, Henry-Amar M, Bacigalupo A, et al. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. N Engl J Med 1993; 329:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/61\">",
"      Schrezenmeier H, Marin P, Raghavachar A, et al. Relapse of aplastic anaemia after immunosuppressive treatment: a report from the European Bone Marrow Transplantation Group SAA Working Party. Br J Haematol 1993; 85:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/62\">",
"      Scheinberg P, Nunez O, Young NS. Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia. Br J Haematol 2006; 133:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/63\">",
"      Marsh JC, Hows JM, Bryett KA, et al. Survival after antilymphocyte globulin therapy for aplastic anemia depends on disease severity. Blood 1987; 70:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/64\">",
"      Tichelli A, Passweg J, Nissen C, et al. Repeated treatment with horse antilymphocyte globulin for severe aplastic anaemia. Br J Haematol 1998; 100:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/65\">",
"      Di Bona E, Rodeghiero F, Bruno B, et al. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Br J Haematol 1999; 107:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/66\">",
"      Kosaka Y, Yagasaki H, Sano K, et al. Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia. Blood 2008; 111:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/67\">",
"      Sloand EM, Read EJ, Scheinberg P, et al. Mobilization, collection, and immunomagnetic selection of peripheral blood CD34 cells in recovered aplastic anemia patients. Transfusion 2007; 47:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/68\">",
"      F&uuml;reder W, Valent P. Treatment of refractory or relapsed acquired aplastic anemia: review of established and experimental approaches. Leuk Lymphoma 2011; 52:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/69\">",
"      Risitano AM, Schrezenmeier H. Alternative immunosuppression in patients failing immunosuppression with ATG who are not transplant candidates: Campath (Alemtuzumab). Bone Marrow Transplant 2013; 48:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/70\">",
"      Scheinberg P, Nunez O, Weinstein B, et al. Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia. Blood 2012; 119:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/71\">",
"      Tang Y, Chen J, Young NS. Expansion of haematopoietic stem cells from normal donors and bone marrow failure patients by recombinant hoxb4. Br J Haematol 2009; 144:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/72\">",
"      Risitano AM, Selleri C, Serio B, et al. Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. Br J Haematol 2010; 148:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/73\">",
"      Kim H, Min YJ, Baek JH, et al. A pilot dose-escalating study of alemtuzumab plus cyclosporine for patients with bone marrow failure syndrome. Leuk Res 2009; 33:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/74\">",
"      G&oacute;mez-Almaguer D, Jaime-P&eacute;rez JC, Garza-Rodr&iacute;guez V, et al. Subcutaneous alemtuzumab plus cyclosporine for the treatment of aplastic anemia. Ann Hematol 2010; 89:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/75\">",
"      Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med 2012; 367:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/76\">",
"      Oshima Y, Yuji K, Tojo A. Eltrombopag in refractory aplastic anemia. N Engl J Med 2012; 367:1162; author reply 1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/77\">",
"      Kaito K, Kobayashi M, Katayama T, et al. Long-term administration of G-CSF for aplastic anaemia is closely related to the early evolution of monosomy 7 MDS in adults. Br J Haematol 1998; 103:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/78\">",
"      Ohara A, Kojima S, Hamajima N, et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood 1997; 90:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/79\">",
"      Locasciulli A, Arcese W, Locatelli F, et al. Treatment of aplastic anaemia with granulocyte-colony stimulating factor and risk of malignancy. Italian Aplastic Anaemia Study Group. Lancet 2001; 357:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/80\">",
"      Griscelli-Bennaceur A, Gluckman E, Scrobohaci ML, et al. Aplastic anemia and paroxysmal nocturnal hemoglobinuria: search for a pathogenetic link. Blood 1995; 85:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/81\">",
"      Schubert J, Vogt HG, Zielinska-Skowronek M, et al. Development of the glycosylphosphatitylinositol-anchoring defect characteristic for paroxysmal nocturnal hemoglobinuria in patients with aplastic anemia. Blood 1994; 83:2323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/82\">",
"      Scheinberg P, Marte M, Nunez O, Young NS. Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine. Haematologica 2010; 95:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/83\">",
"      Dunn DE, Tanawattanacharoen P, Boccuni P, et al. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med 1999; 131:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/84\">",
"      Piaggio G, Podest&agrave; M, Pitto A, et al. Coexistence of normal and clonal haemopoiesis in aplastic anaemia patients treated with immunosuppressive therapy. Br J Haematol 1999; 107:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/85\">",
"      Maciejewski JP, Risitano A, Sloand EM, et al. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood 2002; 99:3129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/86\">",
"      Strasser SI, McDonald GB. Hepatitis viruses and hematopoietic cell transplantation: A guide to patient and donor management. Blood 1999; 93:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/14/29930/abstract/87\">",
"      Tichelli A, Soci&eacute; G, Marsh J, et al. Outcome of pregnancy and disease course among women with aplastic anemia treated with immunosuppression. Ann Intern Med 2002; 137:164.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7158 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-218.28.111.102-5CC63B1F68-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_14_29930=[""].join("\n");
var outline_f29_14_29930=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Disease severity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Moderate AA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Severe AA (SAA)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Very severe AA (vSAA)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Patient age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other predictive factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Under age 20",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Ages 20 to 45",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Over age 45",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      IMMUNOSUPPRESSIVE REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ATG alone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ATG and cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Addition of G-CSF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Complications of ATG and cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8466382\">",
"      - Horse versus rabbit ATG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      High dose cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3908418\">",
"      - Modified high dose cyclophosphamide plus cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Viral reactivation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      RELAPSING OR RESISTANT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Retreatment with ATG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Resistant disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Alemtuzumab plus cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16503636\">",
"      - Use of a thrombopoietin mimetic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      OCCURRENCE OF CLONAL DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Development of MDS/AML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Development of PNH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Other clonal changes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      HEPATITIS-ASSOCIATED APLASTIC ANEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      PREGNANCY FOLLOWING TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Under age 20",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Age 20 to 45 years",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Age over 45",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7158\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7158|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/20/34125\" title=\"figure 1\">",
"      BMT v immunosuppression in AA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7158|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/43/35513\" title=\"picture 1\">",
"      Aplastic anemia bone marrow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/53/28500\" title=\"picture 2\">",
"      Normal bone marrow Low",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7158|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/49/7964\" title=\"table 1\">",
"      Causes acquired aplastic anemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?12/1/12305?source=related_link\" title=\"calculator 1\">",
"      Calculator: Absolute neutrophil count",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3738?source=related_link\">",
"      Acquired aplastic anemia in children and young adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14441?source=related_link\">",
"      Acute cardiac allograft rejection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/586?source=related_link\">",
"      Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16680?source=related_link\">",
"      Biology and physiology of thrombopoietin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14121?source=related_link\">",
"      Clinical manifestations of paroxysmal nocturnal hemoglobinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=related_link\">",
"      Cyclosporine and tacrolimus nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39594?source=related_link\">",
"      Cytogenetics in acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=related_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11562?source=related_link\">",
"      Hematopoietic cell transplantation for idiopathic severe aplastic anemia and Fanconi anemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18217?source=related_link\">",
"      Hematopoietic cell transplantation in aplastic anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16890?source=related_link\">",
"      Introduction to recombinant hematopoietic growth factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=related_link\">",
"      Overview of the management of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/4/30785?source=related_link\">",
"      Patient information: Aplastic anemia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10425?source=related_link\">",
"      Prevention and treatment of acute graft-versus-host disease: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8842?source=related_link\">",
"      Serum sickness and serum sickness-like reactions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_14_29931="Radiation toxicity gastrointest";
var content_f29_14_29931=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F70498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F70498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Radiation toxicity: Gastrointestinal system",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Symptom",
"       </td>",
"       <td class=\"subtitle1\">",
"        Degree 1",
"       </td>",
"       <td class=\"subtitle1\">",
"        Degree 2",
"       </td>",
"       <td class=\"subtitle1\">",
"        Degree 3",
"       </td>",
"       <td class=\"subtitle1\">",
"        Degree 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stool (number/day)",
"       </td>",
"       <td>",
"        2 to 3",
"       </td>",
"       <td>",
"        4 to 6",
"       </td>",
"       <td>",
"        7 to 9",
"       </td>",
"       <td>",
"        &ge;10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stool consistency",
"       </td>",
"       <td>",
"        Bulky",
"       </td>",
"       <td>",
"        Loose",
"       </td>",
"       <td>",
"        Loose",
"       </td>",
"       <td>",
"        Watery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GI bleeding",
"       </td>",
"       <td>",
"        Occult",
"       </td>",
"       <td>",
"        Intermittent",
"       </td>",
"       <td>",
"        Persistent",
"       </td>",
"       <td>",
"        Persistent large amount",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal cramps or pain",
"       </td>",
"       <td>",
"        Minimal",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        Intense",
"       </td>",
"       <td>",
"        Excruciating",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Waselenko JK, MacVittie TJ, Blakely WF, et al. Medical management of the acute radiation syndrome: Recommendations of the strategic national stockpile radiation working group. Ann Int Med 2004; 140:1039. Copyright &copy; 2004 American College of Physicians.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_14_29931=[""].join("\n");
var outline_f29_14_29931=null;
var title_f29_14_29932="Immunohistochemistry CUP";
var content_f29_14_29932=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F56518&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F56518&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Immunoperoxidase tumor staining patterns useful in the differential diagnosis of poorly differentiated neoplasms",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Tumor type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Immunoperoxidase staining",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carcinoma",
"       </td>",
"       <td>",
"        Epithelial stains (eg, CK 7, 20 variable), EMA (+) CLA, S-100, vimentin (-)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colorectal carcinoma",
"       </td>",
"       <td>",
"        CK 7 (-); CK 20 (+); CDX-2 (+)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Lung carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Adenocarcinoma",
"       </td>",
"       <td class=\"sublist_other\">",
"        TTF-1 (+), Surf-A and Surf-B (+)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Other non-small-cell carcinoma",
"       </td>",
"       <td class=\"sublist_other\">",
"        CK 7 (+), CK 20 (-), TTF-1 (-)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Small-cell carcinoma",
"       </td>",
"       <td class=\"sublist_other\">",
"        TTF-1 (+), chromogranin (+), NSE (+)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuroendocrine carcinoma",
"       </td>",
"       <td>",
"        Chromogranin (+), synaptophysin (+), epithelial stains (+)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Germ cell tumor",
"       </td>",
"       <td>",
"        HCG, AFP (+)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oct4 transcription factor (+)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Placental alkaline phosphatase (+)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epithelial stains (+)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Prostate carcinoma",
"       </td>",
"       <td>",
"        PSA (+), rare false (-) and (+)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epithelial stains (+)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CK 7 (-), CK 20 (-)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Pancreas carcinoma",
"       </td>",
"       <td>",
"        Ca",
"        <sup>",
"         19-9",
"        </sup>",
"        (+), CK 7 (+)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mesothelin (+), trifoil factor 1 (+)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Breast carcinoma",
"       </td>",
"       <td>",
"        ER, PR (+)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Her-2-neu (+)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CK 7 (+), CK 20 (-)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gross cystic fluid protein 15 (+)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epithelial stains (+)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     EMA: epithelial membrane antigen; CLA: common leukocyte antigen; TTF-1: thyroid transcription factor-1; NSE: neuron-specific enolase; HCG: human chorionic gonadotropin; AFP: &alpha;-fetoprotein; PSA: prostate-specific antigen; ER: estrogen receptor; PR: progesterone receptor.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Greco, FA, Hainsworth, JD. Cancer of Unknown Primary site. In: Cancer: Principles and Practice of Oncology 8th edition, DeVita, VT, Lawrence, TS, Rosenberg, SA (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_14_29932=[""].join("\n");
var outline_f29_14_29932=null;
var title_f29_14_29933="Contents: Complementary medicine";
var content_f29_14_29933=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?23/51/24382\">",
"       Adult Primary Care and Internal Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Complementary medicine",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Complementary medicine",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/50/28457\">",
"           Acupuncture",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/63/23542\">",
"           Clinical use of echinacea",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/28/11720\">",
"           Clinical use of ginkgo biloba",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/18/33061\">",
"           Clinical use of saw palmetto",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/8/27784\">",
"           Clinical use of St. John's wort",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/17/26903\">",
"           Homeopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/4/20554\">",
"           Overview of herbal medicine and dietary supplements",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-B2E72208A6-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f29_14_29933=[""].join("\n");
var outline_f29_14_29933=null;
var title_f29_14_29934="Laboratory monitoring of HIV patients";
var content_f29_14_29934=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74729&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74729&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Laboratory monitoring schedule for adolescent and adult patients with HIV prior to and after initiation of antiretroviral therapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Entry into care",
"       </td>",
"       <td class=\"subtitle1\">",
"        Follow-up before ART",
"       </td>",
"       <td class=\"subtitle1\">",
"        ART initiation or modification",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        2 to 8 weeks post-ART initiation or modification",
"       </td>",
"       <td class=\"subtitle1\">",
"        Every 3 to 6 months",
"       </td>",
"       <td class=\"subtitle1\">",
"        Every 6 months",
"       </td>",
"       <td class=\"subtitle1\">",
"        Every 12 months",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatment failure",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinically indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD4 count",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        every 3 to 6 months",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        In clinically stable patients with suppressed viral load, CD4 count can be monitored every 6 to 12 months",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        In clinically stable patients with suppressed viral load, CD4 count can be monitored every 6 to 12 months",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Viral load",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        every 3 to 6 months",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &radic;",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        &radic;",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Resistance testing",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HLA-B*5701 testing",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic; if considering ABC",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tropism testing",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic; if considering a CCR5 antagonist",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic; if considering a CCR5 antagonist or for failure of CCR5 antagonist-based regimen",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis B serology",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"        <br/>",
"        May repeat if HBsAg (-) and HBsAb (-) at baseline",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Basic chemistry",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        every 6 to 12 months",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ALT, AST, T. bilirubin",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        every 6 to 12 months",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CBC with differential",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        every 3 to 6 months",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &radic; if on ZDV",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fasting lipid profile",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        if normal, annually",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &radic;",
"        <br/>",
"        Consider 4 to 8 weeks after starting new ART",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic; if abnormal at last measurement",
"       </td>",
"       <td>",
"        &radic; if normal at last measurement",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fasting glucose",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        if normal, annually",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic; if abnormal at last measurement",
"       </td>",
"       <td>",
"        &radic; if normal at last measurement",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinalysis**",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic; if on TDF",
"        <sup>",
"         &bull;&bull;",
"        </sup>",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregnancy test",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic; if starting EFV",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     3TC: lamivudine; ABC: abacavir; ALT: alanine aminotransferase; ART: antiretroviral therapy; AST: aspartate aminotranserase; CBC: complete blood count; EFV: efavirenz; FTC: emtricitabine; HBsAb: hepatitis B surface antibody; HBsAg: hepatitis B surface antigen; HBV: hepatitis B virus; MDRD: modification of diet in renal disease (equation); TDF: tenofovir; ZDV: zidovudine.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      ARV modification may be done for treatment failure, adverse effects, or simplification.",
"      <br>",
"       &Delta; For the patient on a suppressive regimen whose CD4 cell count has increased well above the threshold for opportunistic infection risk, the CD4 count can be measured less frequently than the viral load. In such patients, CD4 count may be monitored every 6 to 12 months, unless there are changes in the patient's clinical status, such as new HIV-associated clinical symptoms or initiation of treatment with interferon, corticosteroids, or antineoplastic agents.",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        If HIV RNA is detectable at 2 to 8 weeks, repeat every 4 to 8 weeks until suppression to &lt;200 copies/mL, then every 3 to 6 months.",
"        <br>",
"         &sect; For adherent patients with suppressed viral load and stable clinical and immunologic status for &gt;2 to 3 years, some experts may extend the interval for HIV RNA monitoring to every 6 months.",
"         <br>",
"          &yen; For ART-na&iuml;ve patients, if resistance testing was performed at entry into care, repeat testing is optional; for patients with viral suppression who are switching therapy for toxicity or convenience, resistance testing will not be possible and therefore is not necessary.",
"          <br>",
"           ������ If HBsAg is positive at baseline or prior to initiation of ART, TDF + (FTC or 3TC) should be used as part of ARV regimen to treat both HBV and HIV infections. If HBsAg and HBsAb are negative at baseline, hepatitis B vaccine series should be administered.",
"           <br>",
"            ������ Serum Na, K, HCO3, Cl, BUN, creatinine, glucose (preferably fasting); some experts suggest monitoring phosphorus while on TDF; determination of renal function should include estimation of creatinine clearance using Cockcroft-Gault equation or estimation of glomerular filtration rate based on MDRD equation.",
"            <br>",
"             ** For patients with renal disease, consult: Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005; 40:1559.",
"             <br>",
"              <span class=\"double_bullet\">",
"               &bull;&bull;",
"              </span>",
"              More frequent monitoring may be indicated for patients with increased risk of renal insufficiency, such as patients with diabetes, hypertension, etc.",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services. Available at",
"     <a href=\"file://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf\" target=\"_blank\">",
"      file://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf",
"     </a>",
"     (accessed on July 20, 2011).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_14_29934=[""].join("\n");
var outline_f29_14_29934=null;
var title_f29_14_29935="Digital block great toe II";
var content_f29_14_29935=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74315&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74315&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Great toe digital block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 278px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    To perform a three-sided toe block or four-sided ring block, insert the needle just distal to the MTP (metatarsal/phalangeal) joint at the lateral edge of the toe. Slowly advance the needle straight from the dorsal to the plantar surface, injecting as the needle is advanced. This picture shows the position of the needle after it has been advanced.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Baldor, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_14_29935=[""].join("\n");
var outline_f29_14_29935=null;
